<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> Aptose Biosciences Inc. (Form: 20-F, Received: 03/30/2016 06:23:54) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_IDENTITY_OF_PERSONNEL **FIS_OFFER_STATISTICS **FIS_KEY_INFORMATION **FIS_COMPANY_INFORMATION **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_OPERATING_AND_FINANCIAL_REVIEW **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_COMPENSATION_TABLE **FIS_OPTIONS **FIS_OPTIONS_AGGREGATE **FIS_BENEFICIAL_OWNERS **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS_2 **FIS_FINANCIAL_DATA **FIS_LISTING **FIS_ADDITIONAL_INFORMATION **FIS_MARKET_RISK **FIS_OTHER_SECURITIES **FIS_PART_II **FIS_DEFAULTS **FIS_MATERIAL_MODIFICATIONS **FIS_CONTROL_AND_PROCEDURES **FIS_AUDIT_COMMITTEE_EXPERT **FIS_CODE_OF_ETHICS **FIS_ACCOUNTANT_FEES **FIS_EXEMPTIONS_FROM_LISTING **FIS_PURCHASES_OF_EQUITY **FIS_CHANGE_IN_ACCOUNTANT **FIS_CORPORATE_GOVERNANCE **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_III **FIS_FINANCIAL_STATEMENTS **FIS_FINANCIAL_STATEMENTS_2 **FIS_EXHIBITS **FIS_SIGNATURES **FIS_EXHIBIT_INDEX **FIS_AUDITORS_OPINION **FIS_CASH_FLOW **FIS_CASH_FLOW_2 FIS_EXHIBIT_8 FIS_EXHIBIT_12 FIS_EXHIBIT_12_2 FIS_EXHIBIT_13 FIS_EXHIBIT_13_2 FIS_EXHIBIT_15 ">
<META NAME="DETECTED PAGES" CONTENT="144">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="F20F_032916_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 0.75PT; BORDER-TOP: BLACK 0.75PT SOLID; BORDER-BOTTOM: BLACK 0.75PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	UNITED STATES
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	SECURITIES AND EXCHANGE COMMISSION
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	Washington, D.C. 20549
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	FORM 20-F
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	(Mark One)
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20%; PADDING-LEFT: 27PT">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
<TD STYLE="WIDTH: 80%">
<FONT STYLE="FONT-SIZE: 10PT">
	Registration statement pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 27PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Or
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 27PT">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	x
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 27PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Or
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 27PT">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 27PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Or
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 27PT">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Shell company report pursuant to Section 13 or 15(d) of the Securities Exchange Act of
	1934.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Date of event requiring this shell company report _______________.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	Commission file number 001-32001
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	APTOSE BIOSCIENCES INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<I>
	(Exact Name of Registrant as Specified in Its Charter)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Canada
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<I>
	(Jurisdiction of Incorporation or Organization)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	5955 Airport Road, Suite #228
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Mississauga, Ontario
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	L4V 1R9
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Canada
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<I>
	(Address of Principal Executive Offices)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Gregory Chow
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Chief Financial Officer
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	5955 Airport Road, Suite #228
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Mississauga, Ontario
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	L4V 1R9
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Canada
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Telephone: (647) 479-9828
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Facsimile: (905) 234-2120
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<I>
	(Name, Telephone, E-mail and/or Facsimile number and Address of
	Company Contact Person)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Securities registered or to be registered pursuant to Section 12(b) of the Act: None
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Title of Each Class
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 59%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name of Each Exchange On Which Registered
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Common Shares
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	The NASDAQ Capital Market
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Securities registered or to be registered pursuant to Section 12(g)
	of the Act:
<B>
	None
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Securities for which there is a reporting obligation pursuant to
	Section 15(d) of the Act:
<B>
	None
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Indicate the number of outstanding shares of each of the issuer&rsquo;s
	classes of capital or common stock as of the close of the period covered by the annual report.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Common Shares, without par value, at December 31, 2015: 12,047,452
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Indicate by check mark if the registrant is a well-known seasoned
	issuer, as defined in Rule 405 of the Securities Act.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	If this is an annual or transition report, indicate by check mark
	if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant: (1) has filed all
	reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such
	shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for
	the past 90 days.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant has submitted electronically
	and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule
	405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
	was required to submit and post such files).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant is a large accelerated
	filer, an accelerated filer, or a non-accelerated filer. See definition of &ldquo;accelerated filer and large accelerated filer&rdquo;
	in Rule 12b-2 of the Act.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Large accelerated filer
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	Accelerated filer
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	Non-accelerated filer
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Indicate by check mark which basis of accounting the registrant
	has used to prepare the financial statements included in this filing.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	U.S. GAAP
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	International Financial Reporting Standards as issued by the International Accounting Standards Board
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	Other
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	If &ldquo;Other&rdquo; has been checked in response to the previous
	question, indicate by check mark which financial statement item the registrant has elected to follow.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Item 17
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	Item 18
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	If this is an annual report, indicate by check mark whether the
	registrant is a shell company (as defined in Rule 12b-2 of the Act).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<U>
</U>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<U>
	TABLE OF CONTENTS
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 75%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Page
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<A HREF="#F20F_032916_HTM_P1">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
<B>
<U>
	PART I
</U>
</B>
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_P1">
<B>
	1
</B>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I1">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 1.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I1">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Identity of Directors, Senior Management and Advisors
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I1">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	1
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I2">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 2.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I2">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Offer Statistics and Expected Timetable
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I2">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	1
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I3">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 3.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I3">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Key Information
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I3">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	1
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I4">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 4.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I4">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Information on the Company
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I4">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	15
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I4A">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 4A.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I4A">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Unresolved Staff Comments
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I4A">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	32
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I5">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 5.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I5">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Operating and Financial Review and Prospects
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I5">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	32
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I6">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 6.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I6">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Directors, Senior Management and Employees
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I6">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	33
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I7">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 7.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I7">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Major Shareholders and Related Party Transactions
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I7">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	46
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I8">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 8.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I8">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Financial Information
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I8">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	49
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I9">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 9.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I9">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	The Offer and Listing
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I9">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	49
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I10">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 10.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I10">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Additional Information
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I10">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	51
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I11">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 11.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I11">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Qualitative and Quantitative Disclosures about Market Risk
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I11">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	59
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I12">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 12.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I12">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Description of Securities Other Than Equity Securities
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I12">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	60
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<A HREF="#F20F_032916_HTM_P2">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
<B>
<U>
	PART II
</U>
</B>
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_P2">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
<B>
	61
</B>
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I13">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 13.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I13">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Defaults, Dividends, Arrearages and Delinquencies
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I13">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	61
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I14">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 14.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I14">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Material Modifications to the Rights of Security Holders and Use of Proceeds
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I14">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	61
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I15">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 15.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I15">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Controls and Procedures
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I15">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	61
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I16">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 16.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I16">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	[Reserved]
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I16">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	62
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I16A">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 16A.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I16A">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Audit Committee Financial Expert
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I16A">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	62
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I16B">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 16B.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I16B">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Code of Ethics
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I16B">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	62
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I16C">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 16C.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I16C">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Principal Accountant Fees and Services
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I16C">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	62
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I16D">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 16D.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I16D">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Exemptions from the Listing Standards for Audit Committees
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I16D">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	62
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I16E">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 16E.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I16E">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Purchases of Equity Securities by the Issuer and Affiliated Purchasers
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I16E">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	63
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<A HREF="#F20F_032916_HTM_P3">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
<B>
<U>
	PART III
</U>
</B>
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_P3">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
<B>
	64
</B>
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I17">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 17.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I17">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Financial Statements
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I17">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	64
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I18">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 18.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I18">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Financial Statements
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I18">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	64
</FONT>
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<A HREF="#F20F_032916_HTM_I19">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Item 19.
</FONT>
</A>
</TD>
<TD>
<A HREF="#F20F_032916_HTM_I19">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	Exhibits
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F20F_032916_HTM_I19">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
	64
</FONT>
</A>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	i
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	GENERAL
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On July&nbsp;10, 2007 (the&nbsp;&rdquo;
<B>
	Arrangement
	Date
</B>
	&rdquo;), the Company completed a plan of arrangement and corporate reorganization with, among others, 4325231&nbsp;Canada&nbsp;Inc.
	(now Global Summit Real Estate Inc.), formerly Lorus Therapeutics&nbsp;Inc. (&ldquo;
<B>
	Old&nbsp;Lorus
</B>
	&rdquo;), 6707157&nbsp;Canada&nbsp;Inc.
	and Pinnacle International Lands,&nbsp;Inc. (the&nbsp;&ldquo;
<B>
	Arrangement
</B>
	&rdquo;). As a result of the plan of arrangement
	and reorganization, among other things, each common share of Old Lorus was exchanged for one common share (&ldquo;
<B>
	Common Share
</B>
	&rdquo;)
	of the Company and the assets (excluding certain deferred tax assets) and liabilities of Old Lorus (including all of the shares
	of its subsidiaries) were transferred, directly or indirectly, to the Company and/or our subsidiaries. We continued the business
	of Old Lorus after the Arrangement Date with the same officers and employees and continued to be governed by the same directors
	as Old Lorus prior to the Arrangement Date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On August 28, 2014 (the &ldquo;
<B>
	Name Change
	Date
</B>
	&rdquo;), we changed our name from Lorus Therapeutics Inc. to Aptose Biosciences Inc. In this Annual Report on Form 20-F,
	all references to &ldquo;
<B>
	Aptose
</B>
	&rdquo;, the &ldquo;
<B>
	Corporation
</B>
	&rdquo;, the &ldquo;
<B>
	Company
</B>
	&rdquo;, &ldquo;
<B>
	we
</B>
	&rdquo;,
	&ldquo;
<B>
	our
</B>
	&rdquo;, &ldquo;
<B>
	us
</B>
	&rdquo; and similar expressions, unless otherwise stated, are references to Old Lorus
	prior to the Arrangement Date, Lorus Therapeutics Inc. after the Arrangement&nbsp;Date and Aptose Biosciences Inc. after the Name
	Change Date. References to this &ldquo;
<B>
	Form 20-F
</B>
	&rdquo; and this &ldquo;
<B>
	Annual Report
</B>
	&rdquo; mean references to this
	Annual Report on Form 20-F for the twelve months ended December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We use the Canadian dollar as our reporting
	currency. All references in this Annual Report to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; are expressed in Canadian dollars, unless
	otherwise indicated. See also &ldquo;Item 3. Key Information&rdquo; for more detailed currency and conversion information. Our
	consolidated financial statements, which form part of this Annual Report, are presented in Canadian dollars and are prepared in
	accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (&ldquo;
<B>
	IFRS
</B>
	&rdquo;),
	which differ in certain respects from accounting principles generally accepted in the United States (&ldquo;
<B>
	U.S. GAAP
</B>
	&rdquo;).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On October 1, 2014, we consolidated our outstanding
	Common Shares on the basis of one post-consolidation Common Share for each twelve pre-consolidation Common Shares. Historical trading
	prices and volumes disclosed are on a post-consolidated basis and reflect the one for twelve consolidation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our reporting and functional currency is the
	Canadian dollar. Unless otherwise indicated, all references to &ldquo;dollars&rdquo; or the use of the symbol &ldquo;$&rdquo; or
	&ldquo;CDN$&rdquo; are to Canadian dollars. See Item 3&ldquo;Key Information - Exchange Rate Information&rdquo;.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	FORWARD-LOOKING STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	This Annual Report contains forward-looking
	statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 or &ldquo;forward-looking information&rdquo;
	(within the meaning of applicable Canadian securities legislation). Such statements include, but are not limited to, statements
	relating to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our business strategy;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our clinical development plans;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to obtain the substantial capital we require to fund research and operations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our plans to secure strategic partnerships to assist in the further development of our product
	candidates and to build our pipeline;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our plans to conduct clinical trials and pre-clinical programs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our expectations regarding the progress and the successful and timely completion of the various
	stages of our drug discovery, pre-clinical and clinical studies and the regulatory approval process;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 76.5PT">
	our plans, objectives, expectations and intentions; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	ii
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 3.05PT">
	other statements including words such as &ldquo;anticipate&rdquo;, &ldquo;contemplate&rdquo;,
	&ldquo;continue&rdquo;, &ldquo;believe&rdquo;, &ldquo;plan&rdquo;, &ldquo;estimate&rdquo;, &ldquo;expect&rdquo;, &ldquo;intend&rdquo;,
	&ldquo;will&rdquo;, &ldquo;should&rdquo;, &ldquo;may&rdquo;, and other similar expressions.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 35.05PT; MARGIN: 0PT 2.8PT 0PT 5.05PT">
	The forward-looking statements
	reflect our current views with respect to future events, are subject to significant risks and uncertainties, and are based upon
	a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business,
	economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance
	or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied
	by such forward-looking statements, including, among others:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 35.05PT; MARGIN: 0PT 2.8PT 0PT 5.05PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to obtain the substantial capital we require to fund research and operations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our lack of product revenues and history of operating losses;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our early stage of development, particularly the inherent risks and uncertainties associated with
	(i)&nbsp;developing new drug candidates generally, (ii) demonstrating the safety and efficacy of these drug candidates in clinical
	studies in humans, and (iii) obtaining regulatory approval to commercialize these drug candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our drug candidates require time-consuming and costly preclinical and clinical testing and regulatory
	approvals before commercialization;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	clinical studies and regulatory approvals of our drug candidates are subject to delays, and may
	not be completed or granted on expected timetables, if at all, and such delays may increase our costs and could delay our ability
	to generate revenue;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the regulatory approval process;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to recruit patients for clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the progress of our clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to find and enter into agreements with potential partners;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to attract and retain key personnel;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to obtain and maintain patent protection;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to protect our intellectual property rights and not infringe on the intellectual property
	rights of others;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to comply with applicable governmental regulations and standards;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	development or commercialization of similar products by our competitors, many of which are more
	established and have or have access to greater financial resources than us;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	commercialization limitations imposed by intellectual property rights owned or controlled by third
	parties;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our business is subject to potential product liability and other claims;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to maintain adequate insurance at acceptable costs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	further equity financing may substantially dilute the interests of our shareholders;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	iii
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changing market conditions; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	other risks detailed from time-to-time in our on-going quarterly filings, annual information forms,
	annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission
	(&ldquo;
<B>
	SEC
</B>
	&rdquo;), and those which are discussed under the heading &ldquo;Item 3. Key Information&mdash;D. Risk Factors&rdquo;
	in this document.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Should one or more of these risks or uncertainties
	materialize, or should the assumptions set out in the section entitled &ldquo;Item 3. Key Information&mdash;D.
<I>
</I>
	Risk Factors&rdquo;
	underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These
	forward-looking statements are made as of the date of this Annual Report or, in the case of documents incorporated by reference
	herein, as of the date of such documents, and we do not intend, and do not assume any obligation, to update these forward-looking
	statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ
	materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees
	of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the
	inherent uncertainty therein. New factors emerge from time to time, and it is not possible for management of the Company to predict
	all of these factors or to assess in advance the impact of each such factor on the Company&rsquo;s business or the extent to which
	any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
	statement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	iv
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F20F_032916_HTM_P1">
</A>
	PART I
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_IDENTITY_OF_PERSONNEL>
<A NAME="FIS_IDENTITY_OF_PERSONNEL"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<A NAME="F20F_032916_HTM_I1">
</A>
<B>
	Item 1. Identity of Directors,
	Senior Management and Advisers
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_IDENTITY_OF_PERSONNEL>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OFFER_STATISTICS>
<A NAME="FIS_OFFER_STATISTICS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<A NAME="F20F_032916_HTM_I2">
</A>
<B>
	Item 2. Offer Statistics
	and Expected Timetable
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_OFFER_STATISTICS>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_KEY_INFORMATION>
<A NAME="FIS_KEY_INFORMATION"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<A NAME="F20F_032916_HTM_I3">
</A>
<B>
	Item 3. Key Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Selected financial data
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following tables present our selected consolidated
	financial data. You should read these tables in conjunction with our audited consolidated financial statements and accompanying
	notes included in
<B>
</B>
	Item 18
<B>
</B>
	of this Annual Report and the &ldquo;Management&rsquo;s Discussion and Analysis of Financial
	Condition and Results of Operations&rdquo; included in Item 5 of this Annual Report.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The selected consolidated financial information
	set forth below has been derived from the Company's audited consolidated financial statements that are prepared in accordance with
	IFRS, which differ in certain respects from the principles the Company would have followed had its consolidated financial statements
	been prepared in accordance with U.S. GAAP. The selected audited consolidated financial information should be read in conjunction
	with our audited consolidated financial statements and related notes thereto.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Effective July 17, 2014, we changed our fiscal
	year end from May 31 to December 31. As a result of that change, the period ending December 31, 2014 is for a seven month transition
	period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table presents a summary of our
	consolidated statements of operations derived from our audited consolidated financial statements for the fiscal year ended December
	31, 2015, the seven months ended December 31, 2014 and fiscal years ended May 31, 2014, 2013 and 2012.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Consolidated statements of operations data
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="21" STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	(In&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	May&nbsp;31,
<BR>
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	May&nbsp;31,
<BR>
	2013
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	May&nbsp;31,
<BR>
	2012
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	In accordance with IFRS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#9472;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#9472;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9472;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9472;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,254
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,404
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,015
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,317
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,170
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,845
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,542
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,317
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,257
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,417
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,099
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,946
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,332
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,589
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,600
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Finance expense
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	43
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	104
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	297
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	33
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Finance income
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,516
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(279
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14,626
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,771
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,553
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(5,565
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4,614
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Basic and diluted loss per Common Share (post-consolidation)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1.23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.67
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2.02
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1.58
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2.76
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Weighted average number of Common Shares outstanding (post-consolidation)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,906
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,605
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,216
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,521
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,688
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table presents a summary of our
	consolidated balance sheets as at December 31, 2015, 2014 and May 31, 2014, 2013 and 2012.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Consolidated balance sheet data
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; BORDER-BOTTOM: BLACK 1PT SOLID">
	(In thousands, except per share data)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	As at December 31
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	As at May 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2012
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	In accordance with IFRS
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	11,503
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,365
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,367
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	653
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	320
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,245
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,180
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,019
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,249
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	31,600
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	30,899
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,035
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	668
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,356
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,328
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,460
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,816
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,696
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total shareholders&rsquo; equity (deficit)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	18,893
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	29,272
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,439
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(781
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,028
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Number of Common Shares outstanding (post- consolidation)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	12,048
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,700
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,388
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,521
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,769
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dividends paid on Common Shares
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&#9472;
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9472;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9472;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9472;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9472;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Exchange Rate Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table sets out the average exchange
	rates of CDN$1.00 for US$1.00 for the following periods as taken from the Bank of Canada&rsquo;s website.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Period
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Average Close
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 85%; FONT-SIZE: 10PT">
	Fiscal Year Ended December 31, 2015
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.2787
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Seven Months Ended December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.1080
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Fiscal Year Ended May 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.0662
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Fiscal Year Ended May 31, 2013
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.0042
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Fiscal Year Ended May 31, 2012
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.0005
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Fiscal Year Ended May 31, 2011
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.0066
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table sets forth the high and
	low exchange rates of CDN$1.00 for US$1.00 for each month during the previous six months.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Period
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT">
	February 2016
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.4082
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.3480
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	January 2016
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.4661
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.3983
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	December 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.4003
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.3398
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	November 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.3390
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.3112
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	October 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.3280
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.2940
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	September 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.3457
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.3205
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On March 29, 2016, the noon buying rate of
	CDN$1.00 for US$1.00, as per the Bank of Canada, was USD $1.00=CDN$1.3154.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Capitalization and indebtedness
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Reasons for the offer and use of proceeds
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Risk factors
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Investing in our securities involves a high
	degree of risk. Before making an investment decision with respect to our Common Shares, you should carefully consider the following
	risk factors, in addition to the other information included or incorporated by reference in this Annual Report. Additional risks
	not currently known by us or that we consider immaterial at the present time may also impair our business, financial condition,
	prospects or results of operations. If any of the following risks occur, our business, financial condition, prospects or results
	of operations would likely be materially adversely affected. In that case, the trading price of our Common Shares could decline
	and you may lose all or part of the money you paid to buy our Common Shares. The risks set out below are not the only risks and
	uncertainties we currently face; other risks may arise in the future.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	RISKS RELATED TO OUR BUSINESS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	We are an early stage development company.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We are at an early stage of development. In
	the past five years, none of our potential products has obtained regulatory approval for commercial use and sale in any country
	and as such, no significant revenues have resulted from product sales. Significant additional investment will be necessary to complete
	the development of any of our product candidates. Preclinical and clinical trial work must be completed before our potential products
	could be ready for use within the markets that we have identified. We may fail to develop any products, obtain regulatory approvals,
	enter clinical trials or commercialize any products. We do not know whether any of our potential product development efforts will
	prove to be effective, meet applicable regulatory standards, obtain the requisite regulatory approvals, be capable of being manufactured
	at a reasonable cost or be accepted in the marketplace. We also do not know whether sales, license fees or related royalties will
	allow us to recoup any investment we make in the commercialization of our products.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The product candidates we are currently developing
	are not expected to be commercially viable for at least the next several years and we may encounter unforeseen difficulties or
	delays in commercializing our product candidates. In addition, our potential products may not be effective or may cause undesirable
	side effects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our product candidates require significant funding
	to reach regulatory approval assuming positive clinical results. For example, our lead product candidate APTO-253 began enrolment
	in a Phase I clinical trial in patients with relapsed or refractory hematologic malignancies and was placed on clinical hold by
	the United States Food and Drug Administration (&ldquo;
<B>
	FDA
</B>
	&rdquo;) following a voluntary suspension of dosing by us. We
	are currently working with the FDA to have such hold lifted but significant additional funding or a partnership will be necessary
	to complete, if required, Phase II or Phase III clinical trials. Such funding may be very difficult, or impossible to raise in
	the public or private markets or through partnerships. If funding or partnerships are not attainable, the development of these
	product candidates may be significantly delayed or stopped altogether. The announcement of a delay or discontinuation of development
	would likely have a negative impact on our share price.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	We need to raise additional capital.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have an ongoing need to raise additional
	capital. To obtain the necessary capital, we must rely on some or all of the following: additional share issues, debt issuances
	(including promissory notes), collaboration agreements or corporate partnerships and grants and tax credits to provide full or
	partial funding for our activities. Additional funding may not be available on terms that are acceptable to us or in amounts that
	will enable us to carry out our business plan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our need for capital may require us to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	engage in equity financings that could result in significant dilution to existing investors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	delay or reduce the scope of or eliminate one or more of our development programs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	obtain funds through arrangements with collaborators or others that may require us to relinquish
	rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	license rights to technologies, product candidates or products on terms that are less favourable
	to us than might otherwise be available;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	considerably reduce operations; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	cease our operations.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	We have a history of operating losses. We expect to incur
	net losses and we may never achieve or maintain profitability.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have not been profitable since our inception
	in 1986. We reported net losses of $14.6 million in the fiscal year ended December 31, 2015, $7.8 million in the 7 months ended
	December 31, 2014 and $10.6 million in the fiscal years ended May 31, 2014, and as of December 31, 2015, we had an accumulated
	deficit of $232.9 million.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have not generated any significant revenue
	to date and it is possible that we will never have sufficient product sales revenue (if any) to achieve profitability. We expect
	to continue to incur losses for at least the next several years as we or our collaborators and licensees pursue clinical trials
	and research and development efforts. To become profitable, we, either alone or with our collaborators and licensees, must successfully
	develop, manufacture and market our current product candidate APTO-253 as well as continue to identify, develop, manufacture and
	market new product candidates. It is possible that we will never have significant product sales revenue or receive royalties on
	our licensed product candidates. If funding is insufficient at any time in the future, we may not be able to develop or commercialize
	our products, take advantage of business opportunities or respond to competitive pressures.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Delays in clinical testing could result
	in delays in commercializing our product candidates and our business may be substantially harmed.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We cannot predict whether
	any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Our product
	development costs will increase if we experience delays in clinical testing. Significant clinical trial delays could shorten any
	periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring
	products to market before us, which would impair our ability to successfully commercialize our product candidates and may harm
	our financial condition, results of operations and prospects. The commencement and completion of clinical trials for our products,
	including the APTO-253 phase I clinical trial, may be delayed for a number of reasons, including delays related, but not limited,
	to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	failure by regulatory authorities to grant permission to proceed or placing the clinical trial on hold;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	patients failing to enroll or remain in our trials at the rate we expect;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	suspension or termination of clinical trials by regulators for many reasons, including concerns about patient safety or failure of our contract manufacturers to comply with cGMP requirements;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	any changes to our manufacturing process that may be necessary or desired;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	delays or failure to obtain clinical supply from contract manufacturers of our products necessary to conduct clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	product candidates demonstrating a lack of safety or efficacy during clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	patients choosing an alternative treatment for the indications for which we are developing any of our product candidates or participating in competing clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	patients failing to complete clinical trials due to dissatisfaction with the treatment, side effects or other reasons;
</FONT>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	reports of clinical testing on similar technologies and products raising safety and/or efficacy concerns;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	competing clinical trials and scheduling conflicts with participating clinicians;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	clinical investigators not performing our clinical trials on their anticipated schedule, dropping out of a trial, or employing methods not consistent with the clinical trial protocol, regulatory requirements or other third parties not performing data collection and analysis in a timely or accurate manner;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	failure of our contract research organizations, or CROs, to satisfy their contractual duties or meet expected deadlines;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	inspections of clinical trial sites by regulatory authorities or Institutional Review Boards, or IRBs, or ethics committees finding regulatory violations that require us to undertake corrective action, resulting in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	one or more IRBs or ethics committees rejecting, suspending or terminating the study at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial; or
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	failure to reach agreement on acceptable terms with prospective clinical trial sites.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	Our product development costs will increase
	if we experience delays in testing or approval or if we need to perform more or larger clinical trials than planned. Additionally,
	changes in regulatory requirements and policies may occur, and we may need to amend study protocols to reflect these changes. Amendments
	may require us to resubmit our study protocols to regulatory authorities or IRBs or ethics committees for re-examination, which
	may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material
	adverse effect on our business, financial condition and prospects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We rely on contract manufacturers
	over whom we have limited control. If we are subject to quality, cost or delivery issues with the preclinical and clinical grade
	materials supplied by contract manufacturers, our business operations could suffer significant harm.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We rely on contract
	manufacturing organizations, or CMOs, to manufacture our product candidates for some preclinical studies and clinical trials. We
	rely on CMOs for manufacturing, filling, packaging, storing and shipping of drug product in compliance with cGMP regulations applicable
	to our products. The FDA ensures the quality of drug products by carefully monitoring drug manufacturers&rsquo; compliance with
	cGMP regulations. The cGMP regulations for drugs contain minimum requirements for the methods, facilities and controls used in
	manufacturing, processing and packing of a drug product.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We have contracted
	with multiple CMOs for the manufacture of APTO-253 to supply both the Active Pharmaceutical Ingredient (&ldquo;API&rdquo;) as
	well as to perform formulation and optimization studies with the intent of supplying drug product acceptable to the FDA for our
	phase I clinical trial. The formulation and manufacture of APTO-253 is a complex process with many variables involved. We believe
	these pre-qualified CMOs have the capacity, the systems and the experience to supply APTO-253 for our phase I clinical trial and
	future clinical trials. We have qualified the manufacturing facilities and the FDA has also performed site audits for our selected
	CMOs. Any manufacturing failures, delays or compliance issues could cause further delays in the re-initiation of the phase I clinical
	trial. If we are able to re-initiate the phase I clinical trial any manufacturing failures, delays or compliance issues could
	impact our ability to complete the phase I clinical trial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	There can be no assurances
	that CMOs will be able to meet our timetable and requirements. We have not contracted with alternate suppliers in the event our
	current CMOs are unable to scale up production, or if our current CMOs otherwise experience any other significant problems. If
	we are unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms or in a timely manner,
	we may be further delayed in the development of our product candidates. Further, contract manufacturers must operate in compliance
	with cGMP and failure to do so could result in, among other things, the disruption of product supplies. Our dependence upon third
	parties for the manufacture of our products may adversely affect our profit margins and our ability to develop and deliver products
	on a timely and competitive basis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	Clinical trials are long, expensive and
	uncertain processes and the FDA or Health Canada may ultimately not approve any of our product candidates. We may never develop
	any commercial drugs or other products that generate revenues.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In the past five years, none of our product
	candidates has received regulatory approval for commercial use and sale in North America. We cannot market a pharmaceutical product
	in any jurisdiction until it has completed thorough preclinical testing and clinical trials in addition to that jurisdiction&rsquo;s
	extensive regulatory approval process. Approval in one country does not assure approval in another country. In general, significant
	research and development and clinical studies are required to demonstrate the safety and effectiveness of our product candidates
	before we can submit any regulatory applications.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Clinical trials are long, expensive and uncertain
	processes. Clinical trials may not be commenced or completed on schedule and the FDA or Health Canada or any other regulatory body
	may not ultimately approve our product candidates for commercial sale. The clinical trials of any of our drug candidates could
	be unsuccessful, which would prevent us from advancing, commercializing or partnering the drug.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Even if the results of our preclinical studies
	or clinical trials are initially positive, it is possible that we will obtain different results in the later stages of drug development
	or that results seen in clinical trials will not continue with longer term treatment. Positive results in Phase I clinical trials
	may not be repeated in larger Phase II or Phase III clinical trials.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our preclinical studies and clinical trials
	may not generate positive results that will allow us to move towards the commercial use and sale of our product candidates. Furthermore,
	negative preclinical or clinical trial results may cause our business, financial condition, or results of operations to be materially
	adversely affected. For example, our lead product candidate APTO-253 has entered a Phase Ib testing in patients with relapsed or
	refractory hematologic malignancies for which there is a long development path ahead that will take many years to complete and
	is prone to the risks of failure or delays inherent in drug development.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Preparing, submitting and advancing applications
	for regulatory approval is complex, expensive and time intensive and entails significant uncertainty. A commitment of substantial
	resources to conduct time-consuming research, preclinical studies and clinical trials is required if we are to complete development
	of our products.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Clinical trials of our products require that
	we identify and enroll a large number of patients with the illness under investigation. We may not be able to enroll a sufficient
	number of appropriate patients to complete our clinical trials in a timely manner, particularly in smaller indications and indications
	where there is significant competition for patients. If we experience difficulty in enrolling a sufficient number of patients to
	conduct our clinical trials, we may need to delay or terminate ongoing clinical trials and will not accomplish objectives material
	to our success. Delays in planned patient enrolment or lower than anticipated event rates in our current clinical trials or future
	clinical trials also may result in increased costs, program delays, or both.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In addition, unacceptable toxicities or adverse
	side effects may occur at any time in the course of preclinical studies or human clinical trials or, if any product candidates
	are successfully developed and approved for marketing, during commercial use of any approved products. The appearance of any unacceptable
	toxicities or adverse side effects could interrupt, limit, delay or abort the development of any of our product candidates or,
	if previously approved, necessitate their withdrawal from the market. Furthermore, disease resistance or other unforeseen factors
	may limit the effectiveness of our potential products.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our failure to develop safe, commercially viable
	drugs would substantially impair our ability to generate revenues and sustain our operations and would materially harm our business
	and adversely affect our share price.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	We may not achieve our projected development
	goals in the time frames we announce and expect.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We set goals for, and make public statements
	regarding, the expected timing of the accomplishment of objectives material to our success, such as the commencement and completion
	of clinical trials and our ability to secure the financing necessary to continue the development of our product candidates. The
	actual timing of these events can vary dramatically due to factors within and beyond our control, such as delays or failures in
	our clinical trials, issues related to the manufacturing of drug supply, uncertainties inherent in the regulatory approval process,
	market conditions and interest by partners in our product candidates among other things. Our clinical trials may not be completed;
	we may not make regulatory submissions or receive regulatory approvals as planned; or we may not secure partnerships for any of
	our product candidates. Any failure to achieve one or more of these milestones as planned would have a material adverse effect
	on our business, financial condition and results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	If we have difficulty enrolling patients
	in clinical trials, the completion of the trials may be delayed or cancelled.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	As our product candidates
	advance from preclinical testing to clinical testing, and then through progressively larger and more complex clinical trials, we
	will need to enroll an increasing number of patients that meet our eligibility criteria. There is significant competition for recruiting
	cancer patients in clinical trials, and we may be unable to enroll the patients we need to complete clinical trials on a timely
	basis or at all. Certain factors that affect enrollment of patients onto our clinical trials are impacted by external forces that
	may be beyond our control. Such factors include, but are not limited to, the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	size and nature of the patient population;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	eligibility and exclusion criteria for the trial;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	design of the study protocol;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	competition with other companies for clinical sites or patients;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	the perceived risks and benefits of the product candidate under study;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	the patient referral practices of physicians; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	the number, availability, location and accessibility of clinical trial sites.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	If we are unable
	to successfully develop companion diagnostics for our therapeutic product candidates, or experience significant delays in doing
	so, we may not achieve marketing approval or realize the full commercial potential of our therapeutic product candidates.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We plan to develop
	companion diagnostics for our therapeutic product candidates. We expect that, at least in some cases, regulatory authorities may
	require the development and regulatory approval of a companion diagnostic as a condition to approving our therapeutic product candidates.
	We have limited experience and capabilities in developing or commercializing diagnostics and plan to rely in large part on third
	parties to perform these functions. We do not currently have any agreement in place with any third party to develop or commercialize
	companion diagnostics for any of our therapeutic product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	Companion diagnostics
	are subject to regulation by the FDA, Health Canada and comparable foreign regulatory authorities as medical devices and may require
	separate regulatory approval or clearance prior to commercialization. If we,&nbsp;or any third parties that we engage to assist
	us, are unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience delays in doing
	so, our business may be substantially harmed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We rely and will
	continue to rely on third parties to conduct and monitor many of our preclinical studies and our clinical trials, and their failure
	to perform as required could cause substantial harm to our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We rely and will continue
	to rely on third parties to conduct a significant portion of our preclinical and clinical development activities. Preclinical activities
	include in vivo studies providing access to specific disease models, pharmacology and toxicology studies, and assay development.
	Clinical development activities include trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring,
	clinical data management and analysis, safety monitoring and project management, contract manufacturing and quality assurance.
	If there is any dispute or disruption in our relationship with third parties, or if they are unable to provide quality services
	in a timely manner and at a feasible cost, our active development programs will face delays. Further, if any of these third parties
	fails to perform as we expect or if their work fails to meet regulatory requirements, our testing could be delayed, cancelled or
	rendered ineffective.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We heavily rely
	on the capabilities and experience of our key executives and scientists and the loss of any of them could affect our ability to
	develop our products.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	The loss of Dr.&nbsp;William
	G. Rice, our Chairman, President and Chief Executive Officer, or other key members of our staff, including Gregory Chow, our Senior
	Vice President and Chief Financial Officer, or Avanish Vellanki, our Senior Vice President and Chief Business Officer, could harm
	us. We have employment agreements with Dr. Rice and Mr. Chow and Mr. Vellanki, although such employment agreements do not guarantee
	their retention. We also depend on our scientific and clinical collaborators and advisors, all of whom have outside commitments
	that may limit their availability to us. In addition, we believe that our future success will depend in large part upon our ability
	to attract and retain highly skilled scientific, managerial, medical, clinical and regulatory personnel, particularly as we expand
	our activities and seek regulatory approvals for clinical trials. We routinely enter into consulting agreements with our scientific
	and clinical collaborators and advisors, key opinion leaders and academic partners in the ordinary course of our business. We also
	enter into contractual agreements with physicians and institutions who will recruit patients into our clinical trials on our behalf
	in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition for these types of
	personnel from other companies, research and academic institutions, government entities and other organizations. We cannot predict
	our success in hiring or retaining the personnel we require for continued growth. The loss of the services of any of our executive
	officers or other key personnel could potentially harm our business, operating results or financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Our employees may engage in misconduct
	or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse
	effect on our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We are exposed to the
	risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with FDA regulations, provide
	accurate information to the FDA, comply with manufacturing standards we have established, comply with federal and state health-care
	fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us.
	In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations
	intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit
	a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
	arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials,
	which could result in regulatory sanctions and serious harm to our reputation. If any such actions are instituted against us, and
	we are not successful in defending ourselves or asserting our rights, those actions could have a substantial impact on our business
	and results of operations, including the imposition of substantial fines or other sanctions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	Exchange rate risk
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We are exposed to fluctuations of the Canadian
	dollar against certain other currencies because we publish our consolidated financial statements and hold most of our investments
	in Canadian dollars, while we incur many of our expenses in foreign currencies, primarily the United States dollar. Fluctuations
	in the value of currencies such as the recent depreciation of the Canadian dollar against the United States dollar could cause
	us to incur currency exchange losses. We do not currently employ a hedging strategy against exchange rate risk. We cannot assert
	with any assurance that we will not suffer losses as a result of unfavorable fluctuations in the exchange rates between the Canadian
	dollar, the United States dollar and other currencies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We may expand our business through
	the acquisition of companies or businesses or by entering into collaborations or by in-licensing product candidates, each of which
	could disrupt our business and harm our financial condition.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We may in the future
	seek to expand our pipeline and capabilities by acquiring one or more companies or businesses, entering into collaborations or
	in-licensing one or more product candidates. For example, in November 2015, we licensed intellectual property from the Moffitt
	Cancer Center&nbsp;for exclusive global rights to potent, multi-targeting, single-agent inhibitors for the treatment of hematologic
	and solid tumor cancers.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	Acquisitions, collaborations and in-licenses
	involve numerous risks, including, but not limited to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	substantial cash expenditures;
</FONT>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	technology development risks;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	potentially dilutive issuances of equity securities;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	difficulties in assimilating the operations of the acquired companies;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	potential disputes regarding contingent consideration;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	diverting our management&rsquo;s attention away from other business concerns;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	entering markets in which we have limited or no direct experience;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&bull;
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	potential loss of our key employees or key employees of the acquired companies
	or businesses; and
</P>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&bull;
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	failure of the in-licenses agents or technologies to deliver the desired activities or functions.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We have experience
	in entering collaborations and in-licensing product candidates, however, we cannot provide assurance that any acquisition, collaboration
	or in-license will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
	company or business or in-licensed product candidate. In addition, our future success would depend in part on our ability to manage
	the rapid growth associated with some of these acquisitions, collaborations and in-licenses. We cannot assure you that we would
	be able to successfully combine our business with that of acquired businesses, manage a collaboration or integrate in-licensed
	product candidates. Furthermore, the development or expansion of our business may require a substantial capital investment by us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Negative results from clinical trials
	or studies of others and adverse safety events involving the targets of our products may have an adverse impact on our future commercialization
	efforts
</I>
</B>
	.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	From time to time,
	studies or clinical trials on various aspects of biopharmaceutical products are conducted by academic researchers, competitors
	or others. The results of these studies or trials, when published, may have a significant effect on the market for the biopharmaceutical
	product that is the subject of the study. The publication of negative results of studies or clinical trials or adverse safety events
	related to our product candidates, or the therapeutic areas in which our product candidates compete, could adversely affect our
	share price and our ability to finance future development of our product candidates, and our business and financial results could
	be materially and adversely affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	As a result of intense competition and
	technological change in the biotechnical and pharmaceutical industries, the marketplace may not accept our products or product
	candidates, and we may not be able to compete successfully against other companies in our industry and achieve profitability.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Many of our competitors have:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	drug products that have already been approved or are in development, and operate large, well-funded
	research and development programs in the biotechnical and pharmaceutical fields;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	substantially greater financial, technical and management resources, stronger intellectual property
	positions and greater manufacturing, marketing and sales capabilities, areas in which we have limited or no experience; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	significantly greater experience than we do in undertaking preclinical testing and clinical trials
	of new or improved pharmaceutical products and obtaining required regulatory approvals.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Consequently, our competitors may obtain FDA,
	Health Canada and other regulatory approvals for product candidates sooner and may be more successful in manufacturing and marketing
	their products than we or our collaborators are.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our competitor&rsquo;s existing and future products,
	therapies and technological approaches will compete directly with the products we seek to develop. Current and prospective competing
	products may be more effective than our existing and future products insofar as they may provide greater therapeutic benefits for
	a specific problem or may offer easier delivery or comparable performance at a lower cost.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Any product candidate that we develop and that
	obtains regulatory approval must then compete for market acceptance and market share. Our products may not gain market acceptance
	among physicians, patients, healthcare payers, insurers, the medical community and other stakeholders. Further, any products we
	develop may become obsolete before we recover any expenses we incurred in connection with the development of these products. As
	a result, we may never achieve profitability.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	We may be unable to obtain patents to
	protect our technologies from other companies with competitive products, and patents of other companies could prevent us from manufacturing,
	developing or marketing our products.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Patent protection
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The patent positions of pharmaceutical and biotechnology
	companies are uncertain and involve complex legal and factual questions. The United States Patent and Trademark Office and many
	other patent offices in the world have not established a consistent policy regarding the breadth of claims that they will allow
	in biotechnology patents.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our pending patent applications may not result
	in issued patents and our issued patents may not be held valid and enforceable if challenged. Competitors may be able to circumvent
	any such issued patents by adoption of a competitive, though non-infringing product or process. Interpretation and evaluation of
	pharmaceutical or biotechnology patent claims present complex and often novel legal and factual questions. Our business could be
	adversely affected by increased competition in the event that any patent granted to it is held to be invalid or unenforceable or
	is inadequate in scope to protect our operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Allowable patentable subject matter and the
	scope of patent protection obtainable may differ between jurisdictions. If a patent office allows broad claims, the number and
	cost of patent interference proceedings in the United States, or analogous proceedings in other jurisdictions and the risk of infringement
	litigation may increase. If it allows narrow claims, the risk of infringement may decrease, but the value of our rights under our
	patents, licenses and patent applications may also decrease.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The scope of the claims in a patent application
	can be significantly modified during prosecution before the patent is issued. Consequently, we cannot know whether our pending
	applications will result in the issuance of patents or, if any patents are issued, whether they will provide us with significant
	proprietary protection or will be circumvented, invalidated or found to be unenforceable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Publication of discoveries in scientific or
	patent literature often lags behind actual discoveries. Patent applications filed in the United States generally will be published
	18 months after the filing date unless the applicant certifies that the invention will not be the subject of a foreign patent application.
	In many other jurisdictions, such as Canada, patent applications are published 18 months from the priority date. We may not be
	aware of such literature. Accordingly, we cannot be certain that the named inventors of our products and processes were the first
	to invent that product or process or that we were the first to pursue patent coverage for our inventions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In addition, U.S. patent laws may change which
	could prevent or limit us from filing patent applications or patent claims in the United States to protect our products and technologies
	or limit the exclusivity periods that are available to patent holders for U.S. patents. For example, the Leahy-Smith America Invents
	Act, (the &ldquo;
<B>
	Leahy-Smith Act
</B>
	&rdquo;) was signed into law in 2011 and includes a number of significant changes to U.S.
	patent law. These include changes to transition from a &ldquo;first-to-invent&rdquo; system to a &ldquo;first-to-file&rdquo; system
	and to the way issued patents are challenged. These changes may favour larger and more established companies that have more resources
	to devote to patent application filing and prosecution. It is not clear what, if any, impact the Leahy-Smith Act will ultimately
	have on the cost of prosecuting our patent applications in the United States, our ability to obtain patents in the United States
	based on our discoveries and our ability to enforce or defend our U.S. issued patents.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Until such time, if ever, that further patents
	are issued to us, we will rely upon the law of trade secrets to the extent possible given the publication requirements under international
	patent treaty laws and/or requirements under foreign patent laws to protect our technology and our products incorporating the technology.
	In this regard, we have adopted certain confidentiality procedures. These include: limiting access to confidential information
	to certain key personnel; requiring all directors, officers, employees and consultants and others who may have access to our intellectual
	property to enter into confidentiality agreements which prohibit the use of or disclosure of confidential information to third
	parties; and implementing physical security measures designed to restrict access to such confidential information and products.
	Our ability to maintain the confidentiality of our technology is crucial to our ultimate possible commercial success. The procedures
	adopted by us to protect the confidentiality of our technology may not be effective, third parties may gain access to our trade
	secrets or disclose our confidential technology. Further, by seeking patent protection in various countries, it is inevitable that
	a substantial portion of our technology will become available to our competitors, through publication of such patent applications.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Enforcement of intellectual property rights
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Protection of the rights revealed in published
	patent applications can be complex, costly and uncertain. Our commercial success depends in part on our ability to maintain and
	enforce our proprietary rights. If third parties engage in activities that infringe our proprietary rights, our management&rsquo;s
	focus will be diverted and we may incur significant costs in asserting our rights. We may not be successful in asserting our proprietary
	rights, which could result in our patents being held invalid or a court holding that the third party is not infringing, either
	of which would harm our competitive position.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Others may design around our patented technology.
	We may have to participate in interference proceedings declared by the United States Patent and Trademark Office, European opposition
	proceedings, or other analogous proceedings in other parts of the world to determine priority of invention and the validity of
	patent rights granted or applied for, which could result in substantial cost and delay, even if the eventual outcome is favourable
	to us. Our pending patent applications, even if issued, may not be held valid or enforceable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Trade secrets
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We also rely on trade secrets, know-how and
	confidentiality provisions in our agreements with our collaborators, employees and consultants to protect our intellectual property.
	However, these and other parties may not comply with the terms of their agreements with us, and we might be unable to adequately
	enforce our rights or obtain adequate compensation for the damages caused by unauthorized disclosure or use of our trade secrets
	or know how. Our trade secrets or those of our collaborators also may be independently discovered by others.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	We may incur substantial cost in defending
	our intellectual property.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	While we believe that our products and technology
	do not infringe proprietary rights of others, third parties may assert infringement claims in the future and such claims could
	be successful. Even if challenges are unsuccessful, we could incur substantial costs in defending ourselves against patent infringement
	claims brought by others or in prosecuting suits against others. In addition, others may obtain patents that we would need to license,
	which may not be available to us on reasonable terms. Whether we are able to obtain a necessary license would depend on the terms
	offered, the degree of risk of infringement and the need for the patent.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	Our products and product candidates may
	infringe the intellectual property rights of others, or others may infringe on our intellectual property rights which could increase
	our costs.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our success also depends on avoiding infringement
	of the proprietary technologies of others. In particular, there may be certain issued patents and patent applications claiming
	subject matter which we or our collaborators may be required to license in order to research, develop or commercialize APTO-253,
	our lead product candidate. In addition, third parties may assert infringement or other intellectual property claims against us.
	An adverse outcome in these proceedings could subject us to significant liabilities to third-parties, require disputed rights to
	be licensed from third-parties or require us to cease or modify our use of the technology. If we are required to license third-party
	technology, a license under such patents and patent applications may not be available on acceptable terms or at all. Further, we
	may incur substantial costs defending ourselves in lawsuits against charges of patent infringement or other unlawful use of another&rsquo;s
	proprietary technology. We may also need to bring claims against others who we believe are infringing our rights in order to become
	or remain competitive and successful. Any such claims can be time consuming and expensive to pursue.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	If product liability, clinical trial liability
	or environmental liability claims are brought against us or we are unable to obtain or maintain product liability, clinical trial
	or environmental liability insurance, we may incur substantial liabilities that could reduce our financial resources.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The clinical testing and commercial use of pharmaceutical
	products involves significant exposure to product liability, clinical trial liability, environmental liability and other risks
	that are inherent in the testing, manufacturing and marketing of our products. These liabilities, if realized, could have a material
	adverse effect on the Company&rsquo;s business, results of operations and financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have obtained limited product liability insurance
	coverage for our clinical trials on humans; however, our insurance coverage may be insufficient to protect us against all product
	liability damages. Regardless of merit or eventual outcome, liability claims may result in decreased demand for a future product,
	injury to reputation, withdrawal of clinical trial volunteers, loss of revenue, costs of litigation, distraction of management
	and substantial monetary awards to plaintiffs. Additionally, if we are required to pay a product liability claim, we may not have
	sufficient financial resources to complete development or commercialization of any of our product candidates and our business and
	results of operations will be adversely affected. In general, insurance will not protect us against some of our own actions, such
	as negligence.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As the Company&rsquo;s development activities
	progress towards the commercialization of product candidates, our liability coverage may not be adequate, and the Company may not
	be able to obtain adequate product liability insurance coverage at a reasonable cost, if at all. Even if the Company obtains product
	liability insurance, its financial position may be materially adversely affected by a product liability claim. A product liability
	claim could also significantly harm the Company&rsquo;s reputation and delay market acceptance of its product candidates. Additionally,
	product recalls may be issued at the direction of the FDA, other government agencies or other companies having regulatory control
	for pharmaceutical sales. If a product recall occurs in the future, such a recall could adversely affect our business, financial
	condition or reputation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	We may be unable to obtain partnerships
	for our product candidates, which could curtail future development and negatively affect our share price. In addition, our partners
	might not satisfy their contractual responsibilities or devote sufficient resources to our partnership.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our strategy for the research, development and
	commercialization of our products requires entering into various arrangements with corporate collaborators, licensors, licensees
	and others, and our commercial success is dependent upon these outside parties performing their respective contractual responsibilities.
	The amount and timing of resources that such third parties will devote to these activities may not be within our control. These
	third parties may not perform their obligations as expected and our collaborators may not devote adequate resources to our programs.
	In addition, we could become involved in disputes with our collaborators, which could result in a delay or termination of the related
	development programs or result in litigation. We intend to seek additional collaborative arrangements to develop and commercialize
	some of our products. We may not be able to negotiate collaborative arrangements on favourable terms, or at all, in the future,
	and our current or future collaborative arrangements may not be successful.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If we cannot negotiate collaboration, license
	or partnering agreements, we may never achieve profitability and we may not be able to continue to develop our product candidates.
	Phase II and Phase III clinical trials for APTO-253 would require significant amounts of funding and such funding may not be available
	to us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Extensive Government Regulation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Government regulation is a significant factor
	in the development, production and marketing of the Company&rsquo;s products. Research and development, testing, manufacture, marketing
	and sales of pharmaceutical products or related products are subject to extensive regulatory oversight, often in multiple jurisdictions,
	which may cause significant additional costs and/or delays in bringing products to market, and in turn, may cause significant losses
	to investors. The regulations applicable to the Company's product candidates may change. Even if granted, regulatory approvals
	may include significant limitations on the uses for which products can be marketed or may be conditioned on the conduct of post-marketing
	surveillance studies. Failure to comply with applicable regulatory requirements can, among other things, result in warning letters,
	the imposition of civil penalties or other monetary payments, delay in approving or refusal to approve a product candidate, suspension
	or withdrawal of regulatory approval, product recall or seizure, operating restrictions, interruptions of clinical trials or manufacturing,
	injunctions or criminal prosecution. In addition, regulatory agencies many not approve the labeling claims that are necessary or
	desirable for the successful commercialization of the Company&rsquo;s product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Requirements for regulatory approval vary widely
	from country to country. Whether or not approved in Canada or the United States, regulatory authorities in other countries must
	approve a product prior to the commencement of marketing the product in those countries. The time required to obtain any such approval
	may be longer or shorter than in Canada or the United States. Approved drugs, as well as their manufacturers, are subject to continuing
	and ongoing review, and discovery of problems with these products or the failure to adhere to manufacturing or quality control
	requirements may result in regulatory restrictions being imposed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Risks Related to Our Common Shares
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	Our share price has been and is likely
	to continue to be volatile and an investment in our Common Shares could suffer a decline in value.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	You should consider an investment in our Common
	Shares as risky and invest only if you can withstand a significant loss and wide fluctuations in the market value of your investment.
	The market price of our Common Shares has been highly volatile and is likely to continue to be volatile.
<B>
</B>
	This leads to a
	heightened risk of securities litigation pertaining to such volatility.
<B>
</B>
	Factors affecting our Common Share price include
	but are not limited to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to raise additional capital;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	the progress of our clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	our ability to obtain partners and collaborators to
	assist with the future development of our products;
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	general market conditions;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	announcements of technological innovations or new product candidates by us, our collaborators
	or our competitors;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	published reports by securities analysts;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	developments in patent or other intellectual property rights;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the cash and investments held by us and our ability to secure future financing;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	public concern as to the safety and efficacy of drugs that we and our competitors
	develop;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	shareholder interest in our Common Shares; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	low liquidity in the daily trading volume of our Common Shares.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	Future sales of our Common Shares by us
	or by our existing shareholders could cause our share price to fall.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The issuance of Common Shares by us could result
	in significant dilution in the equity interest of existing shareholders and adversely affect the market price of our Common Shares.
	Sales by existing shareholders of a large number of our Common Shares in the public market and the issuance of shares issued in
	connection with strategic alliances, or the perception that such additional sales could occur, could cause the market price of
	our Common Shares to decline and have an undesirable impact on our ability to raise capital.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	We are susceptible to stress in the global
	economy and therefore, our business may be affected by the current and future global financial condition.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If the increased level of volatility and market
	turmoil that have marked recent years continue, our operations, business, financial condition and the trading price of our Common
	Shares could be materially adversely affected. Furthermore, general economic conditions may have a great impact on us, including
	our ability to raise capital, our commercialization opportunities and our ability to establish and maintain arrangements with others
	for research, manufacturing, product development and sales.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	An active trading market in our Common
	Shares may not be sustained.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our Common Shares are listed for trading on
	the NASDAQ Capital Market (&ldquo;
<B>
	NASDAQ
</B>
	&rdquo;) and the Toronto Stock Exchange (&ldquo;
<B>
	TSX
</B>
	&rdquo;). However, an
	active trading market in our Common Shares on the stock exchanges may not be sustained and we may not be able to maintain our listings.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	It may be difficult for non-Canadian investors
	to obtain and enforce judgments against us because of our Canadian incorporation and presence.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We are a corporation existing under the laws
	of Canada. Some of our directors and officers, and many of the experts named in this Annual Report and the documents incorporated
	by reference into this Annual Report, are residents of Canada, and all or a substantial portion of their assets, and a substantial
	portion of our assets, are located outside the United States. Consequently, although we have appointed an agent for service of
	process in the United States, it may be difficult for holders of our shares who reside in the United States to effect service within
	the United States upon our directors and officers and experts who are not residents of the United States. It may also be difficult
	for holders of our shares who reside in the United States to realize in the United States upon judgments of courts of the United
	States predicated upon our civil liability and the civil liability of our directors, officers and experts under the United States
	federal securities laws. Investors should not assume that Canadian courts (i) would enforce judgments of United States courts obtained
	in actions against us or our directors, officers or experts predicated upon the civil liability provisions of the United States
	federal securities laws or the securities or &ldquo;blue sky&rdquo; laws of any state within the United States or (ii) would enforce,
	in original actions, liabilities against us or our directors, officers or experts predicated upon the United States federal securities
	laws or any such state securities or &ldquo;blue sky&rdquo; laws. In addition, we have been advised by our Canadian counsel that
	in normal circumstances, only civil judgments and not other rights arising from United States securities legislation are enforceable
	in Canada and that the protections afforded by Canadian securities laws may not be available to investors in the United States.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	We are likely a &ldquo;passive foreign
	investment company&rdquo; which may have adverse U.S. federal income tax consequences for U.S. shareholders.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	U.S. investors in our Common Shares should be
	aware that the Company believes it was classified as a passive foreign investment company (&ldquo;
<B>
	PFIC
</B>
	&rdquo;) during the
	tax year ended December 31, 2015, and based on the nature of our business, the projected composition of our gross income and the
	projected composition and estimated fair market value of our assets, the Company expects to be a PFIC for the current tax year
	ending December 31, 2016 and may be a PFIC in subsequent tax years. If the Company is a PFIC for any year during a U.S. shareholder&rsquo;s
	holding period, then such U.S. shareholder generally will be required to treat any gain realized upon a disposition of Common Shares,
	or any so-called &ldquo;excess distribution&rdquo; received on its Common Shares, as ordinary income, and to pay an interest charge
	on a portion of such gain or distributions, unless the shareholder makes a timely and effective &ldquo;qualified electing fund&rdquo;
	election (&ldquo;
<B>
	QEF election
</B>
	&rdquo;) or a &ldquo;mark-to-market&rdquo; election with respect to the Common Shares. A U.S.
	shareholder who makes a QEF election generally must report on a current basis its share of the Company&rsquo;s net capital gain
	and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders.
	However, U.S. shareholders should be aware that we do not intend to satisfy record keeping requirements that apply to a qualified
	electing fund, and we do not intend to supply U.S. shareholders with information that such U.S. shareholders require to report
	under the QEF election rules, in the event that we are a PFIC and a U.S. shareholder wishes to make a QEF election. Thus, U.S.
	shareholders should assume that they will not be able to make a QEF election with respect to their Common Shares. A U.S. shareholder
	who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of
	the Common Shares over the taxpayer&rsquo;s basis therein. This paragraph is qualified in its entirety by the discussion below
	under the heading &ldquo;Certain United States Federal Income Tax Considerations.&rdquo; Each U.S. shareholder should consult its
	own tax advisor regarding the U.S. federal, U.S. local, and foreign tax consequences of the PFIC rules and the acquisition, ownership,
	and disposition of our Common Shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We are an &ldquo;emerging growth company,&rdquo;
	and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common shares
	less attractive to investors.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We are an &ldquo;emerging
	growth company,&rdquo; as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we continue
	to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to
	other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation
	requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in
	our periodic reports and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
	approval of any golden parachute payments not previously approved.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We will cease to be
	an emerging growth company upon the earliest of:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; FONT-SIZE: 10PT">
	the last day of the fiscal year during
	which we have total annual gross revenues of $1,000,000,000 (as such amount is indexed for inflation every five years by the SEC
	or more;
<BR>
<BR>
</LI>
<LI STYLE="MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; FONT-SIZE: 10PT">
	the last day of our fiscal year following
	the fifth anniversary of the completion of our first sale of common equity securities pursuant to an effective registration statement
	under the Securities Act;
<BR>
<BR>
</LI>
<LI STYLE="MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; FONT-SIZE: 10PT">
	the date on which we have, during the
	previous three-year period, issued more than $1,000,000,000 in non- convertible debt; or
<BR>
<BR>
</LI>
<LI STYLE="MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; FONT-SIZE: 10PT">
	the date on which we are deemed to be
	a &ldquo;large accelerated filer&rdquo;, as defined in Rule 12b&ndash;2 of the Exchange Act, which would occur if the market value
	of our ordinary shares and ADSs that are held by non-affiliates exceeds $700,000,000 as of the last day of our most recently-completed
	second fiscal quarter.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We cannot predict
	if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our Common
	Shares less attractive as a result, there may be a less active trading market for our Common Shares and our share price may be
	more volatile.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Any failure to maintain an effective
	system of internal controls may result in material misstatements of our consolidated financial statements or cause us to fail to
	meet our reporting obligations or fail to prevent fraud; and in that case, our shareholders could lose confidence in our financial
	reporting, which would harm our business and could negatively impact the price of our common shares.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	Section 404(a) of the
	Sarbanes-Oxley Act of 2002, as amended, or SOX, requires that our management assess and report annually on the effectiveness of
	our internal controls over financial reporting and identify any material weaknesses in our internal controls over financial reporting.
	Although Section 404(b) of the SOX requires our independent registered public accounting firm to issue an annual report that addresses
	the effectiveness of our internal controls over financial reporting, we have opted to rely on the exemptions provided to us by
	virtue of being a foreign private issuer and an emerging growth company, and consequently will not be required to comply with SEC
	rules that implement Section 404(b) of SOX until we lose our emerging growth company status.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	Effective internal
	controls are necessary for us to provide reliable financial reports and prevent fraud. If we fail to maintain an effective system
	of internal controls, we might not be able to report our financial results accurately or prevent fraud; and in that case, our shareholders
	could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our common
	shares. While we believe that we have sufficient personnel and review procedures to allow us to maintain an effective system of
	internal controls, we cannot assure you that we will not experience potential material weaknesses in our internal control. Even
	if we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial
	reporting and the preparation of consolidated financial statements for external purposes in accordance with IFRS, as issued by
	the International Accounting Standards Board, because of its inherent limitations, internal control over financial reporting may
	not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered
	in their implementation, could harm our results of operations or cause us to fail to meet our future reporting obligations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	If we fail to timely
	achieve and maintain the adequacy of our internal control over financial reporting, we may not be able to produce reliable financial
	reports or help prevent fraud. Our failure to achieve and maintain effective internal control over financial reporting could prevent
	us from complying with our reporting obligations on a timely basis, which could result in the loss of investor confidence in the
	reliability of our consolidated financial statements, harm our business and negatively impact the trading price of our common shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	As a foreign private issuer, we are
	not subject to certain United States securities law disclosure requirements that apply to a domestic United States issuer, which
	may limit the information which would be publicly available to our shareholders.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	As a foreign private
	issuer, we are exempt from certain rules under the Exchange Act that impose disclosure requirements as well as procedural requirements
	for proxy solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and principal shareholders are
	exempt from the reporting and &ldquo;short-swing&rdquo; profit recovery provisions of Section 16 of the Exchange Act. Moreover,
	we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as a company that
	files as a domestic issuer whose securities are registered under the Exchange Act, nor are we generally required to comply with
	the SEC&rsquo;s Regulation FD, which restricts the selective disclosure of material non-public information. For as long as we are
	a &ldquo;foreign private issuer&rdquo; we intend to file our annual financial statements on Form 20-F and furnish our quarterly
	updates on Form 6-K to the SEC for so long as we are subject to the reporting requirements of Section 13(g) or 15(d) of the Exchange
	Act. However, the information we file or furnish is not the same as the information that is required in annual and quarterly reports
	on Form 10-K or Form 10-Q for U.S. domestic issuers. Accordingly, there may be less information publicly available concerning us
	than there is for a company that files as a domestic issuer.
</P>
</EFX_KEY_INFORMATION>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_COMPANY_INFORMATION>
<A NAME="FIS_COMPANY_INFORMATION"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<A NAME="F20F_032916_HTM_I4">
</A>
<B>
	Item 4. Information
	on the Company
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	History and development of the Company
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Old Lorus was incorporated under the
<I>
	Business
	Corporations Act
</I>
	(Ontario) on September 5, 1986 under the name RML Medical Laboratories Inc. On October 28, 1991, RML Medical
	Laboratories Inc. amalgamated with Mint Gold Resources Ltd., resulting in Old Lorus becoming a reporting issuer (as defined under
	applicable securities law) in Ontario, on such date. On August 25, 1992, Old Lorus changed its name to IMUTEC Corporation. On November
	27, 1996, Old Lorus changed its name to Imutec Pharma Inc., and on November 19, 1998, Old Lorus changed its name to Lorus Therapeutics
	Inc. On October 1, 2005, Old Lorus continued under the
<I>
	Canada Business Corporations Act
</I>
	.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On the Arrangement Date, Old Lorus completed
	a plan of arrangement and corporate reorganization with, among others, 6650309 Canada Inc. (&ldquo;
<B>
	New Lorus
</B>
	&rdquo;), 6707157
	Canada Inc. and Pinnacle International Lands, Inc. As a result of the plan of arrangement and reorganization, each Common Share
	of Old Lorus was exchanged for one Common Share of New Lorus. New Lorus continued the business of Old Lorus after the Arrangement
	Date with the same officers and employees and continued to be governed by the same board of directors as Old Lorus prior to the
	Arrangement Date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On August 28, 2014, New Lorus changed its name
	from Lorus Therapeutics Inc. to Aptose Biosciences Inc. and on October 1, 2014 we consolidated our outstanding Common Shares on
	the basis of one post-consolidation Common Share for each twelve pre-consolidation Common Shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The address of the Company&rsquo;s head and
	registered office is 5955 Airport Road Suite #228, Mississauga, Ontario, Canada, L4V 1R9 and our phone number is (647) 479-9828.
	Our corporate website is www.aptose.com. The contents of the website and items accessible through the website are specifically
	not incorporated in this Annual Report by reference.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Aptose has three subsidiaries: Aptose Biosciences
	U.S. Inc. (&ldquo;
<B>
	Aptose USA
</B>
	&rdquo;), a company incorporated under the laws of Delaware, USA, Aptose Suisse GmbH (&ldquo;
<B>
	Aptose
	Suisse
</B>
	&rdquo;) a company incorporated under the laws of Zug, Switzerland and NuChem Pharmaceuticals Inc. (&ldquo;
<B>
	NuChem
</B>
	&rdquo;),
	a company incorporated under the laws of Ontario, Canada. Aptose owns 100% of the issued and outstanding voting share capital of
	Aptose USA and Aptose Suisse and 80% of the issued and outstanding voting share capital of NuChem.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our Common Shares are listed on the NASDAQ under
	the symbol &ldquo;APTO&rdquo; and on the TSX under the symbol &ldquo;APS&rdquo;.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Aptose is a clinical stage biotechnology company
	with a commitment to the development of targeted therapies addressing unmet medical needs in oncology. We develop therapeutics
	focused on epigenetic processes and signal transduction abnormalities at the leading edge of cancer research, coupled with companion
	diagnostics to identify the optimal patient population for our products. Our product pipeline includes cancer drug candidates that
	exert potent activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping
	toxicities. Indeed, we believe our targeted products can emerge as first-in-class or best-in-class agents that deliver single agent
	benefit and can serve as the backbone of combination therapies for specific populations of cancer patients.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We believe the future of cancer treatment and
	management lies in the prospective selection and treatment of patients having malignancies that are genetically or epigenetically
	predisposed to response based on a drug&rsquo;s unique mechanism of action. We are of the view that many drugs currently approved
	for the treatment and management of cancer are not selective for the specific genetic alterations (targets) that cause the patient&rsquo;s
	tumor and hence lead to significant toxicities due to off-target effects. Aptose&rsquo;s strategy is to develop agents that address
	a common underlying disease-promoting pathway within a patient population, and we intend to apply this strategy across several
	therapeutic indications in oncology, including hematologic malignancies and solid tumor indications. Our lead program, APTO-253,
	is a first-in-class inducer of the Kr&uuml;ppel-like factor 4 gene (the &ldquo;
<B>
	Klf4 Gene
</B>
	&rdquo;) for patients with advanced
	hematologic malignancies, including acute myeloid leukemia (&ldquo;
<B>
	AML
</B>
	&rdquo;) and myelodysplastic syndromes (&ldquo;
<B>
	MDS
</B>
	&rdquo;).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table sets forth various product
	conditions in our pipeline and their respective stages of development.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<U>
	APTOSE PROGRAM PIPELINE
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001171843-16-008903_PIPELINE.JPG" ALT="">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Capital Expenditures and Divestitures
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Business overview
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As noted above, Aptose is committed to the development
	of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular
	life-threatening malignancy. This targeted approach is intended to impact the disease-causing events in cancer cells without affecting
	normal processes within cells. Such an approach requires that we first identify the underlying oncogenic mechanism in particular
	cancer cells and then create a therapeutic that selectively impacts that oncogenic mechanism. As described below, an underlying
	oncogenic process has been identified as operative in the majority of patients with AML (acute myeloid leukemia), an aggressive
	cancer of the blood and bone marrow for which there is a tremendous need for safe and effective anticancer drugs. Aptose has created
	a small molecule targeted drug (APTO-253) that selectively impacts that underlying oncogenic process, and the drug is under development
	as a novel therapy for AML and the related MDS.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<U>
	APTO-253
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	APTO-253 is a novel small molecule that can
	induce expression of the genes that codes for the Kr&uuml;ppel-like factor 4 (KLF4) master transcription factor and the p21 cell
	cycle inhibitor protein, and can inhibit expression of the c-Myc oncogene, leading to cell cycle arrest and programmed cell death
	(apoptosis) in human-derived solid tumor and hematologic cancer cells.&nbsp; Likewise, in nonclinical pharmacology studies APTO-253
	demonstrates in vivo anti-tumor activity against xenograft models of solid tumors and hematologic cancers, with acute myeloid leukemia
	(AML) cells exhibiting a particular sensitivity to APTO-253. &nbsp;A Phase 1 study with APTO-253 in patients with advanced solid
	tumors was completed in mid-2013. That trial, which employed a suboptimal dosing schedule, demonstrated modest clinical activity
	in the all-comer solid tumor patient population.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The vast majority of patients with AML are reported
	to exhibit inappropriate activation of the CDX2 gene and resultant epigenetic down-regulation (silencing) of KLF4 expression, as
	well as inappropriate upregulation of c-Myc as key leukemogenic events. Aptose scientists performed RT-qPCR expression analysis
	of KLF4 and CDX2 levels in normal PBMC and AML cell lines and confirmed the silencing of KLF4 expression and elevated expression
	of CDX2 in AML cells, and multiple publications have reported the elevation of c-Myc oncogene expression in AML cells. In addition
	to AML, similar roles for KLF4 silencing and c-Myc upregulation have been reported in subpopulations of adult T-cell leukemia,
	lymphoma, multiple myeloma and high-risk MDS. &nbsp;Induction of KLF4 expression and suppression of c-Myc by APTO-253 may therefore
	be an effective therapeutic approach in these patient populations.&nbsp; Because of the robust scientific evidence linking KLF4
	silencing and c-Myc upregulation to cellular transformation in hematologic malignancies, Aptose undertook an ongoing Phase 1b clinical
	study with escalating doses of APTO-253 followed by two planned disease-specific expansions in adults with hematologic malignancies.
	This Phase 1b trial is currently on clinical hold (see discussion below).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Preclinical In Vitro Evaluation of APTO-253
<BR>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	APTO-253 demonstrated potent and selective in
	vitro antiproliferative activity against a variety of leukemia cell lines, including AML, ALL and chronic myeloid leukemia (CML),
	as well as non-Hodgkin&rsquo;s lymphoma (NHL) cell lines, with IC50 values ranging from ~0.007 &ndash; 0.3 &micro;M. These hematologic
	cell lines appeared to be far more sensitive to APTO-253 than the solid tumor cell lines, including colon cancer, non-small cell
	lung cancer (NSCLC), prostate cancer and melanoma, which exhibited IC50 values of ~0.04&ndash; 2.6 &micro;M, which had previously
	served to support the completed Phase 1 solid tumor study.&nbsp;&nbsp;However, new insights from academic publications into the
	significance of KLF4 suppression in patients with hematologic malignancies appear to be broadly corroborated by these data.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	APTO-253 Induces Expression of the KLF4 Gene
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Inappropriate expression of CDX2 in AML cells
	results in epigenetic silencing of the KLF4 gene and subsequent downstream silencing of the pro-apoptotic p21 gene. To characterize
	the effect of APTO-253 treatment of AML cells, the levels of CDX2, KLF4 and p21 gene expression were measured as a function of
	the concentration of APTO-253 and as a function treatment time. As shown in Figure 3, KLF4 and p21 gene expression increased in
	cells treated with APTO-253, while there was no change in the levels of CDX2 expression.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001171843-16-008903_APTOEFFECT.JPG" ALT="">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="COLOR: #943634">
	APTO-253 Induces Expression of KLF4 and p21
</FONT>
<FONT STYLE="COLOR: #C00000">
<B>
	.
</B>
<I>
</I>
</FONT>
<I>
	The MV4-11 AML cell line was treated with the indicated concentrations of APTO-253 or Vehicle for 24 hours (left
	panel) or with 500 nM APTO-253 or Vehicle for the indicated period of time (right panel) and the expression of KLF4, p21 and CDX2
	mRNA levels were determined by qRT-PCR.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Because AML cells are known to exhibit extreme
	epigenetic plasticity and to have inappropriate expression of the c-Myc oncogene, we queried if APTO-253 might also inhibit the
	expression of c-Myc. Indeed, APTO-253 induced a dose-dependent inhibition of c-Myc mRNA expression in three different AML cell
	lines, and caused reductions in the c-Myc protein. In a time course assay, APTO-253 induces the simultaneous induction of the KLF4
	gene and the suppression of the c-Myc gene in AML cells. Moreover, in studies conducted to evaluate apoptotic events, AML cells
	treated with APTO-253 displayed changes in apoptotic markers, including high level induction of caspase-3 activity.&nbsp; APTO-253-treated
	AML cells demonstrated a high percentage of apoptotic (Annexin V-positive) cells that correlated with drug concentration. Together,
	these preclinical studies demonstrate that APTO-253 can affect critical oncogenic process (expression of KLF4, c-Myc and p21 genes)
	which should lead to programmed cell death in AML cells.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT 0 0PT 1.3IN; FONT-SIZE: 10PT; FONT-STYLE: ITALIC; FONT-WEIGHT: BOLD; TEXT-INDENT: -1.3IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	Phase
	Ib Trial
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0 0PT 1.3IN; FONT-SIZE: 10PT; FONT-STYLE: ITALIC; FONT-WEIGHT: BOLD; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	On July 28, 2014, we
	announced that the U.S. FDA had completed its review and cleared the Investigational New Drug (&ldquo;
<B>
	IND
</B>
	&rdquo;) application
	of APTO-253 for the treatment of hematologic malignancies, including AML, high-risk MDS, lymphomas and multiple myeloma. The Phase
	Ib trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamic responses and efficacy of APTO-253 as a single agent.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	For the study, a modified
	dose schedule was selected, such that APTO-253 is being administered on the first two days of each 7-day dosing period of a 28-day
	cycle (i.e., days 1, 2, 8, 9, 15, 16, 22, 23).&nbsp; This results in lower per-administration dose levels to provide the same overall
	exposure per cycle achieved in the prior Phase 1 solid tumor study, and to more consistently achieve the minimum exposure levels
	at the end of each dosing period that may be important for efficacy.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-SIZE: 10PT">
	Approximately
	15 patients will be enrolled in each of two arms of the dose escalation phase of the study: arm (A) will include patients with
	acute leukemias (including AML) and high-risk myelodysplastic syndromes, or
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	MDS; arm (B) will
	include patients with lymphomas (Hodgkin&rsquo;s and non-Hodgkin&rsquo;s Lymphoma) and multiple myeloma, followed by enrollment
	of an additional 15 patients in each of two disease-specific expansion cohorts, for a total estimated enrollment of 60 patients.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	The primary objectives
	of the Phase Ib trial are: (i) to further assess safety on a new and optimized dosing schedule, and (ii) to identify the recommended
	dose for APTO-253 for the upcoming Phase Ib single-agent expansion trials which will include one expansion in AML for up to 15
	patients and one expansion in MDS for up to 15 patients, in hematologic malignancies as well as in subsequent Phase 2 combination
	trials.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We plan to monitor
	patient Kr&uuml;ppel-like factor 4 (&ldquo;
<B>
	KLF4
</B>
	&rdquo;) and the product of the embryonic Cdx2 Gene, the CDX2 Protein levels
	upon entry into the study, throughout the study, and during a post-treatment period. We will not exclude patients based on KLF4
	or CDX2 status from participating in this first study as we believe this approach may be useful in further validating our companion
	diagnostic and observing potential responses among the broader population.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	For future development,
	upon selection of a lead hematologic indication from this Phase 1b study, combination of APTO-253 with a standard therapy will
	be considered.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
	Indications for APTO-253 Clinical Studies
</B>
<BR>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	APTO-253 is being administered to patients who have any of the
	following hematologic malignancies that have failed standard therapies.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; BACKGROUND-COLOR: WHITE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Acute leukemias (including AML, but not including acute promyelocytic leukemia)
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; BACKGROUND-COLOR: WHITE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	High-risk MDS syndromes
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; BACKGROUND-COLOR: WHITE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Lymphoma (Hodgkin&rsquo;s and Non-Hodgkin&rsquo;s)
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; BACKGROUND-COLOR: WHITE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Multiple myeloma
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	Upon completion of
	the dose-escalation stage of the study and determination of the recommended Phase 2 dose (RP2D), two hematologic cancer indications
	will be selected from those indications studied in the dose-escalation phase, for enrollment in two disease-specific single-agent
	expansion cohorts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
	Clinical Hold and Current Status
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	We announced in November
	2015 that the&nbsp;Food and Drug Administration&nbsp;(FDA), following a voluntary suspension of dosing by us and discussions with
	us, placed our Phase Ib clinical trial of APTO-253 in patients with hematologic cancers on clinical hold. This hold was intended
	to ensure patient safety within the trial and to ensure manufacturing and dosing procedures are consistent with the appropriate
	documented quality standards.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	The voluntary suspension
	of dosing by Aptose was initiated as a result of a preliminary review, which was accelerated to evaluate manufacturing processes
	and procedures upon the report of an operational difficulty with an IV infusion pump at a clinical site. The pump experienced back
	pressure during IV patient dosing at the point of the filter. Further review discovered preliminary concerns regarding the documentation
	records of the manufacturing procedures of the drug product associated with APTO-253. A complete safety review of all patient files
	had been completed prior to initial discovery of the manufacturing documentation irregularities, and there have been no drug-related
	serious adverse events (SAEs) reported. The observed pharmacokinetic levels in the patients treated were within the expected range.
	Thus, the clinical hold is based on a manufacturing issue and is not related to safety, efficacy or pharmacokinetics.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<FONT STYLE="COLOR: WINDOWTEXT">
	Currently,
	Aptose is guiding a qualified CMO to introduce new procedures to formulate APTO-253 into a drug product that is safe and stable,
	and which should not result in filter clogging events in the future.
</FONT>
	The CMO now has manufactured new GMP batches of the
	API to provide material for formulation studies and to supply the clinical trials into the future. Aptose also qualified a separate
	CMO with expertise in liquid formulations to perform formulation development studies and to manufacture the final form of the
	drug product for return to the clinic. The CMO has performed numerous formulation studies using a variety of methodologies and
	is now evaluating their solubility and stability over time to select the best methodology to manufacture the new batch of drug
	product to take to the FDA.
<FONT STYLE="COLOR: WINDOWTEXT">
	In order to have the clinical hold lifted and to return APTO-253
	to the clinical trial, Aptose must articulate the root cause of the filter clogging incident to the FDA and demonstrate to the
	FDA that a newly manufactured batch of GMP-grade APTO-253 drug substance has been formulated and is unlikely to cause such incidents
	in the future. The ultimate decisions regarding the lift of the clinical hold, the appropriateness of the new drug product, and
	the starting dose for the trial will reside with the FDA.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Biomarker Strategy for APTO-253 in a Clinical Setting
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Previous basic research studies have utilized RT-qPCR analyses of
	CDX2, KLF4 and p21 transcripts in AML cell lines and the primary blood cells of AML patients (Scholl et al., 2007; Faber et al.,
	2013).&nbsp; Aptose has now optimized the RT-qPCR reagents and procedures for measurement of the CDX2, KLF4 and p21 mRNA expression
	levels in human AML cells. Consequently, analytically validated RT-qPCR assays for the relative quantification of CDX2, KLF4 and
	p21 transcripts may be used to select patients expected to be most sensitive for response to APTO-253 therapy. &nbsp;In addition,
	these assays may be used to monitor on-treatment responses.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Biopsies are collected from lymphoma patients
	that are enrolled in the clinical trial.&nbsp; Blood and bone marrow are collected from AML patients and bone marrow aspirates
	are collected from MDS patients.&nbsp; FFPE core needle biopsy tissue and CD34+ cell pellets derived from blood and bone marrow
	will be used for gene expression profiling.&nbsp; A RT-qPCR method is being developed, optimized and validated for the analysis
	of CDX2, KLF4 and p21 target transcripts and appropriate reference gene transcripts in the samples collected from patients enrolled
	in the clinical trial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	BEAT AML Preclinical Studies of APTO-253 Against Patient Isolates
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On September 29, 2014, we announced, along with
	the Knight Cancer Institute at Oregon Health &amp; Science University (OHSU) and The Leukemia &amp; Lymphoma Society (LLS) that
	we entered into a formal collaboration with the Beat AML initiative. Beat AML is a groundbreaking research initiative that includes
	industry and academic collaborators led by top scientists within the Knight Cancer Institute in collaboration with The Leukemia
	&amp; Lymphoma Society. Its goal is to accelerate development of potential therapies for AML.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	During the 2015 American Society of Hematology
	(ASH) Conference, Aptose&rsquo;s collaborators at OHSU&rsquo;s Knight Cancer Institute presented preclinical data on APTO-253
	that are derived from our participation in the Beat AML Initiative with Dr. Brian Druker. The poster presentation was entitled
	&ldquo;
<FONT STYLE="COLOR: #9B1931; BACKGROUND-COLOR: WHITE">
<I>
	Broad Activity of APTO-253 in AML and Other Hematologic Malignancies
	Correlates with KLF4 Expression Level
</I>
</FONT>
	&rdquo;. The Beat AML initiative, a groundbreaking initiative that was formed
	in collaboration with The Leukemia &amp; Lymphoma Society and the Knight Cancer Institute, has allowed Aptose to evaluate the
	effect of APTO-253, alone or in combination with other anti-cancer agents, in fresh bone marrow isolates from patients with AML,
	myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In the 2015 OHSU ASH presentation, researchers
	used a range of doses, from low nanomolar to ten micromolar, and found that APTO-253 killed AML cells at an IC50 of less than 1uM
	in a significant number of AML patient samples, with a trend toward correlation with baseline KLF4 expression level. Moreover,
	APTO-253 demonstrated enhanced killing of AML patient samples when combined with two other therapeutic strategies, the BET bromodomain
	inhibitor JQ1 and the FLT3 inhibitor quizartinib. Such data support the development of APTO-253 for the treatment of AML, support
	the role of KLF4 in the mechanism of action of APTO-253, and support the ultimate use of APTO-253 in combination with other high
	profile drugs under development for the treatment of AML. OHSU continues to evaluate APTO-253 in additional samples across AML
	and other hematologic malignancies, along with other novel therapeutic combinations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Acute Myeloid Leukemia
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	AML is a rapidly progressing cancer of the blood
	and bone marrow characterized by the uncontrolled proliferation of dysfunctional myeloblasts that do not mature into healthy blood
	cells. It is the most common form of acute leukemia in adults. The American Cancer Society estimates there will be approximately
	19,950 new cases of AML and approximately 10,430 deaths from AML in the U.S. in 2016.&nbsp;Standard induction therapy with chemotherapy
	is successful in many AML patients, but the majority of these patients will relapse with treatment refractory disease. The average
	age of a patient with AML is 67 years. &nbsp;Approximately 48% patients less than age 60, and 34% of patients greater than or equal
	to age 60, with residual disease after induction therapy will achieve a remission, as reported by Datamonitor.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Myelodysplastic Syndromes
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	MDS are a group of blood and bone marrow disorders.
	In MDS, stem cells do not mature normally, and the number of blasts (immature cells) and dysplastic (abnormally developed) cells
	increases. Also, the number of healthy mature cells decreases, meaning there are fewer normal red blood cells, white blood cells,
	and platelets. The numbers of blood cells are often called blood cell counts. Because of the decrease in healthy cells, people
	with MDS often have anemia (a lowered blood cell count), and may have neutropenia (a low white blood cell count) and thrombocytopenia
	(a low platelet count). Also, the chromosomes (long strands of genes) in the bone marrow cells may be abnormal. According to the
	American Cancer Society, there are approximately 13,000 new cases of MDS annually in the US. Additionally, Datamonitor Healthcare
	reports median survival in higher risk MDS patients may range between five months and two years. There are several subtypes of
	MDS, and some subtypes of MDS may eventually turn into AML.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Solid Tumors
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Phase I data with APTO-253 in patients with
	solid tumors and preclinical data in solid tumor cells, including non-small cell lung cancer (&ldquo;
<B>
	NSCLC
</B>
	&rdquo;), identified
	an opportunity for APTO-253 in patients possessing cancers with reduced Klf4 Gene expression. Our prior Phase 1 study with APTO-253
	also revealed a favorable safety profile for APTO-253. Various solid tumors have exhibited suppressed levels of Klf4 Gene in scientific
	publications, including colorectal, gastric, pancreatic, prostate and cervical cancers, as well as NSCLC. NSCLC is an indication
	that we consider to have a large market potential and important unmet need worldwide, in which the Klf4 Gene is a tumor suppressor
	that is present in case-matched normal cells but depressed in NSCLC tumor cells. Aptose may in the future evaluate the clinical
	utility of APTO-253 in additional studies in a subset of NSCLC patients that may be predisposed to a response with a therapeutically
	activating the Klf4 Gene.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In January 2011, Aptose announced the first
	patient enrolment in a Phase I dose-escalation study for APTO-253 in patients with advanced or metastatic solid tumors who are
	unresponsive to conventional therapy or for which no effective therapy is available. The study was initially being conducted at
	Memorial Sloan-Kettering Cancer Center in New York and later added MD Anderson Cancer Center in Houston as a second site. Objectives
	of the study included determination or characterization of the safety profile, maximum tolerated dose, and antitumor activity of
	APTO-253, as well as pharmacokinetics and a recommended Phase II dose for subsequent clinical trials.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In June 2012, Aptose announced the addition
	of MD Anderson Cancer Center as a second site in the then ongoing APTO-253 Phase I clinical trial, under the direction of Dr. Jennifer
	Wheler as the principal investigator. In addition, Aptose announced that the study had successfully completed the accelerated drug
	dose escalation stage (Stage 1), with further escalation under way in the non-accelerated dose escalation stage (Stage 2) for the
	purpose of determining the maximal tolerated dose level and recommended Phase II dose. The addition of a second site expanded patient
	availability for enrollment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In January 2013, Aptose announced that Phase
	I clinical study of APTO-253 has successfully escalated to the target dose level based on predicted and observed clinical effects
	without limitation by toxicity. The success of this study allowed Aptose to initiate a biomarker clinical investigation to further
	explore the effects of the drug at relevant doses determined in the clinical trial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In April 2013, Aptose announced the presentation
	of preclinical data at the 2013 Annual Meeting of the American Association for Cancer Research (&ldquo;
<B>
	AACR
</B>
	&rdquo;), held
	in Washington, DC from April 6, 2013 through April&nbsp;10, 2013. The poster presentation titled &ldquo;Utilization of KLF4 as
	a pharmacodynamic biomarker for in vivo anticancer activity of a novel small molecule drug APTO-253&rdquo; covered data from preclinical
	studies on anticancer activity and tumor biomarker analysis for APTO-253 in animal models of human NSCLC. The studies demonstrate
	that APTO-253 has antitumor activity with a dose-response effect in NSCLC that is associated with a dose dependent increase of
	the KLF4 gene.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In July 2013, Aptose announced the results of
	the Phase 1 clinical trial of APTO-253. In this first-in-man, dose-escalation clinical study, APTO-253 demonstrated a favorable
	safety profile, as well as encouraging signs of antitumor activity. The design of this trial consisted of APTO-253 as a single
	agent in patients with advanced solid tumors resistant to multiple standard therapies. The study enrolled 27 patients, all of which
	had failed a median of four prior chemotherapies. Although this was primarily a dose-escalation safety study, efficacy and pharmacokinetics
	were also explored.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The clinical trial enrolled patients at seven
	dose levels ranging from 20 to 229 mg/m2. Of the 27 patients enrolled, 17 were evaluable for efficacy. Of these 17 patients, seven
	(41%) achieved stable disease by Response Evaluation Criteria In Solid Tumors (&ldquo;
<B>
	RECIST
</B>
	&rdquo;). This included patients
	with colorectal, lung, appendiceal, liver and uterine cancers. Dose related activity was demonstrated at the higher dose levels
	(176 and 229 mg/m2). At these two highest dose levels, four of five evaluable patients (80%) achieved sustained stable disease
	by RECIST ranging from 5.6 months to 8&nbsp;months, representative of disease control. Of these, a patient with non-small cell
	lung cancer at the highest dose level additionally demonstrated non-index tumor shrinkage.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The safety assessment indicated that APTO-253
	was well tolerated at all dose levels tested in this trial. The dose escalation was not limited by toxicity. The most common adverse
	event was Grade 1 or 2 fatigue seen in three patients. There was one Grade 3 toxicity, asymptomatic low blood phosphate level that
	was reversible by supplementation with phosphates. The pharmacokinetic profile was consistent with the predictive profile seen
	preclinically, and the elimination profile and half-life in patients were suggestive of a very rapid distribution phase and prolonged
	retention.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.15PT; MARGIN: 0PT 0 0PT 2.15PT">
<B>
	Small Molecule Program
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.15PT; MARGIN: 0PT 0 0PT 2.15PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In April 2013, Aptose entered into a research
	and license option agreement with Elanco, the animal health division of Eli Lilly and Company (&ldquo;
<B>
	Elanco
</B>
	&rdquo;), to
	investigate a new proprietary series of Aptose compounds for veterinary medicine. Pursuant to the agreement, Elanco will fund the
	research program and was granted an exclusive option to license the worldwide rights to selected compounds for veterinary use;
	the terms of which will be negotiated if the option is exercised by Elanco. Aptose retains the rights to develop and commercialize
	these compounds for human use. Lead optimization is underway and the next goal is to identify a clinical drug candidate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Multi-Targeting Bromodomain Program
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In November 2015, Aptose entered into a definitive
	agreement with Moffitt Cancer Center for exclusive global rights to potent, multi-targeting, single-agent inhibitors for the treatment
	of hematologic and solid tumor cancers. These small molecule agents are highly differentiated inhibitors of the Bromodomain and
	Extra-Terminal motif (BET) protein family members, which simultaneously target specific kinase enzymes. The molecules developed
	by Moffitt exhibit single-digit nanomolar potency against the BET family members and specific oncogenic kinases which, when inhibited,
	are synergistic with BET inhibition. Under the agreement, Aptose will gain access to the drug candidates developed by Moffitt and
	the underlying intellectual property covering the chemical modifications enabling potent bromodomain (BRD) inhibition on the chemical
	backbone of a kinase inhibitor. Aptose expects lead clinical candidates to emerge from the collaboration by late 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In December 2015, collaborators from Moffitt
	Cancer Center presented preclinical data for one of the candidates in the collaboration, MA2-014, at the 57th Annual American Society
	of Hematology (ASH) Meeting. The MA2-014 program was developed to inhibit both the bromodomain 4 (BRD4) protein
	and the Janus kinase 2 (JAK2) for the potential treatment of various hematologic and solid tumor cancers. Moffitt researchers presented
	data for MA2-014 that exhibited similar anti-JAK2 activity as a known JAK2 inhibitor, TG101209, with an approximate ten-fold improvement
	in anti-BRD activity. Moffitt researchers also demonstrated a ten-fold improvement in the ability of MA2-014 to inhibit JAK2-V617F
	signaling over TG101209, and comparable to ruxolitinib. Ruxolitinib is the only FDA approved JAK inhibitor for MPNs. However, MA2-014
	retained its potency against ruxolitinib-resistant cells. Moffitt researchers also determined in long-term culture assays that
	JAK2-V617F driven MPN Uke1 cells do not experience resistance to MA2-014 as readily as they do to TG101209 or ruxolitinib.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Multi-Targeting Epigenetic Program
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In November 2015, Aptose also announced an exclusive
	drug discovery partnership with Laxai Avanti Life Sciences (LALS) for their expertise in next generation epigenetic-based therapies.
	Under the agreement, LALS will be responsible for developing multiple clinical candidates, including optimizing candidates derived
	from Aptose's relationship with the Moffitt Cancer Center. Aptose will own global rights to all newly discovered candidates characterized
	and optimized under the collaboration, including all generated intellectual property.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Discontinued Programs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As of January 2016, Aptose has provided notification
	of termination to Genentech for the intellectual property for IL-17E, and will cease further development activities for APTO-500
	(MELK inhibitor), as the programs fall outside of the scope of Aptose&rsquo;s pipeline and vision.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Business OF THE COMPANY
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.15PT; MARGIN: 0PT 0 0PT 2.15PT">
<B>
	NASDAQ listing
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.15PT; MARGIN: 0PT 0 0PT 2.15PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 34PT; MARGIN: 0PT 0 0PT 2PT">
	On October 21, 2014, Aptose announced
	that its Common Shares were approved for listing on NASDAQ under the symbol &ldquo;APTO&rdquo; and began trading on NASDAQ on October
	23, 2014. Aptose has retained its listing on the TSX under the symbol &ldquo;APS&rdquo;.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 34PT; MARGIN: 0PT 0 0PT 2PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2PT; MARGIN: 0PT 0 0PT 2PT">
<B>
	Reverse Stock Split
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2PT; MARGIN: 0PT 0 0PT 2PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On October 1, 2014, Aptose filed articles of
	amendment to give effect to the reverse stock split (consolidation) of its Common Shares on the basis of one post-consolidation
	Common Share for each 12 pre-consolidation Common Shares (the &ldquo;
<B>
	Reverse Stock Split
</B>
	&rdquo;). The number of Common Shares
	outstanding as of the time of the announcement was 139,324,451. The number of Common Shares outstanding immediately following the
	Reverse Stock Split was 11,610,402.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2PT; MARGIN: 0PT 0 0PT 2PT">
<B>
	Name and year end change
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2PT; MARGIN: 0PT 0 0PT 2PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On September 2, 2014, we announced that we had
	changed our name to Aptose Biosciences Inc. from the previous name of Lorus Therapeutics Inc. The new name reflects our new focus
	and clinical-stage pipeline strategy, as an oncology research and development organization advancing new therapeutics and molecular
	diagnostics based on insights into the genetic profiles of certain cancers and patient populations.&nbsp; Our lead product candidate
	APTO-253 exerts its antitumor effects by activating a key apoptotic pathway in tumor cells. The term &quot;apoptosis&quot; represents
	the innate self-killing capacity of cells triggered upon the onset of cellular damage, and cancer cells employ various mechanisms
	to avoid apoptosis. For these reasons, &quot;apoptosis&quot; is the intuitive root of the name of &quot;Aptose Biosciences.&quot;
	In addition, our stated goal with respect to the name change is to align the product portfolio and product development with the
	strategic course set by its new management team.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Effective July 17, 2014, we changed our fiscal
	year end from May 31 to December 31. As a result of that change the prior year period is for the seven months ended December 31,
	2014 while the current year comparative period is for the twelve months ended December 31, 2015, and therefore not directly comparable
	to the seven month period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2PT; MARGIN: 0PT 0 0PT 2PT">
<B>
	Changes in Management
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2PT; MARGIN: 0PT 0 0PT 2PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On October 28, 2013, William G. Rice, Ph.D.,
	was appointed as Chief Executive Officer and Chairman of the Board while Dr. Aiping Young continued as President and Chief Operating
	Officer of the Company until she departed the Company on March 18, 2014. Aptose also appointed Daniel D. Von Hoff, M.D., to serve
	as a special advisor to fulfill the functions of the Company&rsquo;s Senior Vice President of Medical Affairs. Dr. Von Hoff is
	an independent contractor and advisor but is not an employee of Aptose. The Board, after receiving the recommendation of the Special
	Committee, unanimously approved the appointments. In doing so, the Board determined that such appointments were in the best interest
	of Aptose, as they were considered to enhance the management team and advisory team with the addition of two seasoned and experienced
	biotechnology executives bringing extensive clinical development and capital raising experience and improving the awareness and
	presence of the Company in the United States. On April 10, 2014, Dr. Rice was additionally appointed as President of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On October 29, 2013, Brian Druker, M.D., was
	appointed as the Chair of the Company&rsquo;s Scientific Advisory Board. Like Dr. Von Hoff, Dr. Druker is an independent contractor
	and advisor but not an employee of Aptose.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On December 2, 2013, Avanish Vellanki was appointed
	as Chief Business Officer of the Company, to manage global business development, licensing and corporate strategy, and Gregory
	K. Chow was appointed as Chief Financial Officer, with responsibility for corporate finance and accounting functions for the Company.
	On April 10, 2014, Messrs. Vellanki and Chow were additionally appointed as Senior Vice Presidents of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On September 8, 2014, Stephen B. Howell was
	appointed Chief Medical Officer of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<U>
	Financial Strategy
</U>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	To meet our future financing requirements, we
	intend to finance our operations through some or all of the following methods: public or private equity financings, collaborative
	and licensing agreements. We intend to pursue financing opportunities as they arise. See &ldquo;Item 3. Key Information&mdash;D.
	Risk Factors&rdquo; above.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	At-The-Market (&ldquo;ATM&rdquo;) Facility
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On April 2, 2015, we entered into an ATM equity
	facility with Cowen and Company, LLC, acting as sole agent. Under the terms of this facility, we may, from time to time, sell shares
	of our common stock having an aggregate offering value of up to US$20 million through Cowen and Company, LLC on the Nasdaq Capital
	Market. We determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During the twelve
	months ended December 31, 2015, the Company issued 1,504 Common Shares under the ATM at a price of US$5.20 per share for gross
	proceeds of approximately Cdn $10 thousand.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	April 2014 Public Offering
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In April 2014, we completed a public offering
	in Canada and a simultaneous private placement in the United States of Common Shares. Aptose issued 4,708,334 (56,500,000 pre-consolidation)
	Common Shares at a purchase price of $6.00 ($0.50 pre-consolidation) per Common Share including 541,667 (6,500,000 pre-consolidation)
	Common Shares pursuant to the partial exercise of an over-allotment option, for aggregate gross proceeds of $28,250,000. The total
	costs associated with the transaction were approximately $2,665,914 which includes a cash commission of $1,977,500 based on 7%
	of the gross proceeds received as part of the offering.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	December 2013 Public Offering
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In December 2013, Aptose completed a public
	offering of Common Shares. Aptose issued 1,060,833 (pre-consolidation 12,730,000) common shares at a price of $6.60 (pre-consolidation
	$0.55) per common share and an additional 159,125 (pre-consolidation 1,909,500) common shares upon the exercise of the overallotment
	option for aggregate gross proceeds of $8.1 million.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The total costs associated with the transaction
	were approximately $1.1 million which include a cash commission of $483 thousand based on 6% of the gross proceeds received as
	part of the offering, and the issuance of 73,198 (pre-consolidation 878,370) broker warrants with an estimated fair value of $350
	thousand. The fair value of these warrants was determined using the Black Scholes model with a 24 month time to maturity, an assumed
	volatility of 130% and a risk free interest rate of 1.5%. Each broker warrant was exercisable into one common share of the Company
	at a price of $6.60 (pre-consolidation $0.55) for a period of twenty four months following closing of the offering.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	June 2013 Promissory Notes and Warrants
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In June 2013, we completed a private placement
	of units at a price of $1,000 per unit, for aggregate gross proceeds of $918,000. Each unit consisted of (i)&nbsp;a $1,000 principal
	amount of unsecured promissory note and (ii)&nbsp;1,000 Common Share purchase warrants. The promissory notes bore interest at a
	rate of 10% per annum, payable monthly and were due June 19, 2014. Each warrant entitled the holder to purchase one Common Share
	of Aptose at a price per Common Share equal to $3.00 ($0.25 pre-consolidation) at any time until June 19, 2015. These notes and
	any interest accrued thereon were repaid in full in April 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	September 2013 Convertible Promissory Notes
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In September 2013, we completed a private placement
	of convertible promissory notes for aggregate gross proceeds of $600,000. Each convertible promissory note consisted of a $1,000
	principal amount of unsecured promissory note convertible into Common Shares of the Company at a price per share of $3.60 ($0.30
	pre-consolidation). The promissory notes bore interest at a rate of 10% per annum, payable quarterly and were due September 26,
	2015. At December 31, 2015, all of the convertible promissory notes had been converted into Common Shares of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	September 2013 Loans payable
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In September 2013, we entered into loan agreements
	for proceeds of $150,000. The loan agreements were unsecured, bore interest at a rate of 10% per annum payable quarterly and were
	due September 30, 2015. We repaid the loans and all accrued and unpaid interest thereon on April 25, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Warrant Exercises
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	During the year ended December 31, 2015, 81,000
	Common Share purchase warrants were exercised for proceeds of $348,000.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	Warrants exercised during the year ended December 31, 2015:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Proceeds
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	86
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	June 2013 private placement warrants (ii)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	47
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	141
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	December 2013 broker warrants (iii)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	121
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	81
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	348
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In addition to the cash proceeds received, the original
	fair value related to these warrants of $155 thousand was transferred from warrants to share capital. This resulted in a total
	amount of $503 thousand credited to share capital.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	During the seven months ended December 31, 2014,
	1,231,000 Common Share purchase warrants were exercised for proceeds of $6,648,000.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	Warrants exercised during the seven months ended December 31, 2014:
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Proceeds
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	48
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	June 2012 private placement warrants (iv)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,223
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,600
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,231
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,648
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	During the year ended May 31, 2014, 868,000
	Common Share purchase warrants were exercised for proceeds of $4,458,000.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	Warrants exercised during the year ended May 31, 2014:
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Proceeds
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	327
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,764
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	June 2012 private placement warrants (iv)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	409
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,210
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	June 2012 finder warrants
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	103
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	June 2013 private placement warrants (iii)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	29
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	868
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,458
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(i)
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	August 2011 warrants are exercisable into Common Share
	of Aptose at a price per share of $5.40 ($0.45 pre-consolidation) and expire in August 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT; MARGIN: 0PT 0 0PT 0.75IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(ii)
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	June 2013 private placement warrants were exercisable
	into Common Shares of Aptose at a price per share of $3.00 ($0.25 pre-consolidation) and expired in June 2015.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
	(iii)
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	December 2013 broker warrants were exercisable into Common Shares of Aptose at a price
	per share of $6.60 ($0.55 pre-consolidation) and expired in December 2015.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
	(iv)
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	June 2012 warrants were exercisable into Common Shares of Aptose at a price per share
	of $5.40 ($0.45 pre-consolidation) and expired on June 8, 2014.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Agreements
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Manufacturing Agreements
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We currently rely upon subcontractors for the
	manufacture of our drug candidates. The subcontractors manufacture clinical material according to current Good Manufacturing Practices,
	or GMPs, at contract manufacturing organizations that have been approved by our quality assurance department staff, after having
	conducted audits to ensure such manufacturers meet the requirements of the relative regulatory authorities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Manufactured product for clinical purposes is
	tested for conformance with product specifications prior to release by our quality assurance staff. GMP batches of our drug candidates
	are subjected to prospectively designed stability test protocols.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	License Agreements
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
<B>
	Moffitt Cancer Center
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In November 2015, Aptose entered into a definitive
	agreement with Moffitt Cancer Center for exclusive global rights to potent, multi-targeting, single-agent inhibitors for the treatment
	of hematologic and solid tumor cancers. Under the agreement, Aptose will gain access to the drug candidates developed by Moffitt
	and the underlying intellectual property covering the chemical modifications enabling potent bromodomain (BRD) inhibition on the
	chemical backbone of a kinase inhibitor. Moffitt Cancer Center received an undisclosed upfront payment under the terms of the definitive
	agreement, and will receive milestone payments based on potential successful clinical development, regulatory submissions and approval,
	and commercialization.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
	Laxai Avanti Life Sciences (LALS)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In November 2015, Aptose also announced an exclusive
	drug discovery partnership with Laxai Avanti Life Sciences (LALS) for their expertise in next generation epigenetic-based therapies.
	Under the agreement, LALS will be responsible for developing multiple clinical candidates, including optimizing candidates derived
	from Aptose's relationship with the Moffitt Cancer Center. Aptose will own global rights to all newly discovered candidates characterized
	and optimized under the collaboration, including all generated intellectual property. LALS will receive milestone payments based
	on successful pre-clinical and clinical development, and regulatory accomplishment by Aptose.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
<B>
	Elanco
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In April 2013, Aptose entered into a research
	and license option agreement with Elanco, the animal health division of Eli Lilly and Company, to investigate a new proprietary
	series of Aptose&rsquo;s compounds for veterinary medicine. Pursuant to the agreement, Elanco agreed to fund the research program
	and was granted an exclusive option to license from Aptose our worldwide rights for selected compounds for veterinary use; the
	terms of which will be negotiated if the option is exercised by Elanco. Aptose retains the rights to develop and commercialize
	these compounds for human use and intends to use the animal data from the collaboration as a basis for a partnership with a third
	party to develop the technology for the treatment of patients with cancer. Lead optimization is underway and the next goal is to
	identify a clinical drug candidate that can be developed for both human and animal use.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	Other
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	From time to time, we enter into other research
	and technology agreements with third parties under which research is conducted and monies expended. These agreements outline the
	responsibilities of each participant and the appropriate arrangements in the event the research produces a product candidate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Intellectual Property and Protection of Confidential Information
	and Technology
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We believe that our issued patents and pending
	applications are important in establishing and maintaining a competitive position with respect to our products and technology.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
	APTO-253
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have been issued 21 patents and have 16 pending
	patents worldwide for our in-house small molecules.&nbsp; These patents cover APTO-253 composition of matter and methods of treating
	different cancers with APTO-253, including solid tumors and leukemia.&nbsp; &nbsp;Composition of matter patents expire in 2028
	in the United States and 2026 in other countries.&nbsp; Our patents also include several compounds that are similar to APTO-253,
	which provide protection from competitors seeking to develop anticancer products that are related in chemical structure to APTO-253.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
	Multi-Targeting Bromodomain Program
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Aptose has an exclusive global license from
	Moffitt Cancer Center for intellectual property covering dual BRD4-kinase inhibition.&nbsp; Encompassed in this estate are two
	pending patent applications.&nbsp; The first is an International Patent Application entitled &ldquo;Potent Dual BRD4-Kinase Inhibitors
	as Cancer Therapeutics,&rdquo; filed on September 3, 2015.&nbsp; This International Patent Application can be filed in any PCT
	(Patent Cooperative Treaty) member countries prior to certain national phase filing deadlines and any patent issued from such national
	phase filing is expected to expire September 3, 2035 without any patent term extensions or adjustments.&nbsp; The second application
	is a provisional patent application entitled &ldquo;BRD4-Kinase Inhibitors as Cancer Therapeutics,&rdquo; filed October 13, 2015.&nbsp;
	This provisional application can be used as a priority document for US and internal filings on or before October 13, 2016.&nbsp;
	Any patent issued from such filing is expected to expire October 13, 2036 or twenty years from its filing date without any patent
	term extension or adjustment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Regulatory Strategy
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our overall regulatory strategy is to work with
	the appropriate government departments which regulate the use and sale of therapeutic drug products. This includes Health Canada
	in Canada, the Food and Drug Administration in the United States, the European Medicines Agency in Europe, and other local regulatory
	agencies with oversight of preclinical studies, clinical trials and marketing of therapeutic products. Where possible, we intend
	to take advantage of opportunities for accelerated development of drugs designed to treat rare and serious or life-threatening
	diseases. We also intend to pursue priority evaluation of any application for marketing approval filed in Canada, the United States
	or the European Union and to file additional drug applications in other markets where commercial opportunities exist. We may not
	be able to pursue these opportunities successfully.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Revenues
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Company has not earned substantial revenues
	from its drug candidates and is therefore considered to be in the development stage.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Employees
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As at December 31, 2015, we employed 22 full-time
	persons and 2 part-time persons in research and drug development and administration activities. 5 of our employees hold Ph.D.&rsquo;s
	and numerous others hold degrees and designations such as MSc, BSc, CPA (CA), CPA (California) and MBA. To encourage a focus on
	achieving long-term performance, employees and members of the Board have the ability to acquire an ownership interest in the Company
	through Aptose&rsquo;s share option and alternate compensation plans. See Item 6.B &ndash; Compensation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	None of our employees are unionized, and we
	consider our relations with our employees to be good.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Office Facilities
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our head office, which occupies 5,300 square
	feet, is located 5955 Airport Road Suite #228, Mississauga, Ontario. The leased premise is office space. Our current lease expires
	in April, 2020.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55IN; MARGIN: 0PT 0">
	We have executive offices in San Diego and
	have entered into a lease agreement for office space, located at 12770 High Bluffs Drive, San Diego, California which occupies
	approximately 2,204 square feet. This leased premise is used for administrative purposes only. This lease expires January, 2020.
	We also have administrative offices in San Francisco located at 3 Lagoon Drive, Redwood City, California. The Redwood City premise
	is for 2,854 square feet and the lease expires in June 2018. Finally, we have leased laboratory space in San Diego at 3550 General
	Atomics Court. The lease is for 1,386 square feet and the lease expires in February 2017.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The biotechnology and pharmaceutical industries
	are characterized by rapidly evolving technology and intense competition. There are numerous companies in these industries that
	are focusing their efforts on activities similar to ours. Some of these are companies with established positions in the pharmaceutical
	industry and may have substantially more financial and technical resources, more extensive research and development capabilities,
	and greater marketing, distribution, production and human resources than Aptose. In addition, we face competition from other companies
	for opportunities to enter into partnerships with biotechnology and pharmaceutical companies and academic institutions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Competition with our potential products may
	include chemotherapeutic agents, monoclonal antibodies, antisense therapies, small molecules, immunotherapies, vaccines and other
	biologics with novel mechanisms of action. These drugs may kill cancer cells indiscriminately, or through a targeted approach,
	and some have the potential to be used in non-cancer indications. We also expect that we will experience competition from established
	and emerging pharmaceutical and biotechnology companies that have other forms of treatment for the cancers that we target, including
	drugs currently in development for the treatment of cancer that employ a number of novel approaches for attacking these cancer
	targets. Cancer is a complex disease with more than 100 indications requiring drugs for treatment. The drugs in competition with
	our potential drugs have specific targets for attacking the disease, targets which are not necessarily the same as ours. These
	competitive drugs, however, could potentially also be used together in combination therapies with our drugs to manage the disease.
	Other factors that could render our potential products less competitive may include the stage of development, where competitors&rsquo;
	products may achieve earlier commercialization, as well as superior patent protection, better safety profiles, or a preferred cost-benefit
	profile.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Government Regulation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Overview
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Regulation(s) by government authorities in Canada,
	the United States, and the European Union are significant factors in guiding our current research and drug development activities.
	To clinically test, manufacture and market drug products for therapeutic use, we must be in compliance with guidance and regulations
	established by the regulatory agencies in the countries in which we currently operate or intend to operate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The laws of most of these countries require
	the licensing of manufacturing facilities, carefully controlled research and the extensive testing of products. Biotechnology companies
	must establish the safety and efficacy of their new products in clinical trials; they must establish and comply with current GMP(s)
	for the manufacturing of the product and control over marketing activities before being allowed to market a product. The safety
	and efficacy of a new drug must be shown through human clinical trials of the drug carried out in accordance with the guidance
	and regulations established by local and federal regulatory agencies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The process of completing clinical trials and
	obtaining regulatory approval for a new drug takes a number of years and requires the expenditure of substantial resources. Once
	a new drug or product license application is submitted, regulatory agencies may not review the application in a timely manner and
	may not approve the product. Even after an NDA submission has occurred and or approval has been obtained, further studies, including
	post-marketing studies, may be required to provide additional data on efficacy and safety necessary to confirm the approved indication
	or to gain approval for the use of the new drug as a treatment for clinical indications other than those for which the new drug
	was initially tested. Also, regulatory agencies require post-marketing surveillance programs to monitor a new drug&rsquo;s side
	effects, safety and long term effects of the product. A serious safety or effectiveness problem involving an approved new drug,
	may result in a regulatory agency mandating a withdrawal of the new drug from the market and possible civil action. It is possible
	that we could encounter such difficulties or excessive costs in our efforts to secure necessary approvals, which could delay or
	prevent us from manufacturing or marketing our products.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In addition to the regulatory product approval
	framework, biotechnology companies, including Aptose, are subject to regulation under local, provincial, state and federal law,
	including requirements regarding occupational safety, laboratory practices, environmental protection and hazardous substance control,
	and may be subject to other present and future local, provincial, state, federal and foreign regulation, including possible future
	regulation of the biotechnology industry.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Regulation in Canada
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In Canada, the manufacture and sale of new drugs
	are controlled by Health Canada. New drugs must pass through a number of testing stages, including pre-clinical testing and human
	clinical trials. Pre-clinical testing involves testing the new drug&rsquo;s chemistry, pharmacology and toxicology
<I>
	in vitro
</I>
	and
<I>
	in vivo
</I>
	. Successful results (that is, potentially valuable pharmacological activity combined with an acceptable low
	level of toxicity) enable the developer of the new drug to file a clinical trial application to begin clinical trials involving
	humans.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	To study a drug in Canadian patients, a clinical
	trial application submission must be filed with Health Canada. The clinical trial application submission must contain specified
	information, including the results of the pre-clinical tests completed at the time of the submission and any available information
	regarding use of the drug in humans. In addition, since the method of manufacture may affect the efficacy and safety of a new drug,
	information on manufacturing methods and standards and the stability of the drug substance and dosage form must be presented. Production
	methods and quality control procedures must be in place to ensure an acceptably pure product, essentially free of contamination,
	and to ensure uniformity with respect to all quality aspects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In addition, all federally regulated trials
	must be approved and monitored by an independent committee of doctors, scientists, advocates and others to ensure safety and ethical
	standards. These committees are called Institutional Review Boards (&ldquo;
<B>
	IRBs
</B>
	&rdquo;) or Ethics Review Boards (&ldquo;
<B>
	ERBs
</B>
	&rdquo;).
	The review boards study and approve all study-related documents before a clinical trial begins and also carefully monitor data
	to detect benefit or harm, and validity of results.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Provided Health Canada does not reject a clinical
	trial application submission and IRB or ERB approval has been obtained, clinical trials can begin. Clinical trials for product
	candidates in Canada, as in the U.S. generally are carried out in three phases. Phase I involves studies to evaluate toxicity and
	ideal dose levels in healthy humans. The new drug is administered to human patients who have met the clinical trial entry criteria
	to determine pharmacokinetics, human tolerance and prevalence of any adverse side effects. Phases II and III involve therapeutic
	studies. In Phase II, efficacy, dosage, side effects and safety are established in a small number of patients who have the disease
	or disorder that the new drug is intended to treat. In Phase III, there are controlled clinical trials in which the new drug is
	administered to a large number of patients who are likely to receive benefit from the new drug. In Phase III, the effectiveness
	of the new drug in patients is compared to that of standard accepted methods of treatment in order to provide sufficient data for
	the statistical proof of safety and efficacy for the new drug.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If clinical studies establish that a new drug
	has value, the manufacturer submits a new drug submission application to Health Canada for marketing approval. The new drug submission
	contains all information known about the new drug, including the results of pre-clinical testing and clinical trials. Information
	about a substance contained in new drug submission includes its proper name, its chemical name, and details on its method of manufacturing
	and purification, and its biological, pharmacological and toxicological properties. The new drug submission also provides information
	about the dosage form of the new drug, including a quantitative listing of all ingredients used in its formulation, its method
	of manufacture, manufacturing facility information, packaging and labelling, the results of stability tests, and its diagnostic
	or therapeutic claims and side effects, as well as details of the clinical trials to support the safety and efficacy of the new
	drug. Furthermore, for biological products, an on-site evaluation is completed to assess the production process and manufacturing
	facility. It is required prior to the issuance of a notice of compliance. All aspects of the new drug submission are critically
	reviewed by Health Canada. If a new drug submission is found satisfactory, a notice of compliance is issued permitting the new
	drug to be sold for the approved use. In Canada, an establishment license must be obtained prior to marketing the product.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Health Canada has a policy of priority evaluation
	of new drug submissions for all drugs intended for serious or life-threatening diseases for which no drug product has received
	regulatory approval in Canada and for which there is reasonable scientific evidence to indicate that the proposed new drug is safe
	and may provide effective treatment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The monitoring of a new drug does not cease
	once it is on the market. For example, a manufacturer of a new drug must report any new information received concerning serious
	side effects, as well as the failure of the new drug to produce desired effects. If Health Canada determines it to be in the interest
	of public health, a notice of compliance for a new drug may be suspended and the new drug may be removed from the market.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	A post surveillance program involves clinical
	trials conducted after a drug is marketed (referred to as Phase IV studies in the United States) and is an important source of
	information on as yet undetected adverse outcomes, especially in populations that may not have been involved in the premarketing
	trials (e.g., children, the elderly, pregnant women) and the drug&rsquo;s long-term morbidity and mortality profile. Regulatory
	authorities may require companies to conduct Phase IV studies as a condition of market approval. Companies often conduct post-marketing
	studies in the absence of a regulatory mandate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	An exception to the foregoing requirements relating
	to the manufacture and sale of a new drug is the limited authorization that may be available in respect of the sale of new drugs
	for emergency treatment. Under the special access program, Health Canada may authorize the sale of a quantity of a new drug for
	human use to a specific practitioner for the emergency treatment of a patient under the practitioner&rsquo;s care. Prior to authorization,
	the practitioner must supply Health Canada with information concerning the medical emergency for which the new drug is required,
	such data as is in the possession of the practitioner with respect to the use, safety and efficacy of the new drug, the names of
	the institutions at which the new drug is to be used and such other information as may be requested by Health Canada. In addition,
	the practitioner must agree to report to both the drug manufacturer and Health Canada the results of the new drug&rsquo;s use in
	the medical emergency, including information concerning adverse reactions, and must account to Health Canada for all quantities
	of the new drug made available.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Canadian regulatory approval requirements
	for new drugs outlined above are similar to those of other major pharmaceutical markets. While the testing carried out in Canada
	is often acceptable for the purposes of regulatory submissions in other countries, individual regulatory authorities may request
	supplementary testing during their assessment of any submission. Therefore, the clinical testing conducted under Health Canada
	authorization or the approval of regulatory authorities of other countries may not be accepted by regulatory authorities outside
	Canada or other countries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Regulation in the United States
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In the United States, the FDA controls and investigates
	the investigation, manufacturing, and sale of new drugs. New drugs require FDA approval of a New Drug Application prior to commercial
	sale. In the case of certain biological products, a Biological License Application must be obtained prior to marketing and batch
	releasing. As in Canada, to obtain marketing approval, data from adequate and well-controlled human clinical trials, demonstrating
	to the FDA&rsquo;s satisfaction a new drug&rsquo;s safety and effectiveness for its intended use, are required. Data are generated
	in studies conducted pursuant to an IND submission, similar to that required for a clinical trial application in Canada. Clinical
	trials with human subjects are characterized as Phase I, Phase II and Phase III trials or a combination thereof. In a marketing
	application, the manufacturer must also demonstrate the identity, potency, quality and purity of the active ingredients of the
	new drug involved, and the stability of those ingredients. Further, the manufacturing facilities, equipment, processes and quality
	controls for the new drug must comply with the FDA&rsquo;s current Good Manufacturing Practice regulations for drugs or biological
	products both in a pre-licensing inspection before product licensing and in subsequent periodic inspections after licensing. An
	establishment license grants the sponsor permission to fabricate, package, label, distribute, import, wholesale or test of the
	newly approved drug.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Federally regulated trials must be approved
	and monitored by an independent committee of doctors, scientists, advocates and others to ensure safety and ethical standards.
	These committees are called Institutional Review Boards (&ldquo;
<B>
	IRBs
</B>
	&rdquo;) or Ethics Review Boards (&ldquo;
<B>
	ERBs
</B>
	&rdquo;).
	The review boards study and approve all study-related documents before a clinical trial begins and also carefully monitor data
	to detect benefit or harm, and validity of results.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The above describes briefly what is necessary
	for a new drug to be approved for marketing in North America. The European Medicines Agency and Japanese Pharmaceuticals and Medical
	Devices Agency are also important regulatory authorities in drug development. Together with the FDA, they are the three International
	Conference on Harmonization parties which oversee the three largest markets for drug sales.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Organizational structure
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Old Lorus was incorporated under the
<I>
	Business
	Corporations Act
</I>
	(Ontario) on September 5, 1986 under the name RML Medical Laboratories Inc. On October 28, 1991, RML Medical
	Laboratories Inc. amalgamated with Mint Gold Resources Ltd., resulting in Old Lorus becoming a reporting issuer (as defined under
	applicable securities law) in Ontario, on such date. On August 25, 1992 Old Lorus changed its name to IMUTEC Corporation. On November
	27, 1996, Old Lorus changed its name to Imutec Pharma Inc., and on November 19, 1998, Old Lorus changed its name to Lorus Therapeutics
	Inc. On October 1, 2005, Old Lorus continued under the
<I>
	Canada Business Corporations Act
</I>
	.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On the Arrangement Date, Old Lorus completed
	a plan of arrangement and corporate reorganization with, among others, New Lorus, 6707157 Canada Inc. and Pinnacle International
	Lands, Inc. As a result of the plan of arrangement and reorganization, each Common Share of Old Lorus was exchanged for one Common
	Share of New Lorus. New Lorus continued the business of Old Lorus after the Arrangement Date with the same officers and employees
	and continued to be governed by the same board of directors as Old Lorus prior to the Arrangement Date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On August 28, 2014, New Lorus changed its name
	from Lorus Therapeutics Inc. to Aptose Biosciences Inc. and on October 1, 2014, we consolidated our outstanding Common Shares on
	the basis of one post-consolidation Common Share for each twelve pre-consolidation Common Shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The address of the Company&rsquo;s head and
	registered office is 5955 Airport Road, Suite #228, Mississauga, Ontario, Canada, L4V 1R9 and our phone number is (647) 479-9828.
	Our corporate website is www.aptose.com. The contents of the website and items accessible through the website are specifically
	not incorporated in this Annual Report by reference.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Aptose has three subsidiaries: Aptose USA, a
	company incorporated under the laws of Delaware, USA, Aptose Suisse a company incorporated under the laws of Zug, Switzerland and
	NuChem, a company incorporated under the laws of Ontario, Canada. Aptose owns 100% of the issued and outstanding voting share capital
	of Aptose USA and Aptose Suisse and 80% of the issued and outstanding voting share capital of NuChem.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our Common Shares are listed on the TSX under the symbol &ldquo;APS&rdquo;
	and on NASDAQ under the symbol &ldquo;APTO.&rdquo;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Property, plant and equipment
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our head office, which occupies 5,300 square
	feet, is located 5955 Airport Road Suite #228, Mississauga, Ontario. The leased premise is office space. Our current lease expires
	in April, 2020.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have executive offices in San Diego and
	have entered into a lease agreement for office space, located at 12770 High Bluffs Drive, San Diego, California which occupies
	approximately 2,204 square feet. This leased premise is used for administrative purposes only. This lease expires January, 2020.
	We also have administrative offices in San Francisco located at 3 Lagoon Drive, Redwood City, California. The Redwood City premise
	is for 2,854 square feet and the lease expires in June 2018. Finally, we have leased laboratory space in San Diego at 3550 General
	Atomics Court. The lease is for 1,386 square feet and the lease expires in February 2017.
</P>
</EFX_COMPANY_INFORMATION>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I4A">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 4A.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Unresolved Staff Comments
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OPERATING_AND_FINANCIAL_REVIEW>
<A NAME="FIS_OPERATING_AND_FINANCIAL_REVIEW"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I5">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;5.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Operating and Financial Review and Prospects
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Operating results
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Please see our Management&rsquo;s Discussion
	and Analysis for the fiscal year ended December 31, 2015 in Exhibit 15.1, which is incorporated herein by reference.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Liquidity and capital resources
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Please see our Management&rsquo;s Discussion
	and Analysis for the fiscal year ended December 31, 2015 in Exhibit 15.1, which is incorporated herein by reference.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Research and development, patents and licenses,
	etc
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Certain information concerning research and
	development and intellectual property is set forth in Item&nbsp;4, &ldquo;Information on the Company&rdquo;.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Trend information
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have a history of operating losses and have
	not been profitable since our inception in 1986. We expect to continue to incur losses for at least the next several years as we
	and our collaborators and licensees pursue clinical trials and research and development efforts. See &ldquo;Item 3. Key Information&mdash;D.
	Risk Factors&rdquo; above.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	E.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Off-balance sheet arrangements
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As at December 31, 2015, we had not entered into any off-balance
	sheet arrangements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	F.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Tabular disclosure of contractual obligations
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	As December 31, 2015&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; BORDER-BOTTOM: BLACK 1PT SOLID">
	(In thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Payments due by period
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	Contractual Obligations
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Less than 1
<BR>
	year
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1-3 years
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3-5 years
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	More than
<BR>
	5 years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Operating lease obligations
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,813
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	587
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	907
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	319
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Company has entered into various contracts
	with service providers with respect to the clinical development of APTO-253. These contracts will result in future payment commitments
	of up to approximately $4 million over the related service period. Of this amount, $544 thousand has been paid and $574 thousand
	has been accrued at December 31, 2015. The payments are based on services performed and amounts may be higher or lower based on
	actual services performed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Company enters into research, development
	and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary
	technologies. Milestone and royalty payments that may become due under various agreements are dependent on, among other factors,
	clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which
	is uncertain. Under the license agreement with the Moffitt Cancer Centre, the Company has future contingent milestones payable
	totaling US$9 million relating to the first patient dosed in a phase I, II and III clinical trial and regulatory and commercial
	milestones totalling US$16 million. The Company does not anticipate making any payments under this license agreement in 2016. Under
	the Laxai-Avanti Life Science agreement the Company has total future contingent milestones payable of US$5.3 million related to
	certain research achievements as well as upon the first patient dosed in a phase I, II and III clinical trial and regulatory milestones
	totaling US$5 million. The Company expects to make payments totaling US$300 thousand under this agreement in 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	G.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Safe Harbor
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Please see &ldquo;Forward Looking Statements&rdquo; beginning on
	page 1 above.
</P>
</EFX_OPERATING_AND_FINANCIAL_REVIEW>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I6">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item&nbsp;6.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Directors, Senior Management and Employees
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Directors and senior management
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table and notes thereto provide
	the name, province or state and country of residence, positions with the Company and term of office of each person who serves as
	a director or executive officer of Aptose as at the date hereof.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Each director has been elected or appointed
	to serve until the next annual meeting or until a successor is elected or appointed. We have an Audit Committee, a Corporate Governance
	and Nominating Committee and a Compensation Committee, the members of each such committee are shown below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As at December 31, 2015, our directors and executive
	officers, as a group, beneficially owned, directly or indirectly, or exercised control over, approximately 57,699 Common Shares
	or approximately 0.5% of our outstanding Common Shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 34%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name and Province/State and
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Country of Residence
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 32%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Position
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 32%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Director or Officer Since
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Directors:
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Dr. Denis Burger
</FONT>
<SUP>
	(1)(2)
</SUP>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Oregon, United States&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September 2007
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Dr. Brad Thompson
<SUP>
	(1)(2)(3)
</SUP>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Alberta, Canada&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Director
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	June 2013
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Dr. Mark Vincent
<SUP>
	(3)
</SUP>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Ontario, Canada&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September 2007
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Warren Whitehead
</FONT>
<SUP>
	(1)
</SUP>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Ontario, Canada&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	April 2011
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Dr. William G. Rice&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	California, USA&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chairman
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	October 2013
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Dr. Erich Platzer
</FONT>
<SUP>
	(2)
</SUP>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Switzerland&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Officers:
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Dr. William Rice&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	California, USA
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	President and Chief Executive Officer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	October 2013
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Gregory Chow&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	California, USA
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Senior Vice President and Chief Financial Officer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	November 2013
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Avanish Vellanki&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	California, USA
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Senior Vice President and Chief Business Officer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	November 2013
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(1) Member of Audit Committee.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(2) Member of the Compensation Committee.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(3) Member of the Corporate Governance and Nominating
	Committee.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The principal occupation and employment of each
	of the foregoing persons for the past five years is set forth below:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	Dr. Denis Burger:
</I>
	Dr.&nbsp;Burger currently is the Chief Scientific Officer and member of the board of directors of Cytodyn Inc. (a biotechnology
	company) as well as Chairman of AMES Devices (a medical device company). Dr. Burger co-founded Trinity Biotech plc, based in Dublin,
	Ireland, in June 1992 and acted as Chairman from 1992 to 1995 and now serves on the board of directors of the company. Dr. Burger
	was the past Chairman, Chief Executive Officer and a director of AVI Biopharma Inc., an Oregon based biotechnology company, from
	1992 to March 2007. Dr.&nbsp;Burger is also a partner in Sovereign Ventures, a healthcare consulting and funding firm based in
	Portland, Oregon. Dr.&nbsp;Burger received his MSc and Ph.D. in Microbiology and Immunology from the University of Arizona.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	Dr. Erich Platzer:
</I>
	Dr. Platzer is a board certified physician in internal medicine, hematology and medical oncology. Previously, Dr. Platzer served
	as the business director of oncology, as well as the global strategic marketing and therapeutic area head of oncology at Roche,
	Basel. He was also the medical director in oncology and global development project leader and was responsible for various strategic
	corporate partnerships. Dr. Platzer is a director of Swiss Business Angel Groups, StartAngels and BioBAC, and has served as a pharmaceutical
	industry expert on the board of directors of multiple biotech companies in both the U.S. and Europe such as Probiodrug, AOT, L&eacute;man
	Micro Devices, Credentis, and Viroblock. Dr. Platzer co-founded HBM Healthcare Investments (formerly HBM BioVentures) a global
	leader in healthcare investing. He has over 12 years of experience in academic medicine and research and was a key member of the
	team at MSKCC that purified human G-CSF in 1983 (recombinant form: Neupogen&reg;). He earned his M.D. from the Medical School and
	the Institute of Clinical Immunology and Rheumatology of the University of Erlangen, where he also received his &ldquo;Dr. med.
	habil.&rdquo; (M.D.,Ph.D.).&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<I>
	Dr. William G. Rice:
</I>
	Dr. Rice joined
	Aptose as Chairman and Chief Executive Officer in October 2013.
<I>
</I>
	Prior to joining Aptose, Dr. Rice served as the President,
	Chief Executive Officer and Chairman of the board of Cylene Pharmaceuticals,&nbsp;Inc., a private biotechnology company (&ldquo;
<B>
	Cylene
</B>
	&rdquo;).
	Prior to Cylene, Dr. Rice was the founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He
	also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research
	and Development Center, and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University
	School of Medicine. Dr. Rice received his Ph.D. from Emory University Department of Biochemistry. He continues to serve as the
	Chairman of the board of Cylene and is a member of the board of directors of Oncolytics Biotech Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<I>
	Dr. Brad Thompson:
</I>
	Dr. Thompson is an
	experienced biotechnology professional who has held the positions of Chairman of the Board and President and Chief Executive Officer
	of Oncolytics Biotech Inc. since April 1999. Prior to his role with Oncolytics Dr. Thompson was the Chief Executive Officer of
	Synsorb Biotech from 1994 to 1999. Dr. Thompson also currently is a board member of Immunovaccine Inc. He received his Ph.D. from
	the University of Western Ontario in the Department of Microbiology and Immunology.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<I>
	Dr. Mark Vincent:
</I>
	Dr. Mark&nbsp;Vincent
	is a Professor of Oncology at the University of Western Ontario and a staff medical oncologist at the London Regional Cancer Program,
	where he has been since 1990. Dr.&nbsp;Vincent is also the co-founder and Chief Executive Officer of Sarissa, Inc. since 2000.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<I>
	Mr. Warren Whitehead:
</I>
	Mr. Whitehead is
	a CPA (CMA) who has held senior financial management positions in several biotechnology and pharmaceutical companies. Most recently
	Mr. Whitehead was the Chief Financial Officer of ProMIS Neurosciences Inc. (formerly Amorfix Life Sciences Ltd.). Prior to this,
	he served as Chief Financial Officer of ARIUS Research Inc., providing financial guidance and leadership during the acquisition
	of ARIUS by Roche in 2008. Prior to ARIUS, Mr. Whitehead was Chief Financial Officer at Labopharm Inc., where he completed a series
	of public equity financings and a listing on NASDAQ. He is currently the Chairman of the board of directors of PlantForm Corporation
	and a member of the board of directors of Telesta Therapeutics Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	Gregory Chow
</I>
	:
	Mr. Chow joined Aptose as Chief Financial Officer in December 2013. Previously, Mr. Chow served as Managing Director, Director
	of Private Placements at Wedbush Securities, where he led the private placement capital activities within the Life Sciences Investment
	Banking Group.&nbsp;Prior to joining Wedbush, he was a Director in the Private Placements / Equity Capital Markets Group at RBC
	Capital Markets, where he led life science private capital activities. Previously, he led the Private Capital Group at Wells Fargo
	Securities and was a Senior Auditor at BDO Seidman, LLP in their Century City, CA office. Mr. Chow is a Certified Public Accountant
	(inactive) in the State of California. &nbsp;Mr. Chow received his MBA in Finance from The Wharton School at the University of
	Pennsylvania, and his BA in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<I>
	Avanish Vellanki:
</I>
	Mr. Vellanki became
	Aptose&rsquo;s Chief Business Officer in December 2013
<FONT STYLE="COLOR: #555555">
	,
</FONT>
	having most
<FONT STYLE="COLOR: #555555">
</FONT>
	recently served as Senior Vice President, Investment Banking at Wedbush Securities focusing on the biotechnology sector.
	Prior to Wedbush Securities, Mr. Vellanki held the position of Senior Director of Corporate Development at Proteolix, Inc. (acquired
	by Onyx Pharmaceuticals), a biotechnology company focused on the development of oncology therapeutics. Previously, Mr. Vellanki
	served as Vice President in the Global Healthcare Investment Banking team at Citigroup&rsquo;s Global Healthcare Investment Banking,
	where he focused on large cap global biopharma strategic and financial advisory. Mr. Vellanki began his career at Bear Stearns
	as an equity research analyst covering the small/mid-cap biotechnology sector, and held the title of Vice President as a publishing
	analyst. Mr. Vellanki holds a BA from Carleton College, an MBS in Biochemistry from the University of Minnesota and MBA from the
	Carlson School of Management at the University of Minnesota.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	There are no family relationships among the
	persons named above and there are no arrangements or understanding with major shareholders, customers, suppliers or others pursuant
	to which any person was selected as a director or member of senior management.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Compensation
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Summary of Executive Compensation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table details the compensation
	information for the fiscal year ended December 31, 2015 of the Company, for the Chairman, President and Chief Executive Officer,
	Senior Vice President and Chief Financial Officer and the Senior Vice President and Chief Business Officer (&ldquo;
<B>
	Named Executive
	Officers
</B>
	&rdquo;).
<B>
<I>
</I>
</B>
	The figures are in Canadian dollars.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name and Principal
<BR>
	Position
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended December&nbsp; 31
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Salary
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
<SUP>
	(1)
</SUP>
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share-
<BR>
	based
<BR>
	awards
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Option-
</B>
<BR>
<B>
	based
</B>
<BR>
<B>
	awards
<SUP>
	(2)
</SUP>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	($)
</B>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="5" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Non-equity incentive
<BR>
	plan compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pension
<BR>
	value &nbsp;
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	All other
<BR>
	compensation
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
<BR>
	compensation
<BR>
	($)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Annual
</B>
<BR>
<B>
	incentive
</B>
<BR>
<B>
	plans
<SUP>
	(3) (1)
</SUP>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	($)
</B>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Long-term
<BR>
	incentive
<BR>
	plans
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dr. William G. Rice
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	642,813
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	634,464
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	115,093
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	N/A
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,392,370
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Chairman, President and Chief Executive Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Mr. Gregory K. Chow
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	409,762
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	317,232
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	66,066
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	N/A
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	793,060
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Senior Vice President and Chief Financial Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Mr. Avanish Vellanki
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	409,762
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	317,232
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	66,066
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	N/A
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	793,060
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Senior Vice President and Chief Business Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Dr. Rice, Mr. Chow and Mr. Vellanki are paid in US dollars. Amounts are shown in Canadian
	dollars translated from US dollars based on the exchange rates prevailing on the date of the transaction. The average exchange
	rate was $1USD = $1.2787CDN.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
	(2)
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In determining the fair value of these option-based awards, the Black-Scholes valuation
	methodology was used with the following assumptions: (i)&nbsp;expected life of five years; (ii) volatility 103.5%; (iii) risk
	free interest rate of 1.09%; and (iv) no dividend yield
<B>
	.
</B>
	The Company has decided to use the Black-Scholes valuation methodology
	because it is equivalent to the option value reported in the Company&rsquo;s consolidated financial statements.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
	(3)
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Bonus payments relate to the period from January 1 to May 31, 2015. No bonus payments
	were rewarded for the period from June 1, 2015 to December 31, 2015.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<EFX_OPTIONS>
<A NAME="FIS_OPTIONS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name and Principal Position
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended
<BR>
	December&nbsp; 31
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Salary
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cash
<BR>
	Bonus
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Other Annual
<BR>
	Compensation &nbsp;
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Securities Under
<BR>
	Options/SARs
<BR>
	Granted
<BR>
	(#)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	All Other
<BR>
	Compensation
<BR>
	($)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Dr. William G. Rice
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	642,813
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	115,093
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(1)(2)
</SUP>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	Nil
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	120,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	Nil
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Chairman, President and Chief Executive Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Mr. Gregory K. Chow
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	409,762
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	66,066
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(1)(2)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	Nil
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Senior Vice President and Chief Financial Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Mr. Avanish Vellanki
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	409,762
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	66,066
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(1)(2)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	Nil
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Senior Vice President and Chief Business Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_OPTIONS>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Dr. Rice, Mr. Chow and Mr. Vellanki are paid in US dollars. Amounts are shown in Canadian
	dollars translated from US dollars based on the exchange rates prevailing on the date of the transaction. The average exchange
	rate was $1USD = $1.2787CDN.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
	(2)
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Bonus payments relate to the period from January 1 to May 31, 2015. No bonus payments
	were rewarded for the period from June 1, 2015 to December 31, 2015.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Directors&rsquo; Compensation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table details the compensation
	received by each director for the fiscal year ended December&nbsp;31, 2015:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Fees earned
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	($)
<SUP>
	1
</SUP>
</B>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share-based
<BR>
	awards
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Option-
<BR>
	based
<BR>
	awards
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Non-equity
<BR>
	incentive plan
<BR>
	compensation
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pension value
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	All other
<BR>
	Compensation
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
<BR>
	($)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dr. Denis Burger
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	97,181
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	119,330
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	216,511
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dr. Bradley Thompson
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	61,378
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	119,330
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	180,708
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dr. Mark Vincent
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	49,869
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	119,330
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	169,199
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Mr. Warren Whitehead
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	51,148
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	119,330
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	170,478
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dr. Erich Platzer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	46,033
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	54,241
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100,274
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Directors are paid in US$. The conversion to Canadian dollars was done using an average
	rate of $1USD = $1.2787CDN.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Dr. Rice did not receive any compensation for his role
	as a director of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In January 2015, the Board approved certain
	changes related to the compensation of directors effective for the fiscal year 2015. As of January 1, 2015, directors were entitled
	to an annual fee of US$30,000 with no per meeting fees. The lead director will be entitled to an additional annual fee of US$30,000.
	The chair of each committee will be entitled to an annual fee of US$10,000 with each committee member receiving an annual fee of
	US$6,000 per committee. Upon appointment to the Board a director will be entitled to an option grant of 10,000 options and each
	year thereafter an additional grant of 6,000 options. Non-executive directors are reimbursed for any out-of pocket travel expenses
	incurred in order to attend meetings. Executive directors are not entitled to directors&rsquo; compensation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In the year ended December 31, 2015, Dr. Platzer
	was granted 10,000 options for his appointment in December 2014. All other directors received a grant of 22,000 options which represented
	a grant for fiscal 2015 of 6,000 and 16,000 options for the prior periods when options had not been granted. The options vest 50%
	after one year, 25% after 2 years and 25% after 3 years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Management Contracts
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The employment agreements of Dr. Rice, Mr. Chow
	and Mr. Vellanki provide that if their employment is terminated by the Company other than for cause, each of Dr. Rice, Mr. Chow
	and Mr.&nbsp;Vellanki shall be entitled to a payment equivalent to 12 months of their respective annual base salaries at the time
	of termination (Dr.&nbsp;Rice&rsquo;s current annual base salary represents US$494,400, Mr.&nbsp;Chow&rsquo;s current annual base
	salary represents US$324,450 and Mr.&nbsp;Vellanki&rsquo;s current annual base salary represents US$324,450), plus an amount equal
	to the average bonus remuneration received from the Company during the last three years of employment completed prior to the termination
	date, prorated based on the number of days the executive worked during the year of the termination. In addition, the employment
	agreements of Dr. Rice, Mr. Chow and Mr.&nbsp;Vellanki provide that certain payments related to health benefits will continue to
	be made for a period of 12 months following termination of their employment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If the employment agreements are terminated
	by the Company other than for cause, then all unexercised options then held by each are governed by the terms of the share option
	plan of the Company (&ldquo;
<B>
	Share Option Plan
</B>
	&rdquo;).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The employment agreements of Dr. Rice, Mr. Chow
	and Mr. Vellanki provide that, in the event their employment with the Company is terminated within three months immediately preceding
	or 12 months immediately following the consummation of a change of control, each of Dr. Rice, Mr. Chow and Mr. Vellanki would be
	eligible, subject to certain conditions, to receive a payment equivalent to 18&nbsp;months of their annual base salaries at the
	time of termination, plus an amount equal to 150% of the average bonus remuneration received from the Company during the last three
	years of employment completed prior to the termination date, prorated based on the number of days the executive worked during the
	year of the termination, as well as continuation of the payments related to health benefits for a period of 12 months following
	the termination following a change of control.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table sets out the amount that
	would have been payable to each Named Executive Officer had there been a change of control of the Company on December 31, 2015
	and the severance payment that would have been payable to each Named Executive Officer had the Company terminated employment of
	the Named Executive Officer without cause on December 31, 2015:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; WIDTH: 70%">
	Name
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Termination Without Cause
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Change of Control
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Dr. William G. Rice
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	US$830,000
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	US$1,201,000
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	&nbsp;(2)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Mr. Gregory K. Chow
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	US$484,000
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	US$711,000
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Mr. Avanish Vellanki
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	US$517,000
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	US$744,000
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 15PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	This amount represents 12 months of annual base salary
	at the time of termination, plus an amount equal to the average bonus remuneration received from the Company during the last three
	years of employment completed prior to the termination date (assumed at 100%), prorated based on the number of days the executive
	worked during the year of the termination, as well as continuation of the payments related to health benefits for a period of
	12 months following the termination.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 15PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	This amount represents 18 months of annual base salary
	at the time of termination, plus an amount equal to 150% of the average bonus remuneration received (assumed at 100%) from the
	Company during the last three years of employment completed prior to the termination date, prorated based on the number of days
	the executive worked during the year of the termination, as well as continuation of the payments related to health benefits for
	a period of 12 months following the termination.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Equity Compensation Plans
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table sets forth certain details as at the end of the
	year ended December&nbsp;31, 2015 with respect to compensation plans pursuant to which equity securities of the Company are authorized
	for issuance.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of Shares to&nbsp;be
<BR>
	issued upon exercise of
<BR>
	outstanding options,
<BR>
	warrants and rights
<BR>
	(a)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted-
<BR>
	average
<BR>
	exercise price&nbsp;of
<BR>
	outstanding
<BR>
	options,
<BR>
	warrants and
<BR>
	rights
<BR>
	(b)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of Shares&nbsp;remaining
<BR>
	available for&nbsp;future issuance
<BR>
	under the&nbsp;&nbsp;equity
<BR>
	compensation plans
<BR>
	(Excluding Shares reflected
<BR>
	in&nbsp;Column&nbsp;(a))
<BR>
	(c)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total options, warrants
<BR>
	and rights outstanding
<BR>
	and available for grant
<BR>
	(a) + (c)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Plan Category
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	%&nbsp;of
<BR>
	Shares
<BR>
	outstanding
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	%&nbsp;of Shares
<BR>
	outstanding
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	%&nbsp;of Shares
<BR>
	outstanding
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Equity compensation plans approved by Shareholders
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,689,042
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14.0
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.95
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	419,263
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.5
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,108,305
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	17.5
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
<B>
	Share Option Plan
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Share Option Plan was established to advance
	the interests of Aptose by:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	providing Eligible Persons (as defined below) with additional incentives;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	encouraging stock ownership by Eligible Persons;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	increasing the interest of Eligible Persons in the success of Aptose;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	encouraging Eligible Persons to remain loyal to Aptose; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	attracting new Eligible Persons to Aptose.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Compensation Committee, as authorized by
	the Board, administers the Share Option Plan. The maximum total number of Common Shares available for issuance from treasury under
	the Share Option Plan, together with the Stock Incentive Plan (&ldquo;
<B>
	SIP
</B>
	&rdquo;) and any other security based compensation
	arrangement is 17.5% of the Company&rsquo;s issued and outstanding Common Shares at any given time. Any exercise of options pursuant
	to the Share Option Plan will make new option grants available under the Share Option Plan, provided that the maximum number of
	Common Shares reserved for issuance collectively under the Share Option Plan and the SIP may not exceed 17.5% of the Company&rsquo;s
	issued and outstanding Common Shares at any given time.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Under the Share Option Plan, options may be
	granted to any executive officer, employee, subsidiary of an executive officer or employee, or consultant or consultant entity
	(&ldquo;
<B>
	Eligible Persons
</B>
	&rdquo;). The exercise price of options granted under the Share Option Plan is established by the
	Board and will be equal to the closing market price of the Common Shares on the TSX on the last trading day preceding the date
	of grant. If there is no trading on that date, the exercise price will be the average of the bid and ask on the TSX on the last
	trading date preceding the date of grant. If not otherwise determined by the Board, an option granted under the Share Option Plan
	will vest as to 50% on the first anniversary of the date of grant of the option and 16.66% on the second, third and fourth anniversaries
	after the date of grant. The Board fixes the term of each option when granted, but such term may not be greater than 10&nbsp;years
	from the date of grant. If the date on which an option expires pursuant to an option agreement occurs during, or within 10 days
	after the last day of, a black out period or other restriction period imposed on the trading of Common Shares by the Company, the
	expiry date for the option will be the last day of the 10-day period. Options are personal to the participant and a participant
	may not transfer an option except in accordance with the Share Option Plan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Board may, in its sole discretion, amend,
	suspend or terminate the Share Option Plan or any portion of it at any time in accordance with applicable legislation, without
	obtaining the approval of Shareholders. Any amendment to any provision of the Share Option Plan is subject to any required regulatory
	or Shareholder approval. The Company is, however, required to obtain the approval of the Shareholders for any amendment related
	to (i) the maximum number of Common Shares reserved for issuance under the Share Option Plan, and under any other security based
	compensation arrangements of the Company; (ii) a reduction in the exercise price for options held by insiders of the Company; and
	(iii) an extension to the term of options held by insiders of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If an option holder is terminated without cause,
	resigns or retires, each option that has vested will cease to be exercisable three&nbsp;months after the option holder&rsquo;s
	termination date. Any portion of an option that has not vested on or prior to the termination date will expire immediately. If
	an option holder is terminated for cause, each option that has vested will cease to be exercisable immediately upon the Company&rsquo;s
	notice of termination. Any portion of an option that has not vested on or prior to the termination date will expire immediately.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Stock Incentive Plan
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Company adopted the SIP following shareholder
	approval on June 10, 2015 pursuant to which the Board may grant stock-based awards comprised of restricted stock units (the&nbsp;&ldquo;
<B>
	Restricted
	Stock Units
</B>
	&rdquo;) or dividend equivalents (the &ldquo;
<B>
	Dividend Equivalents&rdquo;
</B>
	and
<B>
</B>
	collectively with the
	Restricted Stock Units, the
<B>
	&ldquo;Awards
</B>
	&rdquo;) to employees, officers, consultants, independent contractors, advisors
	and non-employee directors of the Corporation or any affiliate (the &ldquo;
<B>
	SIP Participants
</B>
	&rdquo;).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The maximum total number of shares available
	for issuance under the SIP and any other security based compensation arrangement of the Corporation (including the Share Option
	Plan) is 17.5% of the number of issued and outstanding shares. Any issuance of shares covered by an award or to which an award
	relates will make new grants available under the SIP. Since the adoption of the SIP, no awards have been granted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Under the SIP, the Board may also grant Dividend
	Equivalents to SIP Participants under which the Participant shall be entitled to receive payments (in cash, Shares, other securities,
	other Awards or other property as determined in the discretion of the Committee) equivalent to the amount of cash dividends paid
	by the company to holders of Shares with respect to a number of shares determined by the Board.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The SIP does not limit insider participation
	and does not provide a maximum number of Shares which may be issued to an individual under the SIP. However, no director of the
	company who is not also an employee of the company or an affiliate may be granted any awards that exceed in the aggregate $150,000
	(such value computed as of the date of grant in accordance with applicable financial accounting principles) in any calendar year.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Subject to the express provisions of the SIP
	and to applicable law, the Board shall have full power and authority to: (i) designate SIP Participants; (ii) determine the type
	of Awards to be granted to each SIP Participant under the SIP and the number of Shares to be covered by each Award; (iii)&nbsp;determine
	the terms and conditions of any Award or Award Agreement, including any terms relating to the forfeiture of any Award and the forfeiture,
	recapture or disgorgement of any cash, Shares or other amounts payable with respect to any Award; (iv) amend the terms and conditions
	of any Award or Award Agreement, subject to the limitations under Section 7 of the SIP; and (v) accelerate the exercisability of
	any Award or the lapse of any restrictions relating to any Award, subject to the limitations in Section 7 of the SIP.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Board may from time to time amend, suspend
	or terminate the SIP, and the Board may amend or alter any previously granted Award, as applicable, without obtaining the approval
	of Shareholders in order to: (i) correct any defect, supply any omission or reconcile any inconsistency in the SIP or in any Award
	or award agreement in the manner and to the extent it shall deem desirable to implement or maintain the effectiveness of the SIP;
	(ii) amend the eligibility for, and limitations or conditions imposed upon, participation in the SIP; (iii)&nbsp;make changes that
	are necessary or desirable to comply with applicable laws, rules, regulations and policies of any applicable governmental entity
	or stock exchange; (iv) amend any terms relating to the administration of the SIP, including the terms of any administrative guidelines
	or other rules related to the SIP; or (v) make any other amendment, whether fundamental or otherwise, not requiring Shareholders&rsquo;
	approval under TSX Company Manual, the rules or regulations of the United States SEC or any other securities exchange that are
	applicable to the Corporation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Prior approval of the shareholders shall be
	required for any amendment to the Plan or an Award that would: (i) require shareholder approval under the TSX Company Manual, the
	rules or regulations of the SEC or any other securities exchange that are applicable to the Corporation; (ii) increase the maximum
	number of shares authorized under the SIP; (iii)&nbsp;increase the annual limit on Awards granted to non-employee directors; or
	(iv) amend the amendment provision of the SIP.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Deferred Share Units Plan
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Company had a Deferred Share Unit Plan (&ldquo;
<B>
	DSU
	Plan
</B>
	&rdquo;) which was terminated on June 10, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	During the period from January 1, 2015 to June
	18, 2015, nil deferred share units were outstanding under the DSU Plan. No units have been outstanding under the DSU Plan since
	April 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Employee Share Purchase Plan
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have an Employee Share Purchase Plan (&ldquo;
<B>
	ESPP
</B>
	&rdquo;),
	the purpose of which is to assist the Company in retaining the services of its employees, securing and retaining the services of
	new employees and providing incentives for such persons to exert maximum efforts for the success of the Company. The ESPP provides
	a means by which employees of the Company and its affiliates may purchase Common Shares on the stock market at a 15% discount through
	accumulated payroll deductions. Eligible participants in the ESPP include all employees, including executive officers, who work
	at least 20&nbsp;hours per week and are customarily employed by the Company or an affiliate of the Company for at least six months
	per calendar year. Generally, each offering is of three months&rsquo; duration with purchases occurring every quarter. Participants
	may authorize payroll deductions of up to 15% of their base compensation for the purchase of Common Shares under the ESPP.
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	During the year ended December 31, 2015, under
	the ESPP, Named Executive Officers, as a group, and employees did not purchase any Common Shares pursuant to the ESPP.
<B>
</B>
	Since
	December 31, 2015, there have been no Common Shares purchased pursuant to the ESPP.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Option Grants During The Year Ended December 31, 2015
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following tables set forth the options granted
	to and exercised by each of the Named Executive Officers during the year ended December&nbsp;31, 2015:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<I>
	Option/SAR Grants During the Most Recently Completed Financial
	Year
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name and Principal
<BR>
	Position
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Securities
<BR>
	Under
<BR>
	Options/SARs
<BR>
	Granted
<BR>
	(#)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	%&nbsp;of&nbsp;Total
<BR>
	Options/SARs
<BR>
	Granted&nbsp;to
<BR>
	Employees&nbsp;in
<BR>
	Financial
<BR>
	Year
<BR>
	(%)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise&nbsp;or
<BR>
	Base&nbsp;Price &nbsp;
<BR>
	($/Security)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Market Value
	of
<BR>
	Securities
<BR>
	Underlying
<BR>
	Options/SARs
<BR>
	on the Date of
<BR>
	Grant
<BR>
	($/Security)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Expiration
<BR>
	Date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 45%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dr. William G. Rice
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	120,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.96
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.96
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	June 9, 2025
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Chairman, President and
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Chief Executive Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Mr. Gregory K. Chow
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.5
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.96
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.96
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	June 9, 2025
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Senior Vice President and
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Chief Financial Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.1PT">
	Mr. Avanish Vellanki
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.5
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.96
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.96
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	June 9, 2025
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Senior Vice President and
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Chief Business Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Incentive Compensation Plans
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
<B>
<I>
	Outstanding Share-Based Awards and Option-Based
	Awards
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table shows all awards outstanding
	to each Named Executive Officer as at December 31, 2015:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Option-based Awards
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="5" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Share-based Awards
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="WIDTH: 44%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name and Principal
<BR>
	Position
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
<BR>
	of
<BR>
	securities
<BR>
	underlying
<BR>
	unexercised
<BR>
	options
<BR>
	(#)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	Option
<BR>
	exercise
<BR>
	price
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	($)
</P>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 7%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Option
<BR>
	expiration
<BR>
	date
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Value of
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	unexercised
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	in-the-
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	money
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	options
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
<SUP>
	(1)
</SUP>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	shares or
<BR>
	units of
<BR>
	shares that
<BR>
	have not
<BR>
	vested
<BR>
	(#)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Market or
<BR>
	payout
<BR>
	value of
<BR>
	share-
<BR>
	based
<BR>
	awards
<BR>
	that have
<BR>
	not vested
<BR>
	($)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Market or
<BR>
	payout
<BR>
	value of
<BR>
	vested
<BR>
	share-
<BR>
	based
<BR>
	awards
<BR>
	not paid
<BR>
	out or
<BR>
	distributed
<BR>
	($)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	Dr. William G. Rice
<BR>
	Chairman, President and Chief Executive Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	35,417
<BR>
	65,136
<BR>
	5,281
<BR>
	140,000
<BR>
	396,129
<BR>
	120,000
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	3.48
<BR>
	7.32
<BR>
	6.96
<BR>
	6.00
<BR>
	5.70
<BR>
	6.96
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Oct 27, 2023
<BR>
	Dec 10, 2023
<BR>
	Jan 29, 2024
<BR>
	Apr 10, 2024
<BR>
	June 16, 2024
<BR>
	June 9, 2025
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	4,250
<BR>
	Nil
<BR>
	Nil
<BR>
	Nil
<BR>
	Nil
<BR>
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nil
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	Mr. Gregory K. Chow
<BR>
	Senior Vice President and Chief Financial Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	35,417
<BR>
	35,417
<BR>
	35,417
<BR>
	22,083
<BR>
	64,167
<BR>
	60,000
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	9.36
<BR>
	7.32
<BR>
	6.00
<BR>
	5.70
<BR>
	5.22
<BR>
	6.96
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nov 4, 2023
<BR>
	Dec 10, 2023
<BR>
	Apr 10, 2024
<BR>
	June 16, 2024
<BR>
	July 18, 2024
<BR>
	June 9, 2025
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Nil
<BR>
	Nil
<BR>
	Nil
<BR>
	Nil
<BR>
	Nil
<BR>
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nil
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	Mr. Avanish Vellanki
<BR>
	Senior Vice President and Chief Business Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	35,417
<BR>
	35,417
<BR>
	35,417
<BR>
	22,083
<BR>
	64,167
<BR>
	60,000
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.36
<BR>
	7.32
<BR>
	6.00
<BR>
	5.70
<BR>
	5.22
<BR>
	6.96
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nov 4, 2023
<BR>
	Dec 10, 2023
<BR>
	Apr 10, 2024
<BR>
	June 16, 2024
<BR>
	July 18, 2024
<BR>
	June 9, 2025
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Nil
<BR>
	Nil
<BR>
	Nil
<BR>
	Nil
<BR>
	Nil
<BR>
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	Nil
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 15PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	These amounts are calculated based on the difference
	between the market value of the securities underlying the options on December 31, 2015 at the end of the fiscal year ($3.60),
	and the exercise price of the options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_OPTIONS_AGGREGATE>
<A NAME="FIS_OPTIONS_AGGREGATE"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<I>
	Aggregated Option/SAR Exercises During the Year Ended December
	31, 2015
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<I>
	and Financial Year-End Option/SAR Values
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Securities
<BR>
	Acquired&nbsp;on
<BR>
	Exercise
<BR>
	(#)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Aggregate
<BR>
	Value
<BR>
	Realized
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Unexercised
<BR>
	Options/SARs at
<BR>
	December 31, 2015
<BR>
	(#)
<BR>
	Exercisable/Unexercisable
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Value of Unexercised
<BR>
	in-the-Money
<BR>
	Options/SARs at
<BR>
	December 31, 2015
<BR>
	($)
<BR>
	Exercisable/Unexercisable
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dr. William G. Rice
<BR>
	Chairman, President and Chief Executive Officer
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	354,975/406,988
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	4,250/0
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;Mr. Gregory K. Chow
<BR>
	Senior Vice President and Chief Financial Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	129,932/122,569
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0/0
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;Mr. Avanish Vellanki
<BR>
	Senior Vice President and Chief Business Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	nil
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	129,932/122,569
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0/0
</TD>
</TR>
</TABLE>
</EFX_OPTIONS_AGGREGATE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Board practices
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Aptose is authorized to have a board of at least
	one director and no more than ten. Aptose currently has six directors. Directors are elected for a term of approximately one year,
	from annual meeting to annual meeting, or until an earlier resignation, death or removal. For the dates our current directors assumed
	their directorships, see Item 6.A. &ndash; &ldquo;Directors and Senior Management&rdquo; above.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Each officer serves at the discretion of the
	Board or until an earlier resignation or death. There are no family relationships among any of our directors or officers.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our non-management directors have no service
	contracts with us or our subsidiaries that provide for benefits upon termination of employment. See &ldquo;&mdash;Management Contracts&rdquo;
	above for a summary of key employment agreements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Committees of the Board of Directors
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Company has an Audit Committee, a Nominating
	and Corporate Governance Committee and a Compensation Committee.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The members of these committees during the year
	months ended December 31, 2015, were as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 46%">
<FONT STYLE="FONT-SIZE: 10PT">
	Audit Committee
</FONT>
</TD>
<TD STYLE="WIDTH: 54%">
<FONT STYLE="FONT-SIZE: 10PT">
	Denis Burger, Bradley Thompson, Warren Whitehead
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Nominating and Corporate Governance Committee:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Bradley Thompson, Mark Vincent
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Compensation Committee:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Denis Burger, Erich Platzer, Bradley Thompson
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On January 16, 2015, Bradley Thompson was appointed
	to the Audit Committee and Erich Platzer was appointed to the Compensation Committee.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Compensation Committee
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Composition of the Compensation Committee
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Board, upon the advice of the Compensation
	Committee, determines executive compensation. The Compensation Committee is currently comprised of independent Board members Dr.&nbsp;Burger,
	Dr. Platzer and Dr. Thompson. Dr. Burger is chair of the Compensation Committee. The Compensation Committee met 3 times during
	the period from January 1, 2015, until December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Members of the Compensation Committee each have
	direct experience relevant to compensation matters resulting from their respective current and past activities. The members of
	the Compensation Committee have experience dealing with compensation matters in comparable organizations, including public companies,
	as well as companies with a strong emphasis on governance in their current and former roles as principal executives.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Compensation Objectives and Philosophy
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Compensation Committee&rsquo;s mandate is
	to review and advise the Board on the recruitment, appointment, performance, compensation, benefits and termination of executive
	officers. The Compensation Committee also administers and reviews procedures and policies with respect to the Share Option Plan,
	the SIP, employee benefit programs, pay equity and employment equity and reviews executive compensation disclosure where it is
	publicly disclosed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Aptose&rsquo;s executive compensation program is designed to:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	attract and retain qualified, motivated and achievement-oriented individuals by offering compensation that is competitive in the industry and marketplace;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	align executive interests with the interests of shareholders; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	ensure that individuals continue to be compensated in accordance with their personal performance and responsibilities and their contribution to the overall objectives of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	These objectives are achieved by offering executives
	and employees a compensation package that is competitive and rewards the achievement of both short-term and long-term objectives
	of the Company. As such, our compensation package consists of three key elements:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	base salary and initial share options;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	short-term compensation incentives to reward corporate and personal performance through potential annual cash bonuses; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	long-term compensation incentives related to long-term increase in share value through participation in the Share Option and SIPs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Compensation Committee reviews each of these
	items on a stand-alone basis and also reviews compensation as a total package. Adjustments to compensation are made as appropriate
	following a review of the compensation package as a whole.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Base Salary&nbsp;&mdash; Initial Share Options
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In establishing base salaries, the objective
	of the Compensation Committee is to establish levels that will enable Aptose to attract and retain executive officers that can
	effectively contribute to the long-term success of the Company. Base salary for each executive officer is determined by the individual&rsquo;s
	skills, abilities, experience, past performance and anticipated future contribution to the success of Aptose. The members of the
	Compensation Committee use their knowledge of the industry and of industry trends as well as independent third party consultants
	to assist with the determination of an appropriate compensation package for each executive officer. In certain cases, the Compensation
	Committee may recommend inclusion of automobile allowances, fitness allowances and the payment of certain professional dues as
	a component of an overall remuneration package for executives.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In certain cases, executive officers may be
	granted share options on the commencement of employment with Aptose in accordance with the responsibility delegated to each executive
	officer for achieving corporate objectives and enhancing shareholder value in accordance with those objectives.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Short-Term Compensation Incentives
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The role of short-term compensation incentives
	at Aptose is to motivate our executive officers to achieve specified performance objectives for 2015 and to reward them for their
	achievement in the event that those objectives are met. Each year, the Compensation Committee approves the annual corporate objectives
	encompassing scientific, clinical, regulatory, business and corporate development and financial criteria. The annual cash bonus
	for the executive officers is based, at least in part, on the level of achievement of these annual objectives, assuming these objectives
	are still relevant at the time of evaluation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	All corporate and executive officer objectives
	are reviewed by the Compensation Committee and approved by the Board. The Compensation Committee recommends to the Board the awarding
	of bonuses, payable in cash, stock or share options, to reward extraordinary individual performance.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	For each executive officer, during the year
	ended December&nbsp;31, 2015, the annual cash bonuses ranged from 40% to 50% of base salary when all corporate and individual executive
	officer objectives were achieved.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Cash bonuses are determined as soon as practicable
	after the end of the fiscal year and, for the Named Executive Officers (as defined hereinafter), are included in the Summary Compensation
	Table in the year in respect of which they are earned.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Long-Term Incentive Plan
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The role of long-term compensation incentives
	at Aptose is to reward an executive&rsquo;s contribution to the attainment of Aptose&rsquo;s long-term objectives, align an executive&rsquo;s
	performance with the long-term performance of Aptose and to provide an additional incentive for an executive to enhance shareholder
	value. Long-term incentive compensation for directors, officers, employees and consultants is reviewed annually and is accomplished
	through the grant of share options under our Share Option Plan or SIP.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The number of options granted for certain executives
	of Aptose for the year ended December 31, 2015, was based on achievement of both corporate and executive officer objectives. The
	Compensation Committee approves the allocation of options and options are priced using the closing market price of the Common Shares
	on the TSX on the last trading day prior to the date of grant. Options to purchase Common Shares expire ten years from the date
	of grant and vest over a term determined by the Compensation Committee. The Compensation Committee takes into account previous
	grants of options when considering new grant of options.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The granting of options to Named Executive Officers
	is included in the Summary Compensation Table in the year in which they are earned.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Performance Metrics
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The performance of the Named Executive Officers
	for the period ended December 31, 2015 was measured with respect to the following objectives:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Site initiation and enrollment goals for APTO-253 Phase Ib Clinical trial;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Analyze corporate structure, implement financing alternatives and consider Board composition;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Expand pipeline;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Other development goals related to APTO-253.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Each of the above objectives is weighted at
	50%, 30%, 10% and 10% respectively in relation to assessment of satisfaction of overall corporate objectives and determination
	of any general corporate bonuses. Due to the clinical hold of the APTO-253 clinical trial it was determined that no bonuses would
	be paid to the Named Executive Officers for the period from June 1, 2015 to December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Hedge or Offset Instruments
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Named Executive Officers or directors are not
	permitted to purchase financial instruments that are designed to hedge or offset a decrease in market value of equity securities
	granted as compensation or held, directly or indirectly, by Named Executive Officers or directors, including, for greater certainty,
	prepaid variable forward contracts, equity swaps, collars, or units of exchange funds.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
<I>
	Risk Assessment of Compensation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The implications of the risks associated with
	the Company&rsquo;s compensation practices were not considered by the Board or a committee of the Board.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Audit Committee
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The charter of our Audit Committee is attached
	as Exhibit 11.2. The current members of the Audit Committee are Bradley Thompson, Denis Burger and Warren Whitehead. Mr. Warren
	Whitehead is the Chairman of the Audit Committee and has been considered to be the Financial Expert. Pursuant to Canadian securities
	laws, the Board has determined that Messrs. Thompson, Burger and Whitehead are financially literate as all have experience in reviewing
	and analyzing the financial reports and ascertaining the financial position of a corporation. Mr. Burger, in his previous position
	as Chairman and Chief Executive Officer of AVI Biopharma, is educated and experienced in reading and analyzing financial statements.
	Mr. Burger has also served on the audit committee of three other publicly listed biotechnology companies. Dr. Thompson has experience
	reading and interpreting financial statements through his role as Chairman and CEO of a publicly listed biotechnology company as
	well as through his extensive experience serving on various company boards.&nbsp; Mr. Whitehead is a CPA (CMA) and has served as
	the Chief Financial Officer of Arius Research Inc. and Labopharm Inc. Additionally, we believe Mr. Thompson, Mr. Whitehead and
	Mr. Burger qualify as &ldquo;independent&rdquo; as that term is defined in the relevant securities laws relating to the composition
	of the audit committee.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 9PT">
<B>
<I>
	Audit Committee Mandate
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Audit Committee&rsquo;s mandate is to assist
	the Board in fulfilling its oversight responsibilities. In particular, the Audit Committee:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	serves as an independent and objective party to monitor the integrity of our financial reporting process and systems of internal controls regarding finance, accounting, and legal compliance, including the review of our consolidated financial statements, MD&amp;A and annual and interim results;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	identifies and monitors the management of the principal risks that could impact our financial reporting;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(c)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	monitors the independence and performance of our independent auditors, including the pre-approval of all audit fees and all permitted non-audit services;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(d)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	provides an avenue of communication among the independent auditors, management, and the Board and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(e)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	encourages continuous improvement of, and foster adherence to, our policies, procedures and practices at all levels.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Audit Committee is also responsible for
	implementing and overseeing our whistle-blowing procedures.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Employees
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As at December 31, 2015, we employed 22 full-time
	persons and 2 part-time persons in research and drug development and administration activities. Our employees 5 hold Ph.D.&rsquo;s
	and numerous others hold degrees and designations such as MSc, BSc, CPA (CA), CPA (California) and MBA. To encourage a focus on
	achieving long-term performance, employees and members of the Board have the ability to acquire an ownership interest in the Company
	through Aptose&rsquo;s share option and alternate compensation plans. See Item 6.B &ndash; Compensation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our ability to develop commercial products and
	to establish and maintain our competitive position in light of technological developments will depend, in part, on our ability
	to attract and retain qualified personnel. There is a significant level of competition in the marketplace for such personnel. We
	believe that to date we have been successful in attracting and retaining the highly skilled personnel critical to our business.
	We have also chosen to outsource activities where skills are in short supply or where it is economically prudent to do so.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	None of our employees are unionized, and we
	consider our relations with our employees to be good.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	E.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Share ownership
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table sets forth information regarding
	beneficial ownership of our Common Shares as of December 31, 2015 with respect to our Named Executive Officers and also with respect
	to our executive officers and directors individually and as a group.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Options to Purchase Common Shares
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	Common
<BR>
	Shares
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total Number
<BR>
	of Common
<BR>
	Shares
<BR>
	Beneficially
<BR>
	Owned
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Percentage of
<BR>
	Common
<BR>
	Shares
<BR>
	Outstanding(+)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	Underlying
<BR>
	Common
<BR>
	Shares
<BR>
	(#)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise Price
<BR>
	(Range)
<BR>
	($)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Expiry
<BR>
	Date
<BR>
	(Range-
<BR>
	Year)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.75PT">
	Dr. William Rice
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.1
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	761,963
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$3.48-7.32
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2023-2025
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.75PT">
	Mr. Gregory Chow
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	252,501
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$5.28-9.36
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2023-2025
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.75PT">
	Mr. Avanish Vellanki
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,200
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,200
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	252,501
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$5.28-9.36
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2023-2025
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.75PT">
	Dr. Denis Burger
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,499
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,499
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	35,334
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.16-6.77
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2021-2025
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.75PT">
	Dr. Bradley Thompson
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,750
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$6.00-6.77
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2024-2025
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.75PT">
	Dr. Erich Platzer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,500
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,500
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	$6.77
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2025
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.75PT">
	Dr. Mark Vincent
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,500
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,500
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	29,083
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.16-6.77
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2021-2025
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.75PT">
	Mr. Warren Whitehead
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.1
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27,500
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.16-6.77
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2021-2025
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 0.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.75PT">
	All directors and executive officers as a group
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	57,699
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	57,699
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.5
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,394,632
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.16-9.36
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2021-2025
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
<B>
	(+) calculated on a partially diluted basis excluding
	options.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	See Item 6.B for a description of arrangements pursuant to which
	employees may become involved in the capital of Aptose.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I7">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 7.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Major Shareholders and Related Party Transactions
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Major shareholders
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	To the knowledge of our directors and officers,
	as of the date hereof, no person or company beneficially owns, directly or indirectly, or exercises control or direction over,
	5% or more of the outstanding Common Shares, other than those discussed below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Approximately 60% of our ordinary Common Shares
	are held in Canada, and there are 288 record holders of our Common Shares in Canada and 84 record holders in the United States.
	All of our shareholders have equal voting rights.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table is based upon information
	supplied by officers, directors and principal Stockholders and Schedules 13D and 13G filed with the SEC.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name of Beneficial Owner(s)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount and Nature
<BR>
	of Beneficial Ownership
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Percent of Class
</B>
<SUP>
	(1)
</SUP>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Franklin Resources Inc.
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,416,666
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11.75
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cormorant Global Healthcare Master Fund LP
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,081,867
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(4)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Pinetree Capital
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	874,300
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.25
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Herbert Abramson
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	805,828
<SUP>
	(6)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.68
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Sheldon Inwentash
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-VARIANT: SMALL-CAPS">
	614,471
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(5)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	(1) Based on 12,047,455 Common Shares outstanding as
	of March 29, 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	(2) This information is based solely on a Schedule 13G
	filed with the SEC on February 13, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	(3) This information is based solely on a Schedule 13G
	filed with the SEC on February 6, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	(4) This information is based solely on a Schedule 13G
	filed with the SEC on February 16, 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	(5) This information is based solely on a Schedule 13G
	filed with the SEC on March 2, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	(6) This information is based solely on a Schedule
	13G filed with the SEC on March 29, 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Related party transactions
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In March 2015, the Company entered into an agreement
	with the Moores Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services to the Company.
	Dr. Stephen Howell is the Acting Chief Medical Officer of Aptose and is also a Professor of Medicine at UCSD and will be overseeing
	the laboratory work. The research services will be provided from April 1, 2015 to March 31, 2016 for an annual fee of US$154,456
	to be paid to UCSD in monthly installments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	There were no related party transactions in
	the seven month transition period ended December 31, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Certain related parties participated in the
	June 2013 private placement described above. Directors and officers, including former president and chief operating officer Dr.
	Aiping Young, former director Dr. Jim Wright and current director Dr. Mark Vincent, acquired an aggregate of $68,000 of the promissory
	notes. A company related to Mr. Hebert Abramson, a former director of the Company, acquired $250,000 of the promissory notes and
	Mr. Inwentash and his joint actors (&ldquo;
<B>
	Mr. Inwentash
</B>
	&rdquo;), a former related party of the Company by virtue of having
	exercised control or direction over more than 10% of the issued and outstanding Common Shares of the Company, acquired $100,000
	of the promissory notes. These promissory notes were repaid by the Company in April 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In the September 2013 convertible promissory
	note private placement described above, a company related to Mr. Abramson, a former director of Aptose, acquired $100,000 of the
	promissory notes; Mr. Inwentash acquired $150,000 of the promissory notes; and Sprott Asset Management, which then held more than
	10% of the Common Shares of Aptose and the ability to acquire control of more than 20% of the Common Shares of Aptose, acquired
	$112,000 of the promissory notes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Mr. Inwentash participated in the December
	2013 Common Share public offering described above and acquired an aggregate of 151,667 (pre-consolidation 1,820,000) Common
	Shares in that offering and an aggregate of 108,333 (pre-consolidation 1,300,000) Common Shares in the April 2014
	public offering described above.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
<I>
	Executive Contracts
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On October 25, 2013, the Company entered into
	an executive employment agreement with William G. Rice, Ph.D., in connection with his appointment as Chief Executive Officer and
	Chairman of the Board of the Company.&nbsp;On August 19, 2014, the Company entered into an amended executive employment agreement
	with William G. Rice, Ph.D.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	On November 29, 2013, the Company entered into
	an executive employment agreement with each of Gregory K. Chow and Avanish Vellanki in connection with their appointments as Chief
	Financial Officer and Chief Business Officer, respectively, of the Company.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The employment agreements for each of Dr. Rice,
	Mr. Chow and Mr. Vellanki provide that if they are terminated by the Company other than for cause, each of Dr. Rice, Mr. Chow and
	Mr. Vellanki would be entitled under their respective agreements to a payment equivalent to 12 months of their respective annual
	base salaries at the time of termination.&nbsp; Dr. Rice&rsquo;s current annual base salary represents U.S. $494,400, Mr. Chow&rsquo;s
	current annual base salary represents U.S. $324,450, and Mr. Vellanki&rsquo;s current annual base salary represents U.S. $324,450.&nbsp;
	They are each additionally entitled to an amount equal to the average bonus remuneration received from the Company during the last
	three years of employment completed prior to the termination date, prorated based on the number of days the executive worked during
	the year of the termination.&nbsp; In addition, the employment agreements for each of Dr. Rice, Mr. Chow and Mr. Vellanki provide
	that certain payments related to health benefits continue to be made for a period of 12 months following termination of their employment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The employment agreements of each of Dr. Rice,
	Mr. Chow and Mr. Vellanki also provide for the grant of options to purchase Common Shares of the Company, at an exercise price
	equal to the fair market value of the shares on the dates of grant.&nbsp; In connection with the execution of his executive employment
	agreement, Dr. Rice received an initial grant of a fully vested option to purchase 35,417 (425,000 pre-consolidation) Common Shares
	at an exercise price equal to the fair market value of the Common Shares on the date of grant.&nbsp; Pursuant to the terms of his
	executive employment agreement, upon satisfaction of the conditions in his agreement, Dr. Rice received additional grants of options
	to purchase 5,281 (63,367 pre-consolidation), 65,136 (781,633 pre-consolidation) and 140,000 (1,680,000 pre-consolidation) Common
	Shares on December 10, 2013, January 29, 2014 and April 10, 2014, respectively, at exercise prices equal to the fair market value
	of the Common Shares on the dates of grant.&nbsp; The options vest in accordance with the Company&rsquo;s standard three year vesting
	term, at a rate of 50% of the shares subject to the option vest on the one-year anniversary of the date of grant and 25% vest on
	each one-year anniversary thereafter.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In addition to the option grants to Mr. Chow
	and Mr. Vellanki described below, Mr. Chow and Mr. Vellanki each received two additional grants of options to purchase 35,417 (425,000
	pre-consolidation) Common Shares pursuant to the terms of their respective executive employment agreements, on December 10, 2013
	and April 10, 2014.&nbsp; Of the 35,417 (425,000 pre-consolidation) options granted on December 10, 2013 to Mr. Chow and Mr. Vellanki,
	16,667 (200,000 pre-consolidation) vested immediately and the remaining 18,750 (225,000 pre-consolidation) options vest 50% after
	one year, 25% after two years and 25% after three years from the date of grant. The options granted in April 10, 2014 vest in equal
	monthly installments over 36 months from the date of grant.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The employment agreements of Dr. Rice, Mr. Chow and Mr. Vellanki
	also provide that, in the event of a change of control (as defined in the agreements), each of Mr. Chow and Mr. Vellanki would
	be eligible to receive a payment equivalent to 18 months of their respective annual base salaries at the time of termination, plus
	an amount equal to 150% of the average bonus remuneration received from the Company during the last three years of employment completed
	prior to the termination date, prorated based on the number of days the executive worked during the year of the termination, as
	well as continuation of the payments related to health benefits for a period of 12 months following the termination following a
	change of control.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Prior to the Company entering into the executive employment agreements
	with Mr. Chow and Mr. Vellanki, Aptose entered into a consulting agreement with each of Mr. Chow and Mr. Vellanki, on November
	4, 2013.&nbsp; Pursuant to the consulting agreements, Mr. Chow provided services to the Company as acting Chief Financial Officer
	prior to the date of his executive employment agreement and Mr. Vellanki provided services as acting Chief Business Officer prior
	to the date of his executive employment agreement.&nbsp; Mr. Chow and Mr. Vellanki each were compensated at the monthly rate of
	$20,833 for their services and each were granted a fully vested option to purchase 35,417 (425,000 pre-consolidation) Common Shares
	at an exercise price equal to the fair market value of the shares on the date of grant.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Interests of experts and counsel
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SECURITY_OWNERS>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I8">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 8.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Financial Information
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Consolidated statements and other financial information
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	See Item 18 for our consolidated financial statements
	and other financial information.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Dividends on our Common Shares are declared
	at the discretion of our board of directors. To date, we have not paid any dividends and do not expect to do so in the foreseeable
	future.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Significant changes
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	None.
</P>
</EFX_FINANCIAL_DATA>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_LISTING>
<A NAME="FIS_LISTING"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
<A NAME="F20F_032916_HTM_I9">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 9.
	The Offer and Listing
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Not applicable, except for Item 9.A.4. and Item 9.C.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Offer and listing details
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Price Range of Common Stock and Trading Markets
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our Common Shares, without par value, are currently
	listed on the TSX under the symbol &ldquo;APS&rdquo; and NASDAQ under the symbol &ldquo;APTO.&rdquo; The following table sets out
	the price ranges and trading volumes of our Common Shares on the TSX for the periods indicated below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="13" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	TSX
<BR>
	(CDN$ and adjusted for post-consolidation)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Five most recent full fiscal years:
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	High
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Low
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Volume
</B>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT">
	Year ended December 31, 2015
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.73
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.06
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,909,034
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Seven months ended December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.14
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.80
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,856,934
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Year ended May 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.48
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.04
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,125,433
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Year ended May 31, 2013
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.68
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	614,114
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Year ended May 31, 2012
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.64
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.92
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	350,900
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Year ended May 31, 2011
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	30.60
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.16
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	217,475
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year ended December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.73
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.06
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,909,034
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.33
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.06
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,843,402
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended September 30, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.66
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,142,997
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended June 30, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.32
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.40
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	905,688
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended March 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.73
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,016,947
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	7 months ended December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.14
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.80
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,856,934
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Three months ended December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.14
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,715,174
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Four months ended September 30, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.84
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.80
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,141,710
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year ended May 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.48
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.04
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,125,433
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended May 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.24
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.16
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,340,234
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended February 28, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10.56
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.88
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,396,513
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended November 30, 2013
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.48
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.16
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,324,830
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended August 31, 2013
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.88
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.04
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	63,850
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Most recent fourteen months:
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	High
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Low
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Volume
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	March 1, 2016 &ndash; March 29, 2016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.16
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.74
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	713,659
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT">
	February 2016
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.11
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.09
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	285,511
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	January 2016
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.21
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.74
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	404,851
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	December 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.06
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.06
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	366,327
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	November 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.33
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.19
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	924,636
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;October 2015
<BR>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.66
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.87
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	552,439
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	September 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.19
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.65
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	440,777
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	August 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.51
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	557,728
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	July 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.40
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.29
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	144,492
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	June 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.60
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.15
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	255,296
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	May 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.80
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.15
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	265,704
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	April 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.32
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.49
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	383,688
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	March 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.73
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	581,181
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	February 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.52
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	272,822
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	January 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.90
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	162,944
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following table sets out the price ranges
	and trading volumes of our Common Shares on NASDAQ following the initial listing on October 23, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	NASDAQ
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT">
	(US$ and adjusted for post-consolidation)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	High
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Low
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Volume
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year ended December 31, 2015
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.81
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.17
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,375,129
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.40
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.17
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,282,712
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended September 30, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.72
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.41
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	944,753
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended June 30, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.63
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.26
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,266,220
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Quarter ended March 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.81
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.01
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,881,444
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Most recent six months:
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	High
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Low
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Volume
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT">
	February 2016
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.01
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.24
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	210,219
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	January 2016
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.41
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.01
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	273,041
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	December 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.14
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.17
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	556,166
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	November 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.40
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,258,777
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;October 2015
<BR>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.68
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	467,769
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	September 2015&#9;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.47
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	250,991
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Period
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	High
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Low
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Volume
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT">
	October 23, 2014 to December 31, 2014
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.80
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.60
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	587,851
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Plan of distribution
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Markets
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	See Item 9.A.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Selling shareholders
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	E.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Dilution
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	F.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Expense of the issue
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_LISTING>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_ADDITIONAL_INFORMATION>
<A NAME="FIS_ADDITIONAL_INFORMATION"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
<A NAME="F20F_032916_HTM_I10">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 10.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Additional Information
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Share capital
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Memorandum and articles of association
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We are incorporated pursuant to the laws of
	Canada (Corporation Number: 6650309). Our articles of incorporation
<B>
</B>
	(&ldquo;
<B>
	Articles
</B>
	&rdquo;) and by-laws provide
	no restrictions as to the nature of our business operations. Under Canadian law, a director must inform us, at a meeting of the
	Board, of any interest in a material contract or proposed material contract with us. Directors may not vote in respect of any such
	contracts made with us or in any such contract in which a director is interested, and such directors shall not be counted for purposes
	of determining a quorum. However, these provisions do not apply to (i)&nbsp;a contract relating primarily to their remuneration
	as a director, officer, employee or agent of the Corporation or affiliate, (ii)&nbsp;a contract for their indemnity or insurance
	as permitted under the
<I>
	Canada Business Corporations Act
</I>
	, or (iii)&nbsp;a contract with an affiliate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We are authorized to issue an unlimited number
	of Common Shares. Our shareholders have no rights to share in our profits, are subject to no redemption or sinking fund provisions,
	have no liability for further capital calls and are not subject to any discrimination due to number of Common Shares owned. By
	not more than 50&nbsp;days nor less than seven days in advance of a dividend, the Board may establish a record date for the determination
	of the persons entitled to such dividend.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The rights of holders of our Common Shares can
	be changed at any time in a shareholder meeting where the modifications are approved by 66 2/3% of the Common Shares represented
	by proxy or in person at a meeting at which a quorum exists.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	All holders of our Common Shares are entitled
	to vote at annual or special meetings of shareholders, provided that they were shareholders as of the record date. The record date
	for shareholder meetings may precede the meeting date by no more than 50&nbsp;days and not less than 21&nbsp;days, provided that
	notice by way of advertisement is given to shareholders at least seven days before such record date. Notice of the time and place
	of meetings of shareholders may not be less than 21 nor greater than 50&nbsp;days prior to the date of the meeting. There are no:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	limitations on share ownership;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	provisions of the Articles or by-laws that would have the effect of delaying, deferring or preventing a change of control of our company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	by-law provisions that govern the ownership threshold above which shareholder ownership must be disclosed; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	conditions imposed by the Articles or by-laws governing changes in capital, but Canadian corporate law requires any changes to the terms of share capital be approved by 66.66% of the Common Shares represented by proxy or in person at a shareholders&rsquo; meeting convened for that purpose at which a quorum exists.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Common Shares
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Each holder of record of Common Shares, without
	par value, is entitled to one vote for each share held on all matters properly submitted to the shareholders for their vote, except
	matters which are required to be voted on as a particular class or series of stock. Cumulative voting for directors is not permitted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Holders of outstanding Common Shares are entitled
	to those dividends declared by the board of directors out of legally available funds. In the event of liquidation, dissolution
	or winding up our affairs, holders of Common Shares are entitled to receive, pro rata, our net assets available after provision
	has been made for the preferential rights of the holders of preferred stock, including any surplus available after such event of
	liquidation, dissolution or winding up of the affairs of the Company. Holders of outstanding Common Shares have no pre-emptive,
	conversion or redemption rights. All of the issued and outstanding Common Shares are, and all unissued Common Shares, when offered
	and sold will be, duly authorized, validly issued, fully paid and non-assessable. To the extent that additional Common Shares may
	be issued in the future, the relative interests of the then existing shareholders may be diluted. There were 12,047,455 Common
	Shares issued and outstanding at December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Common Shares Eligible for Future Sale
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Future sales of substantial amounts of our Common
	Shares in the public market or even the perception that such sales may occur, could adversely affect the market price for our Common
	Shares and could impair our future ability to raise capital through an offering of our equity securities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	As at March 29,
	2016, the Company had 12,046,455 Common Shares issued and outstanding. In addition, as of March 15, 2016 there were 1,681,296
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	Common Shares issuable upon the exercise of outstanding options to purchase an equal number of Common
	Shares at a weighted average price per share of $6.31 and 72,605 Common Shares issuable upon the exercise of Common Share purchase
	warrants priced at $5.40 and expiring in August 2016.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Indemnification of Executive Officers and Directors
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have agreed to indemnify our executive officers
	and directors for all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably
	incurred by them in respect of any civil, criminal or administrative action or proceeding to which they are made a party by reason
	of being or having been a director or officer, if (a)&nbsp;they acted honestly and in good faith with a view to our best interests,
	and (b)&nbsp;in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, they had
	reasonable grounds for believing that their conduct was lawful.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Material contracts
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Other than the agreements described below, we have not, in the two
	years preceding the date hereof, entered into any material agreements other than contracts in the ordinary course of business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Executive Employment Agreement between the Company and Dr. William G. Rice, dated October 25, 2013 and the Amendment dated August 19, 2014.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Underwriting Agreement between the Company and RBC Dominion Securities Inc., Roth Capital Partners, LLC and Cormark Securities Inc. dated March 27, 2014 in connection with the April 2014 public offering.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Underwriting Agreement between the Company and Clarus
	Securities Inc., Canaccord Genuity Corp., Jennings Capital Inc. and D &amp; D Securities Inc
</FONT>
	.
<FONT STYLE="FONT-SIZE: 10PT">
	dated
	November 22, 2013 in Connection with the December 2013 public offering.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	4.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Sales Agreement between the Company and Cowen and Company, LLC, dated April 2, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Please refer to &ldquo;&ldquo;Management Contracts&rdquo;
	for further details on item 1 above.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Exchange controls
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	There is no law or governmental decree or regulation
	in Canada that restricts the export or import of capital, or affects the remittance of dividends, interest or other payments to
	non-resident holders of our voting Common Shares, other than withholding tax requirements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	There is no limitation imposed by Canadian law
	or by our Articles or our other charter documents on the right of a non-resident to hold or vote voting Common Shares, other than
	as provided by the
<I>
	Investment Canada Act
</I>
	, the
<I>
	North American Free Trade Agreement Implementation Act
</I>
	(Canada) and
	the
<I>
	World Trade Organization Agreement Implementation Act
</I>
	.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The
<I>
	Investment Canada Act
</I>
	requires notification
	and, in certain cases, advance review and approval by the government of Canada of the acquisition by a non-Canadian of control
	of a Canadian business, all as defined in the
<I>
	Investment Canada Act.
</I>
	Generally, the threshold for review will be higher
	in monetary terms for a member of the World Trade Organization or North American Free Trade Agreement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	E.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Taxation
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
	CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following discussion is limited to certain
	material U.S. federal income tax considerations relating to the purchase, ownership and disposition of the Common Shares by U.S.
	Holders (as defined below). This discussion applies to U.S. Holders that hold Common Shares as capital assets. This summary is
	for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income
	tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of
	Common Shares. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax
	advice with respect to any U.S. Holder.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	No legal opinion from U.S. legal counsel or
	ruling from the Internal Revenue Service (the &ldquo;
<B>
	IRS
</B>
	&rdquo;) has been requested, or will be obtained, regarding the
	U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares. This summary is not binding
	on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in
	this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS
	and the U.S. courts could disagree with one or more of the conclusions described in this summary.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	This discussion is based on the U.S. Internal
	Revenue Code of 1986, as amended (the &ldquo;
<B>
	Code
</B>
	&rdquo;), U.S. Treasury regulations promulgated thereunder and administrative
	and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with
	retroactive effect. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	This discussion does not address all of the
	U.S. federal income tax considerations that may be relevant to specific U.S. Holders in light of their particular circumstances
	or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as certain financial institutions, insurance
	companies, broker-dealers and traders in securities or other persons that generally mark their securities to market for U.S. federal
	income tax purposes, tax-exempt entities, retirement plans, regulated investment companies, real estate investment trusts, certain
	former citizens or residents of the United States, persons who hold Common Shares as part of a &ldquo;straddle,&rdquo; &ldquo;hedge,&rdquo;
	&ldquo;conversion transaction,&rdquo; &ldquo;synthetic security&rdquo; or integrated investment, persons that have a &ldquo;functional
	currency&rdquo; other than the U.S. dollar, persons that own (or are deemed to own) 10% or more (by voting power or value) of our
	Common Shares, corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass-through entities,
	and investors in such pass-through entities). This discussion does not address any U.S. state or local or non-U.S. tax considerations
	or any U.S. federal estate, gift or alternative minimum tax considerations. In addition, except as specifically set forth below,
	this summary does not discuss applicable tax reporting requirements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As used in this discussion, the term &ldquo;
<B>
	U.S.
	Holder
</B>
	&rdquo; means a beneficial owner of the Common Shares that is, for U.S. federal income tax purposes, (1)&nbsp;an individual
	who is a citizen or resident of the United States, (2)&nbsp;a corporation (or entity treated as a corporation for U.S. federal
	income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia,
	(3)&nbsp;an estate the income of which is subject to U.S. federal income tax regardless of its source or (4)&nbsp;a trust (x)&nbsp;with
	respect to which a court within the United States is able to exercise primary supervision over its administration and one or more
	United States persons have the authority to control all of its substantial decisions or (y)&nbsp;that has elected under applicable
	U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income tax purposes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If an entity treated as a partnership for U.S.
	federal income tax purposes holds the Common Shares, the U.S. federal income tax considerations relating to an investment in the
	Common Shares will depend in part upon the status and activities of such entity and the particular partner. Any such entity should
	consult its own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners of the purchase,
	ownership and disposition of the Common Shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Persons holding Common Shares should consult their own tax advisors
	as to the particular tax considerations applicable to them relating to the purchase, ownership and disposition of Common Shares,
	including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Distributions
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Subject to the discussion below under &ldquo;Passive
	Foreign Investment Company Considerations,&rdquo; a U.S. Holder that receives a distribution with respect to the Common Shares
	generally will be required to include the gross amount of such distribution (before reduction for any Canadian withholding taxes)
	in gross income as a dividend when actually or constructively received to the extent of the U.S. Holder&rsquo;s pro rata share
	of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent
	a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&rsquo;s pro rata share of our current
	and accumulated earnings and profits, it will be treated first as a tax-free return of capital and reduce (but not below zero)
	the adjusted tax basis of the U.S. Holder&rsquo;s Common Shares. To the extent the distribution exceeds the adjusted tax basis
	of the U.S. Holder&rsquo;s Common Shares, the remainder will be taxed as capital gain. Because we may not calculate our earnings
	and profits under U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported to them as dividends.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The U.S. dollar value of any distribution on
	the Common Shares made in Canadian dollars generally should be calculated by reference to the exchange rate between the U.S. dollar
	and the Canadian dollar in effect on the date of receipt (or deemed receipt) of such distribution by the U.S. Holder regardless
	of whether the Canadian dollars so received are in fact converted into U.S. dollars at that time. If the Canadian dollars received
	are converted into U.S. dollars on the date of receipt (or deemed receipt), a U.S. Holder generally should not recognize currency
	gain or loss on such conversion. If the Canadian dollars received are not converted into U.S. dollars on the date of receipt (or
	deemed receipt), a U.S. Holder generally will have a basis in such Canadian dollars equal to the U.S. dollar value of such Canadian
	dollars on the date of receipt (or deemed receipt). Any gain or loss on a subsequent conversion or other disposition of such Canadian
	dollars by such U.S. Holder generally will be treated as ordinary income or loss and generally will be income or loss from sources
	within the United States for U.S. foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method
	of tax accounting. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences
	of receiving, owning, and disposing of foreign currency.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Distributions on the Common Shares that are
	treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and
	generally will constitute passive category income. Such dividends will not be eligible for the &ldquo;dividends received&rdquo;
	deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations. Dividends paid
	by a &ldquo;qualified foreign corporation&rdquo; are eligible for taxation at a reduced capital gains rate rather than the marginal
	tax rates generally applicable to ordinary income provided that a holding period requirement (more than 60 days of ownership, without
	protection from the risk of loss, during the 121-day period beginning 60 days before the ex-dividend date) and certain other requirements
	are met. However, if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year (see discussion
	below under &ldquo;&mdash;Passive Foreign Investment Company Considerations&rdquo;), we will not be treated as a qualified foreign
	corporation, and therefore the reduced capital gains tax rate described above will not apply. Each U.S. Holder is advised to consult
	its tax advisors regarding the availability of the reduced tax rate on dividends.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If a U.S. Holder is subject to Canadian withholding
	tax on dividends paid on the holder&rsquo;s Common Shares, the U.S. Holder may be eligible, subject to a number of complex limitations,
	to claim a credit against its U.S. federal income tax for the Canadian withholding tax imposed on the dividends. A U.S. Holder
	may claim a deduction for the Canadian withholding tax in lieu of a credit, but only for a year in which the U.S. Holder elects
	to do so for all creditable foreign income taxes. The rules governing the foreign tax credit are complex. Each U.S. Holder is advised
	to consult its own tax advisor regarding the availability of the foreign tax credit under its particular circumstances.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Sale, Exchange or Other Disposition of Common Shares
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Subject to the discussion below under &ldquo;Passive
	Foreign Investment Company Considerations,&rdquo; a U.S. Holder generally will recognize capital gain or loss for U.S. federal
	income tax purposes upon the sale, exchange or other disposition of Common Shares. The amount of gain recognized will equal the
	excess of the amount realized (i.e.,&nbsp;the amount of cash plus the fair market value of any property received) over the U.S.
	Holder&rsquo;s adjusted tax basis in the Common Shares sold or exchanged. The amount of loss recognized will equal the excess of
	the U.S. Holder&rsquo;s adjusted tax basis in the Common Shares sold or exchanged over the amount realized. Such capital gain or
	loss generally will be long-term capital gain or loss if, on the date of sale, exchange or other disposition, the Common Shares
	were held by the U.S. Holder for more than one year. Net long-term capital gain derived by a non-corporate U.S. Holder currently
	is subject to tax at reduced rates. The deductibility of a capital loss is subject to limitations. Any gain or loss recognized
	from the sale, exchange or other disposition of Common Shares will generally be gain or loss from sources within the United States
	for U.S. foreign tax credit purposes, except as otherwise provided in an applicable income tax treaty and if an election is properly
	made under the Code.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Passive Foreign Investment Company Considerations
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In general, a corporation organized outside
	the United States will be treated as a PFIC in any taxable year in which either (1)&nbsp;at least 75% of its gross income is &ldquo;passive
	income&rdquo; or (2)&nbsp;at least 50% of the average quarterly value of its assets is attributable to assets that produce passive
	income or are held for the production of passive income. Passive income for this purpose generally includes, among other things,
	dividends, interest, royalties, rents, and gains from commodities transactions and from the sale or exchange of property that gives
	rise to passive income. In determining whether a foreign corporation is a PFIC, a proportionate share of the items of gross income
	and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) are taken into account.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We believe we were a PFIC for our taxable year
	ended December 31, 2015. Based on the nature of our business, the projected composition of our gross income and the projected composition
	and estimated fair market values of our assets, we expect to be a PFIC for our taxable year ending December 31, 2016 and may be
	a PFIC in subsequent tax years. No opinion of legal counsel or ruling from the IRS concerning our status as a PFIC has been obtained
	or is currently planned to be requested. However, the determination of our PFIC status is made annually after the close of each
	taxable year and it is difficult to predict before such determination whether we will be a PFIC for any given taxable year. Even
	if we determine that we are not a PFIC after the close of a taxable year, there can be no assurance that the Internal Revenue Service
	(the &ldquo;
<B>
	IRS
</B>
	&rdquo;) will agree with our conclusion. No assurance can be provided regarded our PFIC status, and neither
	we nor our United States counsel expresses any opinion with respect to our PFIC status for the taxable year ended December 31,
	2015 or for any other taxable year.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If we are a PFIC at any time when a U.S. Holder
	owns Common Shares, such U.S. Holder will generally be subject to federal tax under the excess distribution regime on (1)&nbsp;distributions
	paid during a taxable year that are greater than 125%&nbsp;of the average annual distributions paid in the three preceding taxable
	years, or, if shorter, the U.S. Holder&rsquo;s holding period for the Common Shares, and (2)&nbsp;any gain recognized on a sale,
	exchange or other disposition (which would include a pledge) of Common Shares. Under the excess distribution regime, the U.S. Holder&rsquo;s
	tax liability will be determined by allocating such distribution or gain ratably to each day in the U.S. Holder&rsquo;s holding
	period for the Common Shares. The amount allocated to the current taxable year (i.e.,&nbsp;the year in which the distribution occurs
	or the gain is recognized) and any year prior to the first taxable year in which we were a PFIC in the holding period will be taxed
	as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest
	marginal rate in effect (for individuals or corporations as applicable) for ordinary income in each such taxable year, and an interest
	charge, generally that applicable to the underpayment of tax, will be added to the tax. Once we are a PFIC with respect to a particular
	U.S. Holder, we generally will remain a PFIC with respect to the U.S. Holder, unless we cease to meet the gross income and asset
	tests described above and the U.S. Holder makes a &ldquo;deemed sale&rdquo; election with respect to all of the U.S. Holder&rsquo;s
	Common Shares. If such election is made, the U.S. Holder will be deemed to have sold the Common Shares held at their fair market
	value on the last day of the last taxable year in which we qualified as a PFIC, and any gain from such deemed sale would be taxed
	under the excess distribution regime described above. After the deemed sale election, the U.S. Holder&rsquo;s Common Shares would
	not be treated as Common Shares of a PFIC unless we subsequently became a PFIC.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If we are a PFIC for any taxable year during
	which a U.S. Holder holds the Common Shares and one of our non-United States subsidiaries is also a PFIC (i.e., a lower-tier PFIC),
	the U.S. Holder will be treated as owning a proportionate amount (by value) of the Common Shares of the lower-tier PFIC and will
	be subject to the rules described above on certain distributions by the lower-tier PFIC and a disposition (or deemed disposition)
	of Common Shares of the lower-tier PFIC, even though the U.S. Holder would not receive the distributions or the proceeds from the
	disposition of the Common Shares of the lower-tier PFIC. Each U.S. Holder is advised to consult its tax advisors regarding the
	application of the PFIC rules to any of our subsidiaries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The tax considerations that would apply if we
	were a PFIC would be different from those described above if a U.S. Holder were able to make a valid &ldquo;qualified electing
	fund,&rdquo; or &ldquo;QEF election.&rdquo; We do not intend to provide U.S. Holders with the information required to permit them
	to make a QEF election and, accordingly, prospective investors should assume that a QEF election will not be available.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	A U.S. Holder may avoid taxation under the excess
	distribution regime if the holder makes a valid &ldquo;mark-to-market&rdquo; election. An electing U.S. Holder generally would
	take into account as ordinary income each year, the excess of the fair market value of the Common Shares held at the end of the
	taxable year over the adjusted tax basis of such Common Shares. The U.S. Holder would also take into account, as an ordinary loss
	each year, the excess of the adjusted tax basis of such Common Shares over their fair market value at the end of the taxable year,
	but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as a result of the
	mark-to-market election. The U.S. Holder&rsquo;s tax basis in the Common Shares would be adjusted to reflect any income or loss
	recognized as a result of the mark-to-market election. Any gain from a sale, exchange or other disposition of the Common Shares
	in any taxable year in which we are a PFIC, (i.e., when we meet the gross income test or asset test described above) would be treated
	as ordinary income and any loss from a sale, exchange or other disposition would be treated first as an ordinary loss (to the extent
	of any net mark-to-market gains previously included in income) and thereafter as a capital loss. If we cease to be a PFIC, any
	gain or loss recognized by a U.S. Holder on the sale or exchange of the Common Shares would be classified as a capital gain or
	loss.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	A mark-to-market election is available to a
	U.S. Holder only for &ldquo;marketable stock.&rdquo; Generally, stock will be considered marketable stock if it is &ldquo;regularly
	traded&rdquo; on a &ldquo;qualified exchange&rdquo; within the meaning of applicable U.S. Treasury regulations. A class of stock
	is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities, on
	at least 15&nbsp;days during each calendar quarter. The Common Shares should be marketable stock as long as they are listed on
	the TSX and are regularly traded. A mark-to-market election will not apply to the Common Shares for any taxable year during which
	we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we again become a PFIC. Such
	election will not apply to any subsidiary that we own. Accordingly, a U.S. Holder may continue to be subject to the PFIC rules
	with respect to any lower-tier PFICs notwithstanding the U.S. Holder&rsquo;s mark-to-market election.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Each U.S. person who is a shareholder of a PFIC
	generally must file an annual report with the IRS containing certain information, and the failure to file such report could result
	in the imposition of penalties on such U.S. person and in the extension of the statute of limitations with respect to federal income
	tax returns filed by such U.S. person.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	The U.S. federal income tax rules relating to PFICs are very
	complex. U.S. Holders are urged to consult their own tax advisers with respect to the purchase, ownership and disposition of Common
	Shares, the consequences to them of an investment in a PFIC, any elections available with respect to the Common Shares and the
	IRS information reporting obligations with respect to the purchase, ownership and disposition of Common Shares in the event we
	are considered a PFIC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Additional Tax on Passive Income
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Certain U.S. Holders that are individuals, estates
	or trusts (other than trusts that are exempt from tax) will be subject to a 3.8% tax on all or a portion of their &ldquo;net investment
	income,&rdquo; which includes dividends on the Common Shares, and net gains from the disposition of the Common Shares. Further,
	excess distributions treated as dividends, gains treated as excess distributions, and mark-to-market inclusions and deductions
	are all included in the calculation of net investment income.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Treasury regulations provide, subject to the
	election described in the following paragraph, that solely for purposes of this additional tax, that distributions of previously
	taxed income will be treated as dividends and included in net investment income subject to the additional 3.8% tax. Additionally,
	to determine the amount of any capital gain from the sale or other taxable disposition of Common Shares that will be subject to
	the additional tax on net investment income, a U.S. Holder who has made a QEF election will be required to recalculate its basis
	in the Common Shares excluding QEF election basis adjustments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Alternatively, a U.S. Holder may make an election
	which will be effective with respect to all interests in controlled foreign corporations and QEF election held in that year or
	acquired in future years. Under this election, a U.S. Holder pays the additional 3.8% tax on QEF election income inclusions and
	on gains calculated after giving effect to related tax basis adjustments. U.S. Holders that are individuals, estates or trusts
	should consult their own tax advisors regarding the applicability of this tax to any of their income or gains in respect of the
	Common Shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Information Reporting with Respect to Foreign Financial Assets
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	U.S. individuals that own &ldquo;specified foreign
	financial assets&rdquo; with an aggregate fair market value exceeding certain threshold amounts generally are required to file
	an information report on IRS Form 8938 with respect to such assets with their tax returns. Significant penalties may apply to persons
	who fail to comply with these rules. Specified foreign financial assets include not only financial accounts maintained in foreign
	financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by
	a non-U.S. person. Upon the issuance of future U.S. Treasury regulations, these information reporting requirements may apply to
	certain U.S. entities that own specified foreign financial assets. The failure to report information required under the current
	regulations could result in substantial penalties and in the extension of the statute of limitations with respect to federal income
	tax returns filed by a U.S. Holder. U.S. Holders should consult their own tax advisors regarding the possible implications of these
	U.S. Treasury regulations for an investment in our Common Shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Special Reporting Requirements for Transfers to Foreign Corporations
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	A U.S. Holder that acquires Common Shares generally
	will be required to file Form 926 with the IRS if (1) immediately after the acquisition such U.S. Holder, directly or indirectly,
	owns at least 10% of the Common Shares, or (2) the amount of cash transferred in exchange for Common Shares during the 12-month
	period ending on the date of the acquisition exceeds US$100,000. Significant penalties may apply for failing to satisfy these filing
	requirements. U.S. Holders are urged to contact their tax advisors regarding these filing requirements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Information Reporting and Backup Withholding
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Dividends on and proceeds from the sale or other
	disposition of Common Shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding
	may apply to amounts subject to reporting if (1)&nbsp;the holder fails to provide an accurate taxpayer identification number or
	otherwise establish a basis for exemption, or (2)&nbsp;is described in certain other categories of persons.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Backup withholding is not an additional tax.
	Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a U.S. Holder&rsquo;s
	U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER
	ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A US HOLDER. EACH US HOLDER IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX
	CONSEQUENCES TO IT OF AN INVESTMENT IN COMMON SHARES IN LIGHT OF THE INVESTOR&rsquo;S OWN CIRCUMSTANCES.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The following is, as of the date hereof, a summary
	of the principal Canadian federal income tax considerations under the
<I>
	Income Tax Act
</I>
	(Canada) (the &ldquo;
<B>
	Tax Act
</B>
	&rdquo;)
	generally applicable to a holder of Common Shares of the Company who, for purposes of the Tax Act and at all relevant times, is
	neither resident in Canada nor deemed to be resident in Canada for purposes of the Tax Act and any applicable income tax treaty
	or convention, and who does not use or hold (and is not deemed to use or hold) Common Shares in carrying on a business in Canada,
	deals at arm&rsquo;s length with and is not affiliated with the Company and holds Common Shares as capital property (a &ldquo;
<B>
	Holder
</B>
	&rdquo;).
	Generally, Common Shares will be considered to be capital property to a Holder thereof provided that the Holder does not hold Common
	Shares in the course of carrying on a business of buying and selling securities and such Holder has not acquired them in one or
	more transactions considered to be an adventure or concern in the nature of trade.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	This summary does not apply to a Holder (i)
	that is a &ldquo;financial institution&rdquo; for purposes of the mark-to-market rules contained in the Tax Act; (ii) that is a
	&ldquo;specified financial institution&rdquo; as defined in the Tax Act; (iii) an interest in which is a &ldquo;tax shelter investment&rdquo;
	as defined in the Tax Act; or (iv) that has elected to report its tax results in a functional currency other than Canadian currency.
	Special rules, which are not discussed in this summary, may apply to a Holder that is an &ldquo;authorized foreign bank&rdquo;
	within the meaning of the Tax Act or an insurer carrying on business in Canada and elsewhere. Such Holders should consult their
	own tax advisors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	This summary is based upon the provisions of
	the Tax Act (including the regulations (&ldquo;
<B>
	Regulations
</B>
	&rdquo;) thereunder) in force as of the date hereof and our understanding
	of the current administrative policies and assessing practices of the Canada Revenue Agency (the &ldquo;
<B>
	CRA
</B>
	&rdquo;) published
	in writing by the CRA prior to the date hereof. This summary takes into account all specific proposals to amend the Tax Act (and
	the Regulations) publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the &ldquo;
<B>
	Tax
	Proposals
</B>
	&rdquo;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given
	that the Tax Proposals will be enacted in their current form or at all. This summary does not otherwise take into account any changes
	in law or in the administrative policies or assessing practices of the CRA, whether by legislative, governmental or judicial decision
	or action. This summary is not exhaustive of all possible Canadian federal income tax considerations, and does not take into account
	other federal or any provincial, territorial or foreign income tax legislation or considerations, which may differ materially from
	those described in this summary.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	This summary is of a general nature only and
	is not, and is not intended to be, and should not be construed to be, legal or tax advice to any particular Holder, and no representations
	concerning the tax consequences to any particular Holder are made.
<B>
	Holders should consult their own tax advisors regarding the
	income tax considerations applicable to them having regard to their particular circumstances.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<I>
	Dividends
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Dividends paid or credited (or deemed to be
	paid or credited) to a Holder by the Company are subject to Canadian withholding tax at the rate of 25% unless reduced by the terms
	of an applicable tax treaty. For example, under the Canada-United States Income Tax Convention (1980) (the &ldquo;
<B>
	US
</B>
<B>
	Treaty
</B>
	&rdquo;),
	as amended, the dividend withholding tax rate is generally reduced to 15% in respect of a dividend paid or credited to a Holder
	beneficially entitled to the dividend who is resident in the U.S. for purposes of the US Treaty and whose entitlement to the benefits
	of the US Treaty is not limited by the limitation of benefits provisions of the US Treaty. Holders are urged to consult their own
	tax advisors to determine their entitlement to relief under the US Treaty or any other applicable tax treaty as well as their ability
	to claim foreign tax credits with respect to any Canadian withholding tax, based on their particular circumstances.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<I>
	Disposition of Common Shares
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	A Holder generally will not be subject to tax
	under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of a Common Share, unless the
	Common Share constitutes or is deemed to constitute &ldquo;taxable Canadian property&rdquo; to the Holder thereof for purposes
	of the Tax Act, and the gain is not exempt from tax pursuant to the terms of an applicable tax treaty or convention.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	In general, provided the Common Shares are listed
	on a &ldquo;designated stock exchange&rdquo; (which currently includes the TSX) at the date of the disposition, the Common Shares
	will only constitute &ldquo;taxable Canadian property&rdquo; of a Holder if, at any time within the 60-month period preceding the
	disposition: (i) such Holder, persons with whom the Holder did not deal at arm's length, partnerships in which the Holder or a
	person with whom the Holder did not deal at arm&rsquo;s length holds a membership interest directly or indirectly through one or
	more partnerships, or any combination thereof, owned 25% or more of the issued shares of any class or series of the Company&rsquo;s
	capital stock, and (ii) more than 50% of the fair market value of the Common Shares was derived directly or indirectly from one
	or any combination of (A) real or immovable property situated in Canada, (B) Canadian resource properties, (C) timber resource
	properties, and (D) options in respect of, or interests in, or for civil law rights in, property described in any of subparagraphs
	(ii)(A) to (C), whether or not the property exists. However, and despite the foregoing, in certain circumstances the Common Shares
	may be deemed to be &ldquo;taxable Canadian property&rdquo; under the Tax Act.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Holders whose Common Shares may be &ldquo;taxable
	Canadian property&rdquo; should consult their own tax advisers.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	F.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Dividends and paying agents
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The transfer agent and registrar for our common
	shares is Computershare Investor Services Inc. at its principal office in the City of Toronto.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	G.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Statement by experts
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	H.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Documents on display
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We are subject to the information and reporting
	requirements of the Exchange Act, and file periodic reports and other information with the SEC. However, as a foreign private issuer,
	we are exempt from the rules and regulations under the Exchange Act prescribing the furnishing and content of proxy statements,
	and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions
	contained in Section&nbsp;16 of the Exchange Act. Our reports and other information filed with the SEC may be inspected at the
	public reference facilities maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. Copies of these materials may
	be obtained at prescribed rates from the SEC at that address. Our reports and other information can also be inspected at no charge
	on the SEC&rsquo;s website at www.sec.gov.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We are also subject to the information and reporting
	requirements of the
<I>
	Securities Act
</I>
	(Ontario) and the
<I>
	Canada Business Corporations Act
</I>
	. Such reports and information
	can be inspected at no charge on the website www.sedar.com.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	If you are a shareholder, you may request a
	copy of these filings at no cost by contacting us at:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	Vice President of Finance
<BR>
	Aptose Biosciences Inc.
<BR>
	5955 Airport Road, Suite #228
<BR>
	Mississauga, Ontario L4V 1R9
<BR>
	Canada
<BR>
	Phone (647) 479-9828
<BR>
	Fax (905) 234-2120
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 35PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	I.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Subsidiary information
</I>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Aptose has three subsidiaries: NuChem, a company
	incorporated under the laws of Ontario, Canada, Aptose USA, a company incorporated under the laws of Delaware, USA and Aptose Suisse
	GmbH a company incorporated under the laws of Zug, Switzerland. Aptose owns 80% of the issued and outstanding voting share capital
	of NuChem and 100% of the issued and outstanding voting share capital of Aptose USA and Aptose Suisse.
</P>
</EFX_ADDITIONAL_INFORMATION>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
<A NAME="F20F_032916_HTM_I11">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 11.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Qualitative and Quantitative Disclosures About Market Risk
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Refer to notes 4 and 8 to the consolidated financial
	statements contained in Item 18.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We are exposed to significant market risks as
	outlined below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We do not utilize derivative financial instruments
	to hedge our interest rate or foreign currency rate risks.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Interest Rate Risk
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Company invests its cash resources in liquid
	government and corporate debt instruments. We do not believe that the results of operations or cash flows would be affected to
	any significant degree by a sudden change in market interest rates relative to interest rates on our investments, owing to the
	relative short-term nature of the investments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Credit Risk
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Financial instruments potentially exposing the
	Company to a concentration of credit risk consist principally of cash and cash equivalents and marketable securities. The Company
	manages this credit risk by maintaining bank accounts with Schedule I banks and investing only in highly rated Canadian securities
	that are traded on active markets and are capable of prompt liquidation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Exchange Rate Sensitivity
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The functional currency of the Company is the
	Canadian dollar. We are exposed to currency risk from employee costs as well as the purchase of goods and services primarily in
	the United States and on cash balances held in foreign currencies. Fluctuations in the US dollar exchange rate could have a significant
	impact on our results. Assuming all other variables remain constant, a 10% depreciation or appreciation of the Canadian dollar
	against the US dollar would result in an increase or decrease in loss for the year and comprehensive loss of $576 thousand (December
	31, 2014- $50 thousand, May 31, 2014 - $18 thousand). Balances in foreign currencies are as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 2PT SOLID">
<B>
	US$ Balances
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	May 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	66
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	594
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accounts payable and accrued liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(838
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(565
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(769
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 2PT SOLID">
	Balance, end of period
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PT SOLID">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT SOLID">
	4,162
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PT SOLID">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT SOLID">
	(499
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PT SOLID">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PT SOLID">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT SOLID">
	(175
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PT SOLID">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
	We do not have any forward exchange contracts to hedge
	this risk.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Limitations
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The above discussion includes only those exposures
	that exist as of December 31, 2015, and as a result, does not consider exposures or positions that could arise after that date.
	The Company&rsquo;s ultimate realized gain or loss with respect to interest rate and exchange rate fluctuations would depend on
	the exposures that arise during the period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Risk Factors
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	See Item 3.D.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OTHER_SECURITIES>
<A NAME="FIS_OTHER_SECURITIES"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I12">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 12.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Description of Securities Other Than Equity Securities
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OTHER_SECURITIES>
</EFX_PART_I>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F20F_032916_HTM_P2">
</A>
	PART II
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_DEFAULTS>
<A NAME="FIS_DEFAULTS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I13">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 13.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Defaults, Dividends Arrearages and Delinquencies
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_DEFAULTS>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MATERIAL_MODIFICATIONS>
<A NAME="FIS_MATERIAL_MODIFICATIONS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I14">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 14.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Material Modifications to the Rights of Security Holders and Use of Proceeds
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_MATERIAL_MODIFICATIONS>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I15">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 15.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Controls and Procedures
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(a)
</B>
</FONT>
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Disclosure controls and procedures
</U>
	.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As of the end of the year ended December 31,
	2015, an evaluation of the effectiveness of our &ldquo;disclosure controls and procedures&rdquo; (as such term is defined in Rules
	13a-15(e) and 15d-15(e) under the Exchange Act), was carried out by our management under the supervision of and with the participation
	of the principal executive officer and principal financial officer. Based upon on that evaluation, our principal executive officer
	and principal financial officer have concluded that as of the end of that period, our disclosure controls and procedures were effective
	to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded,
	processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated
	to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding
	required disclosure.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	It should be noted that while our principal
	executive officer and principal financial officer believe that our disclosure controls and procedures are effective and provide
	a reasonable level of assurance, they do not expect that the disclosure controls and procedures or internal control over financial
	reporting will prevent all errors and fraud. A control system, no matter how well conceived or operated, can provide only reasonable,
	not absolute, assurance that the objectives of the control system are met.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(b)
</B>
</FONT>
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Management&rsquo;s annual report on internal control over financial reporting
</U>
	.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Management is responsible for establishing and
	maintaining adequate internal control over our financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under
	the Exchange Act). Our internal control system was designed to provide reasonable assurance that all transactions are accurately
	recorded, that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance
	with IFRS as issued by the IASB, and that our assets are safeguarded.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Management has assessed the effectiveness of
	our internal control over financial reporting as at December&nbsp;31, 2015. In management&rsquo;s opinion, our internal control
	over financial reporting is effective as at December&nbsp;31, 2015. In making its assessment, management used the Committee of
	Sponsoring Organizations of the Treadway Commission framework in Internal Control &ndash; Integrated Framework of 2003 to evaluate
	the effectiveness of our internal control over financial reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The design of any system of controls and procedures
	is based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any design will
	succeed in achieving its stated goals under all potential future conditions, regardless of how remote.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(c)
</B>
</FONT>
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Attestation report of the independent registered public accounting firm
</U>
	.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Because we are a non-accelerated filer and an
	&ldquo;emerging growth company&rdquo; under the rules of the SEC, this Annual Report is not required to include, and does not include,
	an attestation report of our independent registered public accounting firm with respect to our internal control over financial
	reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(d)
</B>
</FONT>
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<U>
	Changes in internal control over financial reporting
</U>
	.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	There has been no change in our internal control
	over financial reporting during the period covered by this Annual Report that has materially affected, or is reasonably likely
	to materially affect, our internal control over financial reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I16">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 16.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	[Reserved]
</B>
</FONT>
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<EFX_AUDIT_COMMITTEE_EXPERT>
<A NAME="FIS_AUDIT_COMMITTEE_EXPERT"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I16A">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 16A.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Audit Committee Financial Expert
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Our board of directors has determined that Mr.
	Warren Whitehead, a director of the Company and the chairman of the Audit Committee, possesses the attributes required of an &ldquo;audit
	committee financial expert,&rdquo; and is &ldquo;independent,&rdquo; within the meaning of applicable NASDAQ rules.
</P>
</EFX_AUDIT_COMMITTEE_EXPERT>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CODE_OF_ETHICS>
<A NAME="FIS_CODE_OF_ETHICS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I16B">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item
	16B.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Code of Ethics
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	We have adopted a code of ethics, as such term
	is defined in Form 20-F, which applies to all of our officers, directors, employees and consultants. A copy of the code of ethics
	is available on our website at www.aptose.com or, without charge, upon written request from our Vice President of Finance at our
	offices located at 5955 Airport Road, Suite #228, Mississauga, Ontario L4V 1R9, Canada. There were no waivers granted under our
	code of ethics during the twelve months ended December 31, 2015.
</P>
</EFX_CODE_OF_ETHICS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I16C">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 16C.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Principal Accountant Fees and Services
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	KPMG LLP has served as our principal independent
	external auditor since October 1994. The total fees billed to us for professional services provided by KPMG LLP for the twelve
	months ended December 31, 2015 and seven months ended December 31, 2014 are as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Twelve Months
<BR>
	Ended
<BR>
	December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Seven Months
<BR>
	Ended
<BR>
	December 31, 2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Audit Fees
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	274,800
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	157,440
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Audit-Related Fees
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Tax Fees
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	180,789
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	36,015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	All Other Fees
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	455,589
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	193,455
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Audit fees consist of the fees paid with respect
	to the audit of our consolidated annual financial statements, quarterly reviews and 20-F filing with the SEC and for any other
	professional services that are normally provided by KPMG LLP in connection with statutory and regulatory filings or engagements.
	Tax fees related to tax planning advice provided with respect to intellectual property and US operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Pre-Approval Policies and Procedures
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The Audit Committee of our board of directors
	has, pursuant to the Audit Committee charter, adopted specific responsibilities and duties regarding the provision of services
	by our external auditor, currently KPMG LLP. Our charter requires Audit Committee pre-approval of all permitted audit, audit-related
	and tax services.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	Subject to the charter, the Audit Committee
	may establish fee thresholds for a group of pre-approved services. The Audit Committee then recommends to the board of directors
	approval of the fees and other significant compensation to be paid to the independent auditors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	No services were provided by KPMG LLP under
	a
<I>
	de minimus
</I>
	exemption for the year ended December&nbsp;31, 2015.
</P>
</EFX_ACCOUNTANT_FEES>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_EXEMPTIONS_FROM_LISTING>
<A NAME="FIS_EXEMPTIONS_FROM_LISTING"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I16D">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 16D.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exemptions from the Listing Standards for Audit Committees
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXEMPTIONS_FROM_LISTING>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<EFX_PURCHASES_OF_EQUITY>
<A NAME="FIS_PURCHASES_OF_EQUITY"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I16E">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 16E.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Purchases of Equity Securities by the Issuer and Affiliated Purchasers
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_PURCHASES_OF_EQUITY>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CHANGE_IN_ACCOUNTANT>
<A NAME="FIS_CHANGE_IN_ACCOUNTANT"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I16F">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 16F.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Change in Registrant&rsquo;s Certifying Accountant
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_CHANGE_IN_ACCOUNTANT>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CORPORATE_GOVERNANCE>
<A NAME="FIS_CORPORATE_GOVERNANCE"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I16G">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 16G.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Corporate Governance
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	On October 23, 2014, we listed our Common Shares for trading on
	NASDAQ.&nbsp;&nbsp;Section 5615(a)(3) of the NASDAQ Marketplace Rules permits NASDAQ to grant exemptions to a foreign private issuer
	for the provisions of the Rule 5600 series and Rule 5250 (d).&nbsp;&nbsp;We are organized under the laws of Canada and our Common
	Shares are listed for trading on the TSX.&nbsp;&nbsp;We comply with the laws of Canada and rules and regulations of the TSX, including
	rules related to corporate governance practices.&nbsp;&nbsp;A description of the significant ways in which our governance practices
	differ from those followed by domestic companies pursuant to the NASDAQ Marketplace Rules is as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Shareholder Meeting Quorum Requirement:&nbsp;
</B>
	The NASDAQ minimum
	quorum requirement for a shareholder meeting under Section 5620(c) of the NASDAQ Marketplace Rules is one-third of the outstanding
	shares of common stock.&nbsp;&nbsp;In addition, a company listed on NASDAQ is required to state a quorum requirement in its bylaws.&nbsp;&nbsp;Our
	quorum requirement is set forth in our corporate bylaws.&nbsp;&nbsp;A quorum for our shareholder meeting is not less than 25% of
	the outstanding shares of the Corporation entitled to be voted at such meeting present or by means of a telephonic, electronic
	or other communication facility that permits all participants to communicate adequately with each other during the meeting and
	each entitled to vote at the meeting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	Compensation Committee Mandate:
</B>
	NASDAQ will require compliance
	with the revised Rule 5605(d) for all companies following the company's first annual meeting occurring after January 15, 2014,
	or October 31, 2014, whichever is earlier. In our case this was following our August 19, 2014 annual general and special meeting.
	The changes to the rule include requiring the mandate of the Compensation Committee to include accountability to external advisors.
	The Compensation Committee Mandate does not currently include such requirements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	The foregoing is consistent with the laws, customs and practices
	in Canada and the rules of the TSX.
</P>
</EFX_CORPORATE_GOVERNANCE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I16H">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 16H.
	Mine Safety Disclosure
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_II>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F20F_032916_HTM_P3">
</A>
	PART III
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I17">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 17.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Financial Statements
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	We have responded to Item 18 in lieu of responding to this Item.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS_2"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I18">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 18.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Financial Statements
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	The consolidated financial statements of Aptose Biosciences Inc.
	are attached as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 88%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Page
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Independent Auditors&rsquo; Report of Registered Public Accounting Firm
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	F-1
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Financial Position as at December 31, 2015 and 2014
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	F-2
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Loss and Comprehensive Loss for the year ended December 31, 2015, seven months ended December 31, 2014 and year ended May 31, 2014
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	F-3
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statement of Changes in Shareholders&rsquo; Equity for the year ended December 31, 2015, seven months ended December 31, 2014 and year ended May 31, 2014
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	F-4
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Cash Flows for the twelve months ended December 31, 2015, seven months ended December 31, 2014 and twelve months ended May 31, 2014
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	F-5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements for the year ended December 31, 2015, seven months ended December 31, 2014 and year ended May 31, 2014
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	F-6
</FONT>
</TD>
</TR>
</TABLE>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<A NAME="F20F_032916_HTM_I19">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item 19.
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exhibits.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	See the Exhibit Index hereto.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_III>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	The registrant hereby certifies that it meets all of the requirements
	for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 52%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 43%">
<FONT STYLE="FONT-SIZE: 10PT">
	APTOSE BIOSCIENCES INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/
<I>
	s/ William G. Rice
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Name: William G. Rice, PhD
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title: Chairman and Chief Executive Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Date: March 29, 2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 52%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 43%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	/s/ Gregory K. Chow
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Name: Gregory K. Chow
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title: Chief Financial Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Date: March 29, 2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	EXHIBIT INDEX
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-WEIGHT: BOLD">
	Exhibit Number
</TD>
<TD STYLE="WIDTH: 2%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 88%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-WEIGHT: BOLD">
	Description
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	1.1
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Articles of Incorporation, Arrangement and Amendment (incorporated herein by reference to Exhibit 99.3 to the Registrant&rsquo;s Current Report on Form 6-K filed with the SEC on June 12, 2015)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	1.2
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	By-law #2 of the Company &nbsp;(incorporated herein by reference to Exhibit 99.2 to the Registrant&rsquo;s Current Report on Form 6-K filed with the SEC on June 12, 2015)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	2.1
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Indemnification Agreement dated July 10, 2007 between Old Lorus and the Company (incorporated herein by reference to Exhibit 99.10 to the Registrant&rsquo;s Current Report on Form 6-K filed with the SEC on September 4, 2007)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	2.2
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Form of Promissory note and Warrant issued June 19, 2013 (incorporated herein by reference to Exhibit 2.25 to the Registrant&rsquo;s Annual Report on Form 20-F filed with the SEC on May 16, 2014)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	2.3
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Form of Convertible Promissory note issued September 26, 2013 (incorporated herein by reference to Exhibit 2.26 to the Registrant&rsquo;s Annual Report on Form 20-F filed with the SEC on May 16, 2014)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	2.4
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Underwriting Agreement dated November 22, 2013 in connection with the December 2013 public offering (incorporated herein by reference to Exhibit 2.27 to the Registrant&rsquo;s Annual Report on Form 20-F filed with the SEC on May 16, 2014)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	2.5
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Underwriting Agreement dated March 27, 2014 in connection with the April 2014 public offering (incorporated herein by reference to Exhibit 2.28 to the Registrant&rsquo;s Annual Report on Form 20-F filed with the SEC on May 16, 2014)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	4.1
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Share Option Plan as amended May 5, 2015 (incorporated herein by reference to Exhibit 99.2 to the Registrant&rsquo;s Current Report on Form 6-K filed with the SEC on June 12, 2015)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	4.2
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Stock Incentive Plan as adopted May 5, 2015 (incorporated herein by reference to Exhibit 99.1 to the Registrant&rsquo;s Current Report on Form 6-K filed with the SEC on June 12, 2015)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	4.2
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Form of Officer and Director Indemnity Agreement (incorporated herein by reference to Exhibit 4.2 to the Registrant&rsquo;s Annual Report on Form 20-F filed with the SEC on November 21, 2006)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	4.3
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Amalgamation Agreement dated August&nbsp;23, 1991, among the Company,
	Mint Gold Resources Ltd., Harry J. Hodge and Wayne Beach (incorporated herein by reference from the Registration Statement on
	Form 20-FR filed with the SEC on March 4, 1992)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	4.4
</P>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Executive Employment Agreement between the Company and Dr. William G. Rice, dated
	October 25, 2013 (incorporated herein by reference to Exhibit 4.9 to the Registrant&rsquo;s Annual Report on Form 20-F
	filed with the SEC on May 16, 2014)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	4.5
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Amendment to the Employment agreement between the Company and Dr. William G. Rice dated
	August 19, 2014 (incorporated herein by reference to Exhibit 4.9A to the Registrant&rsquo;s Annual Report on Form 20-F filed with
	the SEC on March 4, 2015)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	4.6
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Executive Employment Agreement between the Company and Gregory K. Chow, dated November 29, 2013 (incorporated herein by reference to Exhibit 4.9.1 to the Registrant&rsquo;s Annual Report on Form 20-F filed with the SEC on May 16, 2014)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	4.7
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Executive Employment Agreement between the Company and Avanish Vellanki, dated November 29, 2013 (incorporated herein by reference to Exhibit 4.9.2 to the Registrant&rsquo;s Annual Report on Form 20-F filed with the SEC on May 16, 2014)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	4.8
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Sales Agreement between the Company and Cowen and Company, LLC, dated April 2, 2015 (incorporated herein by reference to Exhibit 1.1 to the Registrant&rsquo;s Current Report on Form 6-K filed with the SEC on April 6, 2015)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	8.1
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	List of subsidiaries
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	11.1
</P>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Code of Business Conduct and Ethics (incorporated herein by reference to Exhibit
	11.1 to the Registrant&rsquo;s Annual Report on Form 20-F filed with the SEC on March 4, 2015)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	11.2
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Audit Committee Charter (incorporated herein by reference to Exhibit 11.2 to the Registrant&rsquo;s
	Annual Report on Form 20-F filed with the SEC on March 4, 2015)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	12.1
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	12.2
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	13.1
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	13.2
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	15.1
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Management Discussion and Analysis for the twelve months ended December 31, 2015
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 72 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0 0PT 1.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 1.25IN">
	Consolidated Financial Statements of
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 1.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 1IN 0PT 1.25IN">
	aptose biosciences INC.
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 1IN 0PT 1.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 1.25IN">
	Year ending December 31, 2015, Seven month period ending
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 1.25IN">
	December 31, 2014, Year ending May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 1.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 73 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001171843-16-008903_KPMG.JPG">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 34%">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	KPMG LLP
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 33%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 8PT">
	Bay Adelaide Centre&#9;
</FONT>
</P>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	Telephone&#9; (416) 777-8500
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	333 Bay Street Suite 4600
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	Fax&#9; (416) 777-8818
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	Toronto ON M5H 2S5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	Internet&#9;www.kpmg.ca
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	Canada
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_EXHIBIT_INDEX>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
	INDEPENDENT
	auditors&rsquo; REPORT OF REGISTERED PUBLIC ACCOUNTING FIRM
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	To the Shareholders and Board of Directors of Aptose Biosciences
	Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying consolidated
	financial statements of Aptose Biosciences Inc., which comprise the consolidated statements of financial position as of December
	31, 2015 and December 31, 2014, the consolidated&nbsp;statements of loss and comprehensive loss, changes in shareholders&rsquo;
	equity and cash flows for the year ended December 31, 2015, the seven-month period ended December 31, 2014 and the year ended May
	31, 2014, and notes, comprising a summary of significant accounting policies and other explanatory information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Management&rsquo;s Responsibility for
	the Consolidated Financial Statements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Management is responsible for the preparation
	and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards
	as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary
	to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or
	error.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Auditors&rsquo; Responsibility
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our responsibility is to express an opinion
	on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted
	auditing standards and the standards of the Public Company Accounting Oversight Board (United States). Those standards require
	that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated
	financial statements are free from material misstatement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	An audit involves performing procedures
	to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend
	on our judgment, including the assessment of the risks of material misstatement of the consolidated
<B>
</B>
	financial statements,
	whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity&rsquo;s preparation
	and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the
	circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity&rsquo;s internal control.
<FONT STYLE="COLOR: #3366FF">
<B>
</B>
</FONT>
	An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting
	estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We believe that the audit evidence we have
	obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Opinion
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, the consolidated financial
	statements referred to above present fairly, in all material respects, the consolidated financial position of Aptose Biosciences
	Inc. as at December 31, 2015 and December 31, 2014, and its consolidated financial performance and its consolidated cash flows
	for the year ended December 31, 2015, the seven-month period ended December 31, 2014 and the year ended May 31, 2014 in accordance
	with International Financial Reporting Standards as issued by the International Accounting Standards Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001171843-16-008903_KPMG2.JPG">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Chartered Professional Accountants, Licensed Public Accountants
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	March 29, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Toronto, Canada
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
<FONT STYLE="FONT-SIZE: 7PT">
	KPMG LLP is a Canadian limited liability partnership and a member firm
	of the KPMG network of independent member firms affiliated with KPMG International Cooperative (&ldquo;KPMG International&rdquo;),
	a Swiss entity.
<BR>
	KPMG Canada provides services to KPMG LLP.
</FONT>
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	Aptose biosciences Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	Consolidated Statements of Financial Position
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Expressed in thousands of Canadian dollars)
</P>
</EFX_AUDITORS_OPINION>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	December 31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	December 31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Current assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Cash and cash equivalents (note 4(a))
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,503
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,365
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Investments (note 4(b))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,245
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,180
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Prepaid expenses and other assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,067
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	855
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Total current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20,815
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	31,400
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Non-current assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Equipment and intangibles (note 5)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	434
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Total non-current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	434
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Total assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,249
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	31,600
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Liabilities and Shareholders' Equity
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Current liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Accounts payable
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	522
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	256
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Accrued liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,834
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,662
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Convertible promissory notes (note 7)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	410
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Total current liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,356
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,328
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Shareholders' equity:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Share capital (note 9):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Common shares
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	223,425
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	221,259
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Equity portion of convertible
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 50PT">
	promissory notes (note 7)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Stock options (notes 9(e) and 10)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,256
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,078
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Contributed surplus (note 9(d))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	22,037
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,653
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Warrants (note 9(c))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	501
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Deficit
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(232,909
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(218,283
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Total shareholders' equity
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	18,893
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	29,272
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Total liabilities and shareholders' equity
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,249
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	31,600
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<I>
	Commitments, contingencies and guarantees (Note 15)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	On behalf of the Board:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<U>
	&ldquo;Warren
	Whitehead&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
	Director
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<U>
	&ldquo;Bradley Thompson&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
	Director
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	APTOSE Biosciences Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	Consolidated Statements of Loss and Comprehensive Loss
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Expressed in thousands of Canadian dollars, except for per
	common share data)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	Year ended December 31, 2015, 7 month period ended December
	31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	7 months ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	May 31,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(note 17)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(note 17)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Research and development (notes 11)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,254
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,404
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,015
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	General and administrative (note 12)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,845
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,542
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,317
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,099
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,946
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,332
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Finance expense (note 13)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	43
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	104
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	297
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Finance income (note 13)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,516
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(279
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Net finance (income) expense
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,473
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(175
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	221
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Net loss and total comprehensive loss for the period
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14,626
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,771
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,553
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Basic and diluted loss per common share
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1.23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.67
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2.02
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Weighted average number of common shares outstanding
<BR>
	used in the calculation of (in thousands) (note 9(f)):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Basic and diluted loss per common share
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,906
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,605
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,216
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	Aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	Consolidated Statements of Changes in Shareholders' Equity
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Expressed in thousands of Canadian dollars)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	Year ended December 31, 2015, 7 month period ended December
	31, 2014 and Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	Share
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	Stock
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	Contributed
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	Equity
<BR>
	portion
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	capital
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	options
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Warrants
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	surplus
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	of debt
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Deficit
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="WIDTH: 44%; FONT-SIZE: 10PT; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Balance, December 31, 2014
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	221,259
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,078
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	501
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,653
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(218,283
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	29,272
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Exercise of warrants (note 9(c))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	503
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(155
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	348
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Exercise of stock options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,215
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(566
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	649
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Conversion of promissory notes (note 7)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	438
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(64
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	428
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Common shares issued under the ATM (note 9(b)(i))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0IN">
	Expiry of warrants
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(262
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	262
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Stock-based compensation (note 10)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,812
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,812
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Expiry of stock options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(68
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	68
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Net loss for the period
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14,626
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14,626
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Balance, December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	223,425
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,256
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	22,037
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(232,909
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	18,893
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Balance, May 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	212,938
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,658
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,857
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,410
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(210,512
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,439
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Exercise of warrants (note 9(c))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,814
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,166
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,648
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Exercise of stock options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	345
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(162
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	183
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Conversion of promissory notes (note 7)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	162
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(24
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	146
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0IN">
	Expiry of warrants
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(190
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	190
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Stock-based compensation (note 10)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,627
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,627
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Expiry of stock options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Net loss for the seven month period
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,771
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,771
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Balance, December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	221,259
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,078
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	501
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,653
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(218,283
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	29,272
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Balance, June 1, 2013
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	174,522
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,018
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,421
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,217
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(199,959
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(781
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Issuance of common shares (note 9(b)(ii))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,927
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	350
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,277
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Issuance of common shares (note 9(b)(i))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,584
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,584
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Issuance of warrants (note 9(b)(iii))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Issuance of convertible notes (note 7)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Exercise of warrants (note 9(c))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,422
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(964
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,458
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Exercise of options and DSU&rsquo;s (note 9(g))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	483
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	465
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0IN">
	Expiry of warrants
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(25
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Stock-based compensation (note 10)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,826
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,826
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Cancellation and forfeiture of stock options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(168
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	168
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Net loss for the year
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,553
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,553
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Balance, May 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	212,938
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,658
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,857
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,410
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(210,512
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,439
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	Aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	Consolidated Statements of Cash Flows
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Expressed in thousands of Canadian dollars)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	7 months ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	May 31,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Cash flows from operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Net loss for the year
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14,626
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,771
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,553
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Items not involving cash:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Stock-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,812
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,627
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,826
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Depreciation and amortisation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	96
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Interest income
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(286
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(279
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Unrealized foreign exchange gain
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(929
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Interest and accretion expense
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	43
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	58
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	259
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 45PT">
	Other
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Change in non-cash operating
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 40PT">
	working capital (note 6)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	226
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(374
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(14
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Cash used in operating activities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(12,664
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,717
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(8,536
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Cash flows from financing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Issuance of common shares and warrants,
<BR>
	net of issuance costs (note 9(b)(i) and (ii))
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	32,861
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Exercise of warrants, options and DSU&rsquo;s (note 9)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	997
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,831
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,923
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Issuance of convertible notes
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	600
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Debt issuance costs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(40
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Issuance of promissory notes and loans
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,068
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Repayment of promissory notes and loans
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,068
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Interest paid on notes and loans
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(25
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(30
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(129
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Cash provided by financing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	982
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,801
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	38,215
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Cash flows from investing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Maturity (acquisition) of investments
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,935
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(5,161
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,019
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Purchase of equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(330
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(204
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(22
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Interest received
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	286
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	279
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	76
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 27PT">
	Cash provided by (used in) investing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,891
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(5,086
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,965
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Effect of exchange rate fluctuations on cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 20PT">
	and cash equivalents held
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	929
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Increase (decrease) in cash and cash equivalents
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,862
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(5,002
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	18,714
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Cash and cash equivalents, beginning of year
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,365
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,367
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	653
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Cash and cash equivalents, end of year
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,503
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,365
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,367
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	Supplemental cash flow information (note 6)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Reporting entity:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Aptose Biosciences Inc. (&quot;Aptose&quot; or the &quot;Company&quot;)
	is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical
	needs in oncology. Aptose is a publicly listed company incorporated under the laws of Canada. The Company's shares are listed on
	the Nasdaq Capital Markets and the Toronto Stock Exchange. The head office, principal address and records of the Company are located
	at 5955 Airport Road, Mississauga, Ontario, Canada, L4V 1R9.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Aptose changed its name from Lorus Therapeutics Inc. effective
	August 28, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Effective July 17, 2014, the Company changed its fiscal
	year end from May 31 to December 31. As a result of that change, the current reporting fiscal period is for the twelve months ended
	December 31, 2015, while the prior year comparative periods are for the seven months ended December 31, 2014 and the twelve months
	ended May 31, 2014, and therefore are not directly comparable to the current twelve month period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Basis of presentation:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Statement of compliance:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	These consolidated financial statements of the Company
	and its subsidiaries are prepared in accordance with International Financial Reporting Standards (&quot;IFRS&quot;) as issued
	by the International Accounting Standards Board (&quot;IASB&quot;). The consolidated financial statements of the Company were
	approved and authorized for issue by the Board of Directors on March 29, 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Functional and presentation currency:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The functional and presentation currency of the Company
	is the Canadian dollar.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Significant accounting judgments, estimates and assumptions:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	The preparation of these consolidated financial statements
	in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting
	policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts
	of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The consolidated financial
	statements include estimates, which, by their nature, are uncertain.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Basis of presentation (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	The impacts of such estimates are pervasive throughout
	the consolidated financial statements and may require accounting adjustments based on future occurrences.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	The estimates and underlying assumptions are reviewed
	on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any
	future periods affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	The key assumptions concerning the future and other
	key sources of estimation uncertainty as of the date of the statement of financial position that have a significant risk of causing
	material adjustment to the carrying amounts of assets and liabilities within the next fiscal year include:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Valuation of contingent liabilities:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	The Company utilizes considerable judgment in the measurement
	and recognition of provisions and the Company's exposure to contingent liabilities. Judgment is required to assess and determine
	the likelihood that any potential or pending litigation or any and all potential claims against the Company may be successful.
	The Company must estimate if an obligation is probable as well as quantify the possible economic cost of any claim or contingent
	liability. Such judgments and assumptions are inherently uncertain. The increase or decrease of one of these assumptions could
	materially increase or decrease the fair value of the liability and the associated expense.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Valuation of tax accounts:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	Uncertainties exist with respect to the interpretation
	of complex tax regulations and the amount and timing of future taxable income. Currently, the Company has deductible temporary
	differences which would create a deferred tax asset. Deferred tax assets are recognized for all deductible temporary differences
	to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences
	can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon
	the likely timing and the level of future taxable profits together with future tax planning strategies. To date, the Company has
	determined that none of its deferred tax assets should be recognized. The Company's deferred tax assets are mainly comprised of
	its net operating losses from prior years and prior year research and development expenses not yet deducted for income tax purposes.
	These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable
	income. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support
	the recognition of these losses as deferred tax assets. The generation of future taxable income could result in the recognition
	of some portion or all of the remaining benefits , which could result in an improvement in the Company's results of operations
	through the recovery of future income taxes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
<B>
	2.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Basis of presentation (continued):
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Valuation of share-based compensation and share purchase warrants:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63.35PT">
	Management measures the costs for share-based payments
	and share purchase warrants using market-based option valuation techniques. Assumptions are made and judgment is used in applying
	valuation techniques. These assumptions and judgments include estimating the future volatility of the share price, expected dividend
	yield, and employee turnover rates. Such judgments and assumptions are inherently uncertain. The increase or decrease of one of
	these assumptions could materially increase or decrease the fair value of share-based payments and share purchase warrants issued
	and the associated expense.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0; TEXT-ALIGN: RIGHT">
<B>
</B>
</TD>
<TD STYLE="WIDTH: 27PT">
<B>
	3.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Significant accounting policies:
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Basis of consolidation:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The consolidated financial statements include the accounts
	of the Company its 80% owned subsidiary, NuChem Pharmaceuticals Inc. (&ldquo;NuChem&rdquo;), its 100% owned subsidiaries Aptose
	Biosciences Inc. USA (&ldquo;Aptose USA&rdquo;) and Aptose Suisse GmbH (&ldquo;Aptose Suisse&rdquo;). A subsidiary is an entity
	over which the Company has control, being the power to govern the financial and operating policies of the investee entity so as
	to obtain benefits from its activities. Accounting policies of the subsidiaries are consistent with the Company's accounting policies.
	All intra-group transactions, balances, revenue and expenses are eliminated on consolidation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Foreign currency translation:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	Foreign currency transactions are translated into Canadian
	dollars at rates prevailing on the transaction dates. At the end of each reporting period, monetary assets and liabilities denominated
	in foreign currencies are translated into Canadian dollars at the rates in effect at that date. Gains or losses resulting from
	the translation to Canadian dollars are presented in the statement of loss and comprehensive loss for the period within finance
	income or expense.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Derecognition of financial assets and liabilities:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	A financial asset is derecognized when the right to
	receive cash flows from the asset have expired or when the Company has transferred its rights to receive cash flows from the asset.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	A financial liability is derecognized when its contractual
	obligations are discharged, cancelled or expire.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Significant accounting policies (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Financial assets and liabilities:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Financial assets within the scope of IAS 39,
<I>
	Financial
	Instruments - Recognition and Measurement
</I>
	(&quot;IAS 39&quot;), are classified as either financial assets at fair value through
	profit or loss, loans and receivables, held-to-maturity investments or available-for-sale financial assets, as appropriate. When
	financial assets are recognized initially, they are measured at fair value, plus, in the case of financial assets not at fair value
	through profit or loss, directly attributable transaction costs. The Company determines the classification of its financial assets
	at initial recognition and, where allowed and appropriate, re-evaluates this designation at each financial year end.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company's financial instruments are comprised of the
	following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 33%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	Financial assets
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%; FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	Classification
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 32%; FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	Measurement
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;Cash and cash equivalents
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Loans and receivables
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Amortized cost
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Investments
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Loans and receivables
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Amortized cost
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Financial liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Classification
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Measurement
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Accounts payable, accrued liabilities
<BR>
	and convertible promissory notes payable
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Other liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Amortized cost
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.75IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company considers unrestricted cash on hand and guaranteed
	investment certificates held by Canadian Schedule A banks with original maturities of three months or less as cash and cash equivalents.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Fair value:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	Fair value is the price that would be received to sell
	an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair
	value hierarchy establishes three levels to classify the inputs to valuation techniques used to measure fair value.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 1 - inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 2 - inputs are quoted prices in markets that are not active, quoted prices for similar assets
	or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, or inputs that
	are derived principally from or corroborated by observable market data or other means; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Significant accounting policies (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 3 - inputs are unobservable (supported by little or no market activity). The fair value hierarchy
	gives the highest priority to Level 1 inputs and the lowest priority to Level 3 inputs.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Equipment:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Equipment is measured at cost less accumulated depreciation
	and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The
	Company records depreciation at rates that charge operations with the cost of the assets over their estimated useful lives on a
	straight-line basis as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	Furniture
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 47%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	3 years
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Laboratory Equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5 years
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Computer hardware
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3 years
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Leasehold improvements
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Life of lease
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.75IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The assets' residual value, useful life and methods of
	depreciation are reviewed at each reporting period and adjusted prospectively if appropriate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(f)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Intangible assets:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Intangible assets are recorded at
	cost less accumulated amortization and accumulated impairment losses. The Company's intangible assets consist of computer application
	software that is not an integral part of related hardware. Subsequent expenditures that increase application software functionality
	are recognized in the carrying amount of intangible assets if they embody future economic benefit to the Company. All other costs
	including the costs of day-to-day servicing of intangible assets are expensed as incurred. Amortization is recognized in expense
	on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use, since
	this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the assets.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(g)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Research and development:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Expenditures on research activities, undertaken with the
	prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Development activities involve a plan or design for the
	production of new or substantially improved products or processes. Development expenditures are capitalized only if development
	costs can be measured reliably, the product or process is technically and commercially feasible, future economic
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Significant accounting policies (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	benefits are probable, and the Company intends to and has
	sufficient resources to complete development and to use or sell the asset. The expenditures capitalized would include the cost
	of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and borrowing
	costs on qualifying assets. Other development expenditures which do not meet the criteria for capitalization are recognized in
	profit or loss as incurred.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Capitalized development costs are recognized at cost less
	accumulated amortization and accumulated impairment losses.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company has not capitalized any development costs to
	date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(h)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Investment tax credits:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Research and development investment tax credits, which
	are earned as a result of incurring qualifying research and development expenditures, are recorded as a reduction of the related
	expense or cost of the asset acquired when there is reasonable assurance that they will be realized.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company's claim for scientific research and experimental
	development (&quot;SR&amp;ED&quot;) deductions and related investment tax credits for income tax purposes are based on management's
	interpretation of the applicable legislation in the Income Tax Act (Canada). These amounts are subject to review and acceptance
	by the Canada Revenue Agency prior to collection.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Employee benefits:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Short-term employee benefits:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Short-term employee benefit obligations are measured on
	an undiscounted basis and are expensed as the related service is provided.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	A liability is recognized for the amount expected to be
	paid in short-term cash bonuses if the Company expects to pay these amounts as approved by the Board of Directors as a result of
	past services provided by the employee and the obligation can be estimated reliably.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Stock-based compensation:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 45PT">
	The Company has a stock-based compensation
	plan (the &quot;Plan&quot;) available to officers, directors, employees and consultants with grants under the Plan approved by
	the Company's Board of Directors. Under the Plan, the exercise price of each option equals the closing trading price of the
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Significant accounting policies (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Company's stock on the day prior to the grant if the grant
	is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed.
	Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no greater than 10 years
	from the date of grant.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Details regarding the determination of the fair value of
	equity settled share-based transactions are set out in note 10.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company uses the fair value based method of accounting
	for employee awards granted under the Plan. The Company calculates the fair value of each stock option grant using the Black-Scholes
	option pricing model at the grant date. The stock-based compensation cost of the options is recognized as stock-based compensation
	expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Stock options awarded to non-employees are accounted for
	at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the
	goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured,
	the fair value of the options granted will be used.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company has a stock incentive plan pursuant to which
	the Board may grant stock-based awards comprised of restricted stock units or dividend equivalents to employees, officers, consultants,
	independent contractors, advisors and non-employee directors of the Corporation or any affiliate. No units have been issued under
	this plan to date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(j)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Loss per share:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	Basic loss per share is computed by dividing the net
	loss available to common shareholders by the weighted average number of shares outstanding during the year. Diluted loss per share
	is computed similarly to basic loss per share except that the weighted average shares outstanding is increased to include additional
	shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming
	that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common
	stock at the average market price during the year. The inclusion of the Company's stock options and warrants in the computation
	of diluted loss per share has an anti-dilutive effect on the loss per share and, therefore, they have been excluded from the calculation
	of diluted loss per share.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Significant accounting policies (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(k)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Income taxes:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Deferred tax is recognized in respect of temporary differences
	between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Deferred tax assets and liabilities are offset if there
	is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same
	tax authority on the same taxable entity.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Deferred tax is measured at the tax rates that are expected
	to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by
	the reporting date. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences,
	to the extent that it is probable that future taxable profits will be available against which they can be utilized.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(l)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Provisions:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	A provision is recognized if, as a result of a past event,
	the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of
	economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash
	flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.
	The unwinding of the discount is recognized as a finance cost.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(m)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Finance income and finance costs:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Finance income comprises interest income on funds invested.
	Interest income is recognized as it accrues in profit or loss using the effective interest method.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Finance costs comprise interest expense on borrowings and
	are recognized in profit or loss using the effective interest method.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 27PT; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(n)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Standards and Interpretations Adopted in the Twelve Months Ended December 31, 2015:
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 9PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 49.5PT">
	No new accounting policies were adopted in the twelve months ended December
	31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 49.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Significant accounting policies (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN; MARGIN: 0PT 0 0PT 45PT">
	(o) Recent accounting pronouncements:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	IFRS 9,
<I>
	Financial Instruments
</I>
	(&quot;IFRS 9&quot;):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 49.5PT">
	IFRS 9 (2014) introduces new requirements for the classification
	and measurement of financial assets. Under IFRS 9 (2014), financial assets are classified and measured based on the business model
	in which they are held and the characteristics of their contractual cash flows. The standard introduces additional changes relating
	to financial liabilities and also amends the impairment model by introducing a new &lsquo;expected credit loss&rsquo; model for
	calculating impairment. IFRS 9 (2014) also includes a new general hedge accounting standard which aligns hedge accounting more
	closely with risk management. The Company intends to adopt IFRS 9 (2014) in its consolidated financial statements for the annual
	period beginning on January 1, 2018. The extent of the impact of adoption of the standard has not yet been determined.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 49.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 45PT; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Amendments to IAS 1
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 49.5PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 49.5PT">
	On December 18, 2014 the IASB issued amendments to IAS
	1 Presentation of Financial Statements as part of its major initiative to improve presentation and disclosure in financial reports.
	The amendments are effective for annual periods beginning on or after 1 January 2016. Early adoption is permitted. The Company
	intends to adopt these amendments in its consolidated financial statements for the annual period beginning on January 1, 2016.
	The impact of adoption of the amendments is not expected to have a material impact on the financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 49.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 49.5PT">
	(ii) IFRS 16,
<I>
	Leases
</I>
	(&ldquo;IFRS 16&rdquo;)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 49.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 49.5PT">
	On January 13, 2016, the IASB issued IFRS 16 Leases.
	The new standard is effective for annual periods beginning on or after January 1, 2019. Earlier application is permitted for entities
	that apply IFRS 15 Revenue from Contracts with Customers at or before the date of initial adoption of IFRS 16. IFRS 16 will replace
	IAS 17 Leases. This standard introduces a single lessee accounting model and requires a lessee to recognize assets and liabilities
	for all leases with a term of more than 12 months, unless the underlying asset is of low value. The extent of the impact of adoption
	of the standard has not yet been determined.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 49.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
<B>
	4.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Capital disclosures:
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	The Company's objectives when managing capital are to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 17.3PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Maintain its ability to continue as a going concern;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 17.3PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Maintain a flexible capital structure which optimizes the cost of capital at acceptable risk; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
<B>
	4.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Capital disclosures (continued):
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 17.3PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Ensure sufficient cash resources to fund its research and development activity, to pursue partnership
	and collaboration opportunities and to maintain ongoing operations.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	The capital structure of the Company consists of equity
	comprised of share capital, share purchase warrants, stock options, contributed surplus and deficit. The Company manages its capital
	structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board of Directors,
	will balance its overall capital structure through new share issuances, acquiring or disposing of assets, adjusting the amount
	of cash balances or by undertaking other activities as deemed appropriate under the specific circumstances.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	In December 2014, Aptose filed a short form base shelf
	prospectus (the &ldquo;Base Shelf&rdquo;) that qualifies for the distribution of up to US$100,000,000 of common shares, warrants,
	or units comprising any combination of common shares and warrants (&ldquo;Securities&rdquo;). The distribution of Securities may
	be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing
	at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in
	an accompanying prospectus supplement, including transactions that are deemed to be &ldquo;at-the-market&rdquo; distributions.
	The Base Shelf provides the Company with additional flexibility when managing cash resources as, under certain circumstances, it
	shortens the time period required to close a financing and is expected to increase the number of potential investors that may be
	prepared to invest in our Company. Funds received from a Prospectus Supplement will be used in line with our Board approved budget
	and multi-year plan. The Base Shelf expires in December, 2017. The Base Shelf allowed the Company to enter into an &ldquo;At-The-Market&rdquo;
	Facility (&ldquo;ATM&rdquo;) equity distribution agreement (see Note 9). Aptose intends to use this equity arrangement as an additional
	option to assist in achieving the Company&rsquo;s capital objectives. The ATM provides the Company with the opportunity to regularly
	raise capital on the Nasdaq Capital Market, at prevailing market prices, at its sole discretion providing the ability to better
	manage cash resources.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	The Company is not subject to externally imposed capital
	requirements, and the Company's overall strategy with respect to capital risk management remains unchanged from the year ended
	December 31, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cash and cash equivalents:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Cash and cash equivalents consists of cash of $761 thousand
	(December 31, 2014 - $293 thousand) and funds deposited into high interest savings accounts totalling $10.742 million (December
	31, 2014 - $14.072 million). The current interest rate earned on these deposits is between 0.2% and 0.75% (December 31, 2014 &ndash;
	1.2-1.25%).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
<B>
	4.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Capital disclosures (continued):
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT; MARGIN: 0PT 0 0PT 45PT">
	(b) Investments:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	As at December 31, 2015 and 2014, investments consist of
	guaranteed investment certificates with Canadian financial institutions having high credit ratings. Investments include six investments
	(December 31, 2014 &ndash; twelve investments) with maturity dates from April 22, 2016 to June 19, 2016 (December 31, 2014 &ndash;
	April 22, 2015 to June 19, 2016), bearing an interest rate from 1.80% to 2.10% (December 31, 2014 &ndash; 1.50% to 2.10%) per annum.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Equipment and intangible assets:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Equipment:
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	Accumulated
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Net book
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cost
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	depreciation
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	value
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-INDENT: 0IN">
	Equipment
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	229
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	34
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	195
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Computer hardware
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Office furniture
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	52
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Leasehold improvements
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	110
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	449
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	81
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	368
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Accumulated
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Net book
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cost
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	depreciation
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	value
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-INDENT: 0IN">
	Equipment
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	545
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	481
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	64
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Computer hardware
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Office furniture
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Leasehold improvements
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	644
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 27PT">
	During the year ended December 31, 2015,
	the Company disposed of $476 thousand in fully depreciated equipment, $12 thousand in fully depreciated computer hardware and $37
	thousand in fully depreciated furniture no longer in use.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 27PT">
	During the seven months ended December
	31, 2014, the Company disposed of $1.5 million in fully depreciated equipment, $437 thousand in fully depreciated computer hardware
	and $147 in fully depreciated office furniture no longer in use.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 27PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Intangible assets:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Accumulated
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Net book
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cost
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	amortization
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	value
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Computer software
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	66
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp; &#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	66
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Equipment and intangible assets (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Accumulated
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Net book
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cost
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	amortization
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	value
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Computer software
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	105
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	16
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	89
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	89
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 27PT">
	During the seven months ended December 31, 2014, the Company
	disposed of $325 thousand in fully amortized computer software.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Additional cash flow disclosures:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 27PT">
	Net change in non-cash operating working capital is summarized
	as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="WIDTH: 61%; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
	12 months
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
	7 months
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
	12 months
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Dec 31, 2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Dec 31, 2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	May 31,2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Prepaid expenses and other assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(212
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(360
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(130
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	266
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(393
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accrued liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	172
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	379
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Balance, end of period
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	226
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(374
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	During the year ended December 31, 2015, the Company
	incurred and paid interest on the convertible promissory notes described in note 7 of $25 thousand. In addition the Company recorded
	accretion expense of $18 thousand as described in note 7. The notes were all converted by September 30, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	During the seven months ended December 31, 2014, the
	Company incurred interest on the convertible promissory notes described in note 7 of $30 thousand of which $3 thousand was accrued
	and unpaid at December 31, 2014. The interest accrues at a rate of 10% per annum and is paid quarterly. In addition the Company
	recorded accretion expense of $28 thousand as described in note 7.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	During the year ended May 31, 2014, the Company paid
	$75 thousand in interest expense on $918 thousand in promissory notes and recorded accretion expense of $100 thousand related to
	the same promissory notes. These notes and all unpaid interest were repaid in April 2014. The interest accrued at a rate of 10%
	per annum. In addition the Company incurred interest in the year ended May 31, 2014 on certain loan agreements and convertible
	promissory notes described in note 7 of $51 thousand of which $14 thousand was accrued and unpaid at May 31, 2014. The Company
	also recorded $33 thousand of accretion expense related to the convertible promissory notes. Interest accrued at a rate of 10%
	per annum and was paid quarterly. The loan agreements and all interest accrued thereon were repaid in April 2014. The Company also
	paid interest of $3 thousand at a rate of 10% per annum to the withheld pay of employees. All amounts withheld from employees had
	been repaid by December 2013.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 90; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Convertible promissory notes payable:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	In September 2013, the Company completed a private placement
	of convertible promissory notes for aggregate gross proceeds of $600 thousand. Each convertible promissory note consisted of a
	$1 thousand principal amount of unsecured promissory note convertible into common shares of the Company at a price per share of
	$3.60. The promissory notes bore interest at a rate of 10% per annum, payable quarterly and were due September 26, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	The promissory notes were a compound financial instrument
	containing a liability component and an equity component represented by the conversion feature. The fair value of the liability
	component upon issuance was estimated by discounting the future cash flows associated with the debt at a discounted rate of approximately
	19% which represented the estimated borrowing cost to the Company for similar promissory notes with no conversion feature. The
	residual value of $88 thousand was allocated to the conversion feature.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Subsequent to initial recognition, the promissory notes
	were accounted for at amortized cost using the effective interest rate method. The Company incurred costs associated with the financing
	of $17 thousand. These costs along with the adjustment for the conversion feature were being accreted using the effective interest
	rate method over the 24 month life of the notes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	During the year ended December 31, 2015, all of the outstanding
	promissory notes were converted into common shares of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27PT">
<B>
	8.
</B>
</TD>
<TD>
<B>
	Financial instruments:
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Financial instruments:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company has classified its financial instruments as
	follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID">
	December 31,
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Financial assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Cash and cash equivalents, consisting of high interest savings account, measured at amortized cost
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	11,503
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	14,365
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Investments, consisting of guaranteed investment certificates, measured at amortized cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,245
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Financial liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts payable, measured at amortized cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	522
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	256
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrued liabilities, measured at amortized cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,834
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,662
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Convertible promissory notes, measured at amortized cost
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	410
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	At December 31, 2015, there are no significant differences
	between the carrying values of these amounts and their estimated market values due to their short-term nature.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 91; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	8.&#9;Financial instruments (continued):
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Financial risk management:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company has exposure to credit risk, liquidity risk,
	foreign currency risk and market risk. The Company's Board of Directors has the overall responsibility for the oversight of these
	risks and reviews the Company's policies on an ongoing basis to ensure that these risks are appropriately managed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Credit risk:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	Credit risk is the risk of financial loss to the Company
	if a customer, partner or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally
	from the Company's cash and cash equivalents. The carrying amount of the financial assets represents the maximum credit exposure.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	The Company manages credit risk associated with its cash
	and cash equivalents by maintaining minimum standards of R1-low or A-low investments and the Company invests only in highly rated
	Canadian corporations which are capable of prompt liquidation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Liquidity risk:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	Liquidity risk is the risk that the Company will not be
	able to meet its financial obligations as they come due. To the extent that the Company does not believe it has sufficient liquidity
	to meet its current obligations, management and the Board consider securing additional funds through equity, debt or partnering
	transactions. The Company manages its liquidity risk by continuously monitoring forecasts and actual cash flows. All of the Company's
	financial liabilities are due within the current operating period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Market risk:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	Market risk is the risk that changes in market prices,
	such as interest rates, foreign exchange rates and equity prices will affect the Company's income or the value of its financial
	instruments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	The Company is subject to interest rate risk on its cash
	and cash equivalents and investments. The Company does not believe that the results of operations or cash flows would be affected
	to any significant degree by a sudden change in market interest rates relative to interest rates on the investments, owing to the
	relative short-term nature of the investments. The Company does not have any interest bearing liabilities subject to interest rate
	fluctuations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 92; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	8.&#9;Financial instruments (continued):
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	Currency risk is the risk that future cash flows of a financial
	instrument will fluctuate because of changes in foreign exchange rates. We are exposed to currency risk from employee costs as
	well as the purchase of goods and services primarily in the United States and the cash balances held in foreign currencies. Fluctuations
	in the US dollar exchange rate could have a significant impact on the Company&rsquo;s results. Assuming all other variables remain
	constant, a 10% depreciation or appreciation of the Canadian dollar against the US dollar would result in an increase or decrease
	in loss for the year and comprehensive loss of $576 thousand (December 31, 2014- $50 thousand, May 31, 2014 - $18 thousand). Balances
	in foreign currencies are as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 63PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	US$ Balances
</B>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD COLSPAN="5" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;December 31,
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	5,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	66
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	594
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accounts payable and accrued liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(838
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(565
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(769)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Balance, end of period
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	4,162
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(499)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(175
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
	The Company does not have any forward
	exchange contracts to hedge this risk.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
	The Company does not invest in equity
	instruments of other corporations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	9.&#9;Share capital:
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN; MARGIN: 0PT 0 0PT 45.35PT">
<B>
	Share consolidation
</B>
	:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN; MARGIN: 0PT 0 0PT 45.35PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	In accordance with the authority granted by shareholders
	at the Company's annual and special meeting on August 19, 2014 to permit it to implement a consolidation of the Company's outstanding
	common shares in a ratio of between 1-for-5 and 1-for-15, the Company's Board of Directors approved a 1-for-12 share consolidation
	which became effective October 1, 2014. The share consolidation affected all of the Company's common shares, stock options and
	warrants outstanding at the effective time. Fractional shares were not issued. Prior to consolidation the Company had approximately
	139 million shares outstanding. Following the share consolidation, the Company has approximately 11.6 million common shares outstanding.
	Similarly, prior to consolidation, the Company had approximately 17.1 million stock options and 2.6 million warrants to purchase
	common shares outstanding. Following the share consolidation, the Company had approximately 1.4 million stock options and 218 thousand
	warrants to purchase common shares outstanding. In these consolidated financial statements, all references to number of shares,
	stock options and warrants in the current and past periods have been adjusted to reflect the impact of the share consolidation.
	All amounts based on the number of shares, stock options or warrants, unless otherwise specified, such as earnings (loss) per share
	and weighted average issuance price in the case of stock options have been adjusted to reflect the impact of 1-for-12 share consolidation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 93; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share capital (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Continuity of common shares and warrants:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="5" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	Common shares
</P>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="5" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	Warrants
</P>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Number
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Amount
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Number
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Amount
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	(In thousands)
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	(In thousands)
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-INDENT: 0IN">
	Balance, May 31, 2013
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	3,521
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	174,522
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	2,262
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	2,421
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Expiry of broker warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Issuance of warrants (b)(iv)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	76
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Warrant exercises
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	868
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,422
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(868
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(964
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Finders warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	103
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Option exercises
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	December equity offering and
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	overallotment (b)(iii)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,220
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,927
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	73
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	April equity offering and
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	overallotment (b)(ii)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,708
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25,584
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	DSU exercise
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	444
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Balance, May 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	10,388
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	212,938
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,630
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,857
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Warrant exercises
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,231
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,814
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,231
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,166
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Warrant expiry
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Option exercises
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	345
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Promissory note conversion
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	162
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	Balance, December 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	11,700
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	221,259
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	209
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	501
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Warrant exercises
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	81
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	503
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(81
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(155
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Warrant expiry
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(55
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(262
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Option exercises
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	143
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,215
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Common shares under the ATM(b)(i)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Promissory note conversion
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	122
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	438
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Balance, December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	12,048
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	223,425
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	73
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	84
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Equity issuances:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	(i) At-The-Market (&ldquo;ATM&rdquo;) Facility
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	On April 2, 2015, we entered into an ATM equity facility
	with Cowen and Company, LLC, acting as sole agent. Under the terms of this facility, we may, from time to time, sell shares of
	our common stock having an aggregate offering value of up to US$20 million through Cowen and Company, LLC on the Nasdaq Capital
	Market. We determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During the twelve
	months ended December 31, 2015, the Company issued 1,504 common shares under the ATM at a price of US$5.20 per share for gross
	proceeds of approximately Cdn $10 thousand.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	(ii) April 2014 Public Equity Offering and Overallotment
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	In April 2014, the Company completed a public offering
	of common shares. The Company issued 4,166,667 (pre-consolidation 50,000,000) common shares at a purchase price of $6.00 ($0.50
	pre-consolidation) per common share and an additional 541,667 (pre consolidation 6,500,000) common shares upon the partial exercise
	of the over-allotment option for aggregate gross proceeds of $28.3
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 94; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share capital (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	million. The total costs associated with the transaction
	were approximately $2.7 million which includes a cash commission of $2.0 million based on 7% of the gross proceeds received as
	part of the offering.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	(iii) December 2013 Public Equity Offering and Overallotment
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	In December 2013, Aptose completed a public offering
	of common shares. Aptose issued 1,060,833 (pre-consolidation 12,730,000) common shares at a price of $6.60 (pre-consolidation $0.55)
	per common share and an additional 159,125 (pre-consolidation 1,909,500) common shares upon the exercise of the overallotment option
	for aggregate gross proceeds of $8.1 million.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	The total costs associated with the transaction were
	approximately $1.1 million which include a cash commission of $483 thousand based on 6% of the gross proceeds received as part
	of the offering, and the issuance of 73,198 (pre-consolidation 878,370) broker warrants with an estimated fair value of $350 thousand.
	The fair value of these warrants was determined using the Black Scholes model with a 24 month time to maturity, an assumed volatility
	of 130% and a risk free interest rate of 1.5%. Each broker warrant was exercisable into one common share of the Company at a price
	of $6.60 (pre-consolidation $0.55) for a period of twenty four months following closing of the offering.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	(iv) June 2013 Private Placement
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	In June 2013, the Company completed a private placement
	of units (&ldquo;Units&rdquo; in this section) at a price of $1 thousand per unit, for aggregate gross proceeds of $918 thousand.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	Each Unit consisted of (i)&nbsp;a $1 thousand principal
	amount of unsecured promissory note and (ii)&nbsp;83 (pre-consolidation 1,000) common share purchase warrants. The promissory notes
	bore interest at a rate of 10% per annum, payable monthly and were due June 19, 2014. Each warrant entitled the holder thereof
	to acquire one common share of the Company at a price per common share equal to $3.00 (pre-consolidation $0.25) at any time until
	June 19, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	The Units contained a liability component and an equity
	component represented by the warrants to purchase common shares. The fair value of the liability component of $843 thousand was
	estimated by discounting the future cash flows associated with the debt at a discounted rate of approximately 19% which represents
	the estimated borrowing cost to the Company for similar promissory notes with no warrants. The residual value of $75 thousand was
	allocated to the warrants. The Company incurred costs associated with the financing of $23 thousand. These costs were amortized
	using the effective interest rate method over the 12 month life of the notes.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	These notes and any interest accrued thereon were repaid
	in full in April 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 95; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share capital (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 13.5PT">
</TD>
<TD STYLE="WIDTH: 22.5PT">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Warrants:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81.35PT">
<I>
	Warrants exercised during the twelve
	months ended December 31, 2015:
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81.35PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81.35PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	(in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Number
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Proceeds
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: 0IN">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	86
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	June 2013 private placement warrants (ii)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	141
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 2013 broker warrants (iii)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	121
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	81
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	348
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	In addition to the cash proceeds received, the original
	fair value related to these warrants of $155 thousand was transferred from warrants to share capital. This resulted in a total
	amount of $503 thousand credited to share capital.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81.35PT">
<I>
	Warrants exercised during the seven
	months ended December 31, 2014:
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81.35PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Number
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Proceeds
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: 0IN">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	48
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	June 2012 private placement warrants (iv)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,223
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,231
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6,648
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9.35PT; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 45.35PT">
	In addition to the cash proceeds received
	the original fair value related to these warrants of $1.2 million was transferred from warrants to share capital. This resulted
	in a total amount of $7.8 million credited to share capital.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81PT">
<I>
	Warrants exercised during the year
	ended May 31, 2014:
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Number
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Proceeds
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: 0IN">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	327
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,764
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	June 2012 private placement warrants (iv)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	409
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,210
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	June 2012 finder warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	103
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	June 2013 private placement warrants (iii)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	88
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	868
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	4,458
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 45PT">
	In addition to the cash proceeds received
	the original fair value related to these warrants of $964 thousand was transferred from warrants to share capital. This resulted
	in a total amount of $5.4 million credited to share capital.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN; MARGIN: 0PT 0 0PT 81PT">
<I>
	Summary of outstanding warrants:
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0 0PT 0.25IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0 0PT 0.25IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: 0IN">
	August 2011 warrants (i)&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	73
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	89
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	June 2013 private placement warrants (ii)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 2013 broker warrants (iii)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	73
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of warrants outstanding, end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	73
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	209
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9.35PT; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 96; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share capital (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40.3PT">
</TD>
<TD STYLE="WIDTH: 13.7PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(i)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	August 2011 warrants are exercisable into common shares of Aptose
	at a price per share of $5.40 and expire in August 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	June 2013 private placement warrants were exercisable into common shares of Aptose at a price per
	share of $3.00 and expired in June 2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	December 2013 broker warrants were exercisable into common shares of Aptose at a price per share
	of $6.60 and expired in December 2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(iv)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	June 2012 private placement warrants were exercisable into common shares of Aptose at a price per
	share of $5.40 ($0.45 pre-consolidation) and expired on June 8, 2014
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Continuity of contributed surplus:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Contributed surplus is comprised of the cumulative grant
	date fair value of expired share purchase warrants and expired stock options as well as the cumulative amount of previously expensed
	and unexercised equity settled share-based payment transactions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	7 months
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Dec 31, 2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Dec 31, 2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	May 31,2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-INDENT: 0IN">
	Balance, beginning of period
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	21,653
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	21,410
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	21,217
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Expiry of warrants (c)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	262
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Expiry of stock options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Conversion of promissory notes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cancellation of stock options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	103
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Balance, end of period
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	22,037
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	21,653
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	21,410
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 17.65PT">
	(e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Continuity of stock options:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;12 months
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	7 months
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	ended
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Dec 31, 2015
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Dec 31, 2014
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	May 31,2014
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-INDENT: 0IN">
	Balance, beginning of period
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	4,078
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,658
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,018
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Stock option expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,812
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,627
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,826
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Exercise of stock options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(566
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(162
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expiry of stock options
<BR>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cancellation of stock options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(103
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Balance, end of period
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	6,256
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	4,078
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2,658
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 97; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share capital (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.35PT">
</TD>
<TD STYLE="WIDTH: 17.65PT">
	(f)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Loss per share:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	Loss per common share is calculated using the weighted
	average number of common shares outstanding for the year ended December 31, 2015 of 11.906 million, the seven months ending December
	31, 2014 of 11.605 million and the year ending May 31, 2014 of 5.216 million, calculated as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;Year ended
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	7 months ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	Year ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Dec 31, 2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Dec 31, 2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	May 31,2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-INDENT: 0IN">
	Issued common shares beginning of period
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	11,700
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	10,388
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,521
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Effect of ATM issuances
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	Effect of April 2014 public offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	785
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	Effect of December 2013 public offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	597
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Effect of warrant exercises
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	301
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Effect of option and DSU exercises
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	103
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Effect of promissory note conversions
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	54
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Balance, end of period
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	11,906
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	11,605
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5,216
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 45.35PT; TEXT-ALIGN: JUSTIFY">
	The effect of any potential
	exercise of the Company's stock options and warrants outstanding during the year has been excluded from the calculation of diluted
	loss per common share as it would be anti-dilutive.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(g)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Deferred share unit plan:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	As at December 31, 2015 nil deferred share units are outstanding
	(December 31, 2014 &ndash; nil, May 31, 2014 &ndash; nil). 65,000 common shares of the Company were issued in April 2014 in satisfaction
	of the outstanding deferred share unit liability. The shares issued had a fair value of $444 thousand.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Stock-based compensation:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 45PT">
	Under the Company's stock option plan,
	options, rights and other entitlements may be granted to directors, officers, employees and consultants of the Company to purchase
	up to a maximum of 17.5% of the total number of outstanding common shares, estimated at 2,108,000 options, rights and other entitlements
	as at December 31, 2015. Options are granted at the fair market value of the common shares on the closing trading price of the
	Company's stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day
	of grant if the grant is issued after markets have closed. Options vest at various rates (immediate to four years) and have a term
	of 10 years. Stock option transactions for the twelve month period ended December 31, 2015, the seven month period ended December
	31, 2014 twelve months ended May 31, 2014 are summarized as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 98; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Stock-based compensation (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
<I>
	Option numbers are in (000&rsquo;s)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="5" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	December 31, 2015
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Weighted
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	average
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	exercise
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Options
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	price
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: 0IN">
	Outstanding, beginning of period
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,374
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	5.95
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	478
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(143
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.53
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Forfeited/Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	9.85
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Outstanding, end of the period
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,689
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6.31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
<I>
	Option
	numbers are in (000&rsquo;s)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="5" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	7 months ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="5" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	Year
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="5" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 8.35PT; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	December
	31, 2014
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="5" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	May 31, 2014
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	Weighted
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Weighted
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	average
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	average
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	exercise
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	exercise
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Options
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	price
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Options
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	price
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Outstanding, beginning of year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	824
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6.22
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	280
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	5.50
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	604
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.57
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	573
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.63
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	Forfeited
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22.16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cancelled
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Outstanding, end of year
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,374
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5.95
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	824
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	6.22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	The following table summarizes information about stock
	options outstanding at December 31, 2015:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
<I>
	Option numbers are in (000&rsquo;s)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="9" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	Options outstanding
</P>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="5" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	Options exercisable
</P>
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Weighted
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	average
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	Weighted
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	Weighted
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	remaining
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	average
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	average
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-INDENT: 0IN">
	Range of
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	contractual
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	exercise
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	exercise
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	exercise prices
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Options
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	life (years)
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	price
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Options
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	price
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 45%; TEXT-INDENT: 0IN">
	$2.16 - $&nbsp;&nbsp;5.49
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	266
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	7.7
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	4.26
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	188
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	3.85
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	$5.50 - $&nbsp;&nbsp;5.85
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	477
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	257
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	$5.86 - $&nbsp;&nbsp;6.87
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	354
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	$6.88 - $&nbsp;&nbsp;6.98
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	343
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	$6.99 - $118.80
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	249
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	7.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	8.85
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	203
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	9.22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,689
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	8.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	6.31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	785
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	6.23
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 99; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Stock-based compensation (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	The following assumptions were used in the Black-Scholes
	option pricing model to determine the fair value of stock options granted during the period:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year&nbsp;ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	7 months ended
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	Year ended
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Dec 31, 2015
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Dec &nbsp;31, 2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	May 31,2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	Exercise price
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.77-7.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.16-5.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.48-9.36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	Grant date share price
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.77-7.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.16-5.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.48-9.36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Risk-free interest rate
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.75-1.5%
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1.5
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1.5-3%
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected dividend yield
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-INDENT: 0IN; TEXT-ALIGN: RIGHT">
	103-113%
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	53-122%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	125-135%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Expected life of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5 years
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3 months-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5 years
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5 years
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	Weighted average fair value of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;&nbsp;granted or modified during the period
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	5.34
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	4.56
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6.60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	The Company uses historical data to estimate the expected
	dividend yield and expected volatility of its common shares in determining the fair value of stock options. The expected life of
	the options represents the estimated length of time the options are expected to remain outstanding.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	Stock options granted by the Company during the twelve
	months ended December 31, 2015, consist of 128,000 options that vest 50%, 25% and 25% on each of the next three anniversaries and
	350,000 options that vest 50% on the first anniversary and 16.67% on each of the next three anniversaries (total four year vesting).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	Stock options granted by the Company during the seven
	months ended December 31, 2014 vest 50% upon the first anniversary and 25% on each of the second and third anniversaries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	Stock options granted by the Company during the year
	ended May 31, 2014 consisted of 151,708 options which vested immediately, 70,833 options that vested 50% upon issuance and 25%
	on each of the next two anniversaries, 276,667 options which vest 50%, 25% and 25% on each of the next three anniversaries, 70,833
	options which vest in equal installments over 36 months and 3,125 options which vest in October 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Refer to note 11 and 12 for a breakdown of stock option
	expense by function.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 100; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	11.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Research and Development:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Components of research and development expense are as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	7 months ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Research and Development costs
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,015
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,371
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,287
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Severance costs to a former officer
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	326
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Deferred share unit costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stock-based compensation
<BR>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	210
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	296
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Depreciation of equipment
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6,254
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2,404
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	3,015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	12.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	General and Administrative:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	Components of general and administrative expenses:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	7 months ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9PT; TEXT-INDENT: -9PT">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(note 17)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(note 17)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	General and administrative excluding salaries
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	4,327
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,421
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,620
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	Salaries
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,849
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,505
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,217
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Severance costs to a former officer
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	762
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Deferred share unit costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	183
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,602
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,598
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,530
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Depreciation of equipment and amortisation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	67
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	9,845
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	7,317
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	13.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Finance income and expense:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	Components of finance income:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	7 months ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Interest income
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	286
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	279
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	76
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Foreign exchange gain on cash and
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;&nbsp;cash equivalents
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,230
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,516
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	279
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	76
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 101; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	13.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Finance income and expense (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	Components of finance expense:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	7 months ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(note 17)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(note 17)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Interest expense
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	129
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Accretion expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	130
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Foreign exchange loss on cash and
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;&nbsp;cash equivalents
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	46
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	43
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	104
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	297
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	14.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Related party transactions:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	In March 2015, the Company entered into an agreement
	with the Moores Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services to the Company.
	Dr. Stephen Howell is the Acting Chief Medical Officer of Aptose and is also a Professor of Medicine at UCSD and will be overseeing
	the laboratory work. The research services will be provided from April 1, 2015 to March 31, 2016 for an annual fee of US$154,456
	to be paid to UCSD in monthly installments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 22.3PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	This transaction is in the normal course of business
	and will be measured at the amount of consideration established and agreed to by the related parties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 22.3PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
<B>
	Compensation of key management personnel:
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	Key management personnel are those persons having authority
	and responsibility for planning, directing and controlling the Company's activities as a whole. The Company has determined that
	key management personnel consists of the members of the Board of Directors along with the officers of the Company. For the year
	ended December 31, 2015, and for the seven month period ended December 31, 2014, the officers were the Chairman, President and
	Chief Executive Officer, the Chief Financial Officer as well as the Chief Business Officer. For the twelve months ended May 31,
	2014, the officers were the Chairman, President and Chief Executive Officer, the Chief Financial Officer and the Chief Business
	Officer as well as the Director of Finance, the former Vice President of Research and the former President and Chief Operating
	Officer.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 102; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	14.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Related party transactions (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Officer compensation:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	12 months
<B>
</B>
</P>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	7 months
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;December 31,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	May 31,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Salaries and short-term employee benefits
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,863
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,029
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,357
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Severance payment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,088
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	Deferred share units
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	273
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,101
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,452
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,475
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	3,964
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2,481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5,193
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	Director compensation:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	12 months
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	7 months
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Directors' fees
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	328
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	118
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	386
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	307
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	117
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	179
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	635
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	235
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	565
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	Included in accounts payable and accrued liabilities
	at December 31, 2015 is $13 thousand (December 31, 2014 &ndash; $29 thousand, May 31, 2014 - $268 thousand) due to directors and
	officers of the Company relating to directors' fees, and reimbursements for employment expenses. These amounts are unsecured, non-interest
	bearing and have no fixed terms of repayment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	15.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Commitments, contingencies and guarantees:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Operating lease commitments:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company has entered into operating leases for premises
	and equipment under which it is obligated to make minimum annual payments as described below:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 45PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="WIDTH: 48%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Less than 1 year
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	1 - 3 years
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	3 - 5 years
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Total
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Operating leases
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	587
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	907
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	319
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,813
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 103; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	15.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Commitments, contingencies and guarantees (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other contractual commitments:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company has entered into various contracts with service
	providers with respect to the clinical development of APTO-253. These contracts will result in future payment commitments of up
	to approximately $4 million over the related service period. Of this amount, $544 thousand has been paid and $574 thousand has
	been accrued at December 31, 2015. The payments are based on services performed and amounts may be higher or lower based on actual
	services performed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company enters into research, development and license
	agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies.
	Milestone and royalty payments that may become due under various agreements are dependent on, among other factors, clinical trials,
	regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. Under
	the license agreement with the Moffitt Cancer Centre, the Company has future contingent milestones payable totalling US$9 million
	relating to the first patient dosed in a phase I, II and III clinical trial and regulatory and commercial milestones totalling
	US$16 million. The Company does not anticipate making any payments under this license agreement in 2016. Under the Laxai-Avanti
	Life Science agreement the Company has total future contingent milestones payable of US$5.3 million related to certain research
	achievements as well as upon the first patient dosed in a phase I, II and III clinical trial and regulatory milestones totalling
	US$5 million. The Company expects to make payments totalling US$300 thousand under this agreement in 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Guarantees:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company entered into various contracts, whereby contractors
	perform certain services for the Company. The Company indemnifies the contractors against costs, charges and expenses in respect
	of legal actions or proceedings against the contractors in their capacity of servicing the Company. The maximum amounts payable
	from these guarantees cannot be reasonably estimated. Historically, the Company has not made significant payments related to these
	guarantees.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	The Company indemnifies its directors and officers against
	any and all claims or losses reasonably incurred in the performance of their service to the Company to the extent permitted by
	law. The Company has acquired and maintains liability insurance for its directors and officers. The fair value of this indemnification
	is not determinable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 104; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	16.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Income taxes:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN; MARGIN: 0PT 0 0PT 45PT">
	Provision for income taxes:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN; MARGIN: 0PT 0 0PT 45PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Major items causing the Company's income tax rate to differ
	from the statutory rate of approximately 26.5% (December 31, 2014 &ndash; 26.5%, May 31, 2014 - 26.5%) are as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	7 months ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	Year ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;December 31,
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	2014
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Loss before income taxes
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(14,626
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(7,771
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(10,553
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Statutory Canadian corporate tax rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	26.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	26.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	26.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Anticipated tax recovery
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,876
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,059
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,797
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Non-deductible permanent differences
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	754
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	441
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	599
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Change in deferred tax benefits deemed not probable to be recovered
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,255
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,643
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,839
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Undeducted financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(730
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(133
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	89
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	The Company has undeducted research and development
	expenditures, totaling $25.8 million that can be carried forward indefinitely.&nbsp; The Company also has non-refundable federal
	investment tax credits of approximately $5.5 million which are available to reduce future federal taxes payable and begin to expire
	in 2019, as well as non-refundable Ontario research and development tax credits of approximately $537 thousand which are available
	to reduce future Ontario taxes payable and begin to expire in 2028.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	In addition, the Company has non-capital loss carryforwards
	of $42.2 million. To the extent that the non-capital loss carryforwards are not used, they expire as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_51"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 85%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	2026
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	11
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	2027
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,349
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	2028
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,744
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	2029
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	657
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	2030
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,907
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	2031
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,581
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	2032
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,479
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	2033
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,513
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	2034
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,756
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	2035
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	11,160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	42,157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27.35PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 105; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 18PT; FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; MARGIN: 0PT 0">
	aptose biosciences inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Notes to Consolidated Financial Statements (continued)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	(Tabular amounts in thousands of Canadian dollars, except
	per share amounts)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -9PT; MARGIN: 0PT 0 0PT 9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended December 31, 2015, Seven Months ended December 31, 2014 and
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Year ended May 31, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	16.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Income taxes (continued):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Deferred tax assets have not been recognized in respect
	of the following items:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_52"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 30PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Net operating losses carried forward
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	11,209
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	8,148
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Research and development expenditures
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,845
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,478
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Equipment book over tax depreciation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	490
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	459
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Intangible asset
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,097
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,097
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Undeducted financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	389
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	740
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Ontario Research and Development Tax Credit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	442
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cumulative eligible capital
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	398
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	346
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Unrecognized deferred tax asset
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	22,965
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	19,710
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
	17.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Comparative figures:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	Certain comparative figures in the seven months ended December
	31, 2014 and year ended May 31, 2014 have been reclassified in order to conform to the presentation in the current year.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	In the seven months ended December 31, 2014, $46 thousand
	was deducted from general and administrative expense and reclassified to finance expense. This $46 thousand related to foreign
	exchange losses on cash and cash equivalent balances.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	In the year ended May 31, 2014, $38 thousand was deducted
	from general and administrative expense and reclassified to finance expense. This $38 thousand related to foreign exchange losses
	on cash and cash equivalent balances.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0 0PT 27PT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	F-33
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage107"></A>
<A NAME="EXH_81_HTM"></A>
<EFX_EXHIBIT_8>
<A NAME="FIS_EXHIBIT_8"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 8.1
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_53"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	LIST OF SUBSIDIARIES
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Name
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Jurisdiction
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Aptose Biosciences U.S. Inc.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	Delaware
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Aptose Suisse GmbH
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Zug, Switzerland
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Nuchem Pharmaceuticals Inc.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	Canada
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_8>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage108"></A>
<A NAME="EXH_121_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 12.1
</B>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANTTO
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SECURITIES AND EXCHANGE COMMISSION RULE 13a-14(a)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	I, William G. Rice, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	I have reviewed this annual report on Form 20-F of Aptose Biosciences Inc. for the year ended December 31, 2015;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	a.
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	b.
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	c.
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	d.
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	5.
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 88%">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	a.
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	b.
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Date: March 29, 2016
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	/s/ William G. Rice
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	William G. Rice
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Chairman, President and Chief Executive Officer
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage109"></A>
<A NAME="EXH_122_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12_2"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 12.2
</B>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	CERTIFICATION OF CHIEF FINANCIALOFFICER PURSUANTTO
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SECURITIES AND EXCHANGE COMMISSION RULE 13a-14(a)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	I, Gregory K. Chow, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	I have reviewed this annual report on Form 20-F of Aptose Biosciences Inc. for the year ended December 31, 2015;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	a.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	b.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	c.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	d.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	5.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	a.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	b.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Date: March 29, 2016
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	/s/ Gregory K. Chow&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Gregory K. Chow&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Senior Vice President and CFO
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR>
<TD STYLE="WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage110"></A>
<A NAME="EXH_131_HTM"></A>
<EFX_EXHIBIT_13>
<A NAME="FIS_EXHIBIT_13"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 13.1
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	CERTIFICATION OF CHIEF EXECUTIVE OFFICER
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	PURSUANT TO 18 U.S.C. &sect;1350,
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	AS ADOPTED PURSUANT TO
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	In connection with the Annual Report of Aptose Biosciences Inc. (the &ldquo;Company&rdquo;)
	on Form 20-F for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the
	&ldquo;Report&rdquo;), I, William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of the Company, certify, pursuant
	to 18 U.S.C. &sect;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;); and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the end of the period covered by the Report and the results of operations of the Company for the period covered by the Report.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Date: March 29, 2016
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
<U>
	/s/ William G. Rice&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	William G. Rice, Ph.D.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Chairman, President and Chief Executive Officer
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	This certification shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18
	of the Exchange Act or otherwise subject to the liability of Section 18 of the Exchange Act. Such certification shall not be deemed
	to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the
	extent that the Company specifically incorporates it by reference.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_13>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage111"></A>
<A NAME="EXH_132_HTM"></A>
<EFX_EXHIBIT_13>
<A NAME="FIS_EXHIBIT_13_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 13.2
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	CERTIFICATION OF CHIEF FINANCIAL OFFICER
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	PURSUANT TO 18 U.S.C. &sect;1350,
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	AS ADOPTED PURSUANT TO
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	In connection with the Annual Report of Aptose Biosciences Inc. (the &ldquo;Company&rdquo;)
	on Form 20-F for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the
	&ldquo;Report&rdquo;), I, Gregory Chow, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to
	18 U.S.C. &sect;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;); and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the end of the period covered by the Report and the results of operations of the Company for the period covered by the Report.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Date: March 29, 2016
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
<U>
	/s/ Gregory Chow&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Gregory Chow&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Senior Vice President and Chief Financial Officer
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	This certification shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18
	of the Exchange Act or otherwise subject to the liability of Section 18 of the Exchange Act. Such certification shall not be deemed
	to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the
	extent that the Company specifically incorporates it by reference.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_13>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage112"></A>
<A NAME="EXH_151_HTM"></A>
<EFX_EXHIBIT_15>
<A NAME="FIS_EXHIBIT_15"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="COLOR: NAVY; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	Exhibit
	15.1
</FONT>
</P>
<P STYLE="COLOR: NAVY; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="COLOR: NAVY; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="COLOR: NAVY; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="COLOR: RED; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001171843-16-008903_LOGO.JPG">
</P>
<P STYLE="COLOR: NAVY; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="COLOR: NAVY; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Management
	Discussion and Analysis
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	December
	31, 2015
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	MANAGEMENT&rsquo;S
	DISCUSSION AND ANALYSIS
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	March 15, 2016
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	This management&rsquo;s
	discussion and analysis of Aptose Biosciences Inc. (&ldquo;Aptose&rdquo;, the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;our&rdquo;,
	&ldquo;us&rdquo; and similar expressions) should be read in conjunction with the Company&rsquo;s annual audited financial statements
	for the year ended December 31, 2015 and the annual report on form 20-F of the Company for the year ended December 31, 2015 which
	can be found on SEDAR at
<U>
	www.sedar.com
</U>
	and
</I>
	EDGAR at
<I>
<U>
	www.sec.gov/edgar.shtml
</U>
	.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	CAUTION REGARDING FORWARD-LOOKING
	STATEMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	This management&rsquo;s
	discussion and analysis may contain forward-looking statements within the meaning of securities laws. Such statements include,
	but are not limited to, statements relating to:
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our business strategy;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our clinical development plans;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our ability to obtain the substantial
	capital we require to fund research and operations;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our plans to secure strategic partnerships
	to assist in the further development of our product candidates and to build our pipeline;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our plans to conduct clinical trials
	and preclinical programs;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our expectations regarding the progress
	and the successful and timely completion of the various stages of our drug discovery, preclinical and clinical studies and the
	regulatory approval process;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our plans, objectives, expectations
	and intentions; and
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	other statements including words such
	as &ldquo;anticipate&rdquo;, &ldquo;contemplate&rdquo;, &ldquo;continue&rdquo;, &ldquo;believe&rdquo;, &ldquo;plan&rdquo;, &ldquo;estimate&rdquo;,
	&ldquo;expect&rdquo;, &ldquo;intend&rdquo;, &ldquo;will&rdquo;, &ldquo;should&rdquo;, &ldquo;may&rdquo;, and other similar expressions.
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	The forward-looking
	statements reflect our current views with respect to future events, are subject to significant risks and uncertainties, and are
	based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant
	business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results,
	performance or achievements to be materially different from any future results, performance, or achievements that may be expressed
	or implied by such forward-looking statements, including, among others:
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our ability to obtain the substantial
	capital we require to fund research and operations;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our lack of product revenues and history
	of operating losses;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our early stage of development, particularly
	the inherent risks and uncertainties associated with (i) developing new drug candidates generally, (ii) demonstrating the safety
	and efficacy of these drug candidates in clinical studies in humans, and (iii) obtaining regulatory approval to commercialize these
	drug candidates;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our drug candidates require time-consuming
	and costly preclinical and clinical testing and regulatory approvals before commercialization;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	clinical studies and regulatory approvals
	of our drug candidates are subject to delays, and may not be completed or granted on expected timetables, if at all, and such delays
	may increase our costs and could delay our ability to generate revenue;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	the regulatory approval process;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our ability to recruit patients for
	clinical trials;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	the progress of our clinical trials;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our ability to find and enter into
	agreements with potential partners;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our ability to attract and retain key
	personnel;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our ability to obtain and maintain
	patent protection;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our ability to protect our intellectual
	property rights and not infringe on the intellectual property rights of others;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our ability to comply with applicable
	governmental regulations and standards;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	development or commercialization of
	similar products by our competitors, many of which are more established and have or have access to greater financial resources
	than us;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	commercialization limitations imposed
	by intellectual property rights owned or controlled by third parties;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	potential product liability and other
	claims;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	our ability to maintain adequate insurance
	at acceptable costs;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	further equity financing, which may
	substantially dilute the interests of our existing shareholders;
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	changing market conditions; and
</I>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	other risks detailed from time-to-time
	in our on-going quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators
	and the United States Securities and Exchange Commission, and those which are discussed under the heading &ldquo;Risk Factors&rdquo;
	in this document.
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Should one or more
	of these risks or uncertainties materialize, or should the assumptions set out in the section entitled &ldquo;Risk Factors&rdquo;
	underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These
	forward-looking statements are made as of the date of this management&rsquo;s discussion and analysis or, in the case of documents
	incorporated by reference herein, as of the date of such documents, and we do not intend, and do not assume any obligation, to
	update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be
	accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned
	that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue
	reliance on forward-looking statements due to the inherent uncertainty therein.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	corporate
	update
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: WINDOWTEXT">
	The following
	items highlight our corporate activities during the year ended December 31, 2015 and any
<B>
<I>
</I>
</B>
</FONT>
	subsequent development
	up until the date hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	Orphan
	Drug Designation
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On June 2, 2015, we announced that the
	U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) had granted Aptose orphan drug designation for APTO-253 for the treatment
	of acute myeloid leukemia (&ldquo;AML&rdquo;). APTO-253, a first-in-class inducer of the Kr&uuml;ppel-like factor 4 (&ldquo;KLF4&rdquo;)
	gene, is the Company&rsquo;s lead product candidate in a Phase Ib clinical trial in patients with AML, high-risk myelodysplastic
	syndrome (&ldquo;MDS&rdquo;) and other hematologic malignancies in which KLF4 silencing is reported as operative.
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Orphan drug designation is granted by the
	FDA to encourage companies to develop therapies for the treatment of diseases that affect fewer than 200,000 individuals in the
	United States. Orphan drug status provides research and development tax credits, an opportunity to obtain grant funding, exemption
	from FDA application fees and other benefits. If APTO-253 is approved to treat AML, the orphan drug designation provides Aptose
	with seven years of marketing exclusivity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	At-The-Market-Facility
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In early April 2015, Aptose entered into
	an at-the-market (&ldquo;ATM&rdquo;) facility for up to US $20,000,000 of common shares. The ATM will, along with the effective
	shelf prospectus that was filed in December 2014, provide us with the added flexibility to quickly access the market and raise
	capital at market price. During the year ended December 31, 2015, we issued 1,504 common shares under the ATM at a price of US$5.20
	per share for gross proceeds of approximately Cdn $10 thousand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	LALS
	and Moffitt
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 10, 2015, we announced collaborations
	with Moffitt Cancer Center, a prominent research institute that provides us with exclusive rights to multi-targeting epigenetic
	inhibitors and with Laxai-Avanti Life Sciences, a medicinal chemistry institution that will focus on the discovery and optimization
	of novel epigenetic-based therapies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	program
	updates
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	APTO-253
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	APTO-253 is a novel small molecule that
	can induce expression of the genes that codes for the Kr&uuml;ppel-like factor 4 (KLF4) master transcription factor and the p21
	cell cycle inhibitor protein, and can inhibit expression of the c-Myc oncogene, leading to cell cycle arrest and programmed cell
	death (apoptosis) in human-derived solid tumor and hematologic cancer cells.&nbsp; Likewise, in nonclinical pharmacology studies
	APTO-253 demonstrates in vivo anti-tumor activity against xenograft models of solid tumors and hematologic cancers, with acute
	myeloid leukemia (AML) cells exhibiting a particular sensitivity to APTO-253. &nbsp;A Phase 1 study with APTO-253 in patients with
	advanced solid tumors was completed in mid-2013. That trial, which employed a suboptimal dosing schedule, demonstrated modest clinical
	activity in the all-comer solid tumor patient population.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The vast majority of patients with AML
	are reported to exhibit inappropriate activation of the CDX2 gene and resultant epigenetic down-regulation (silencing) of KLF4
	expression, as well as inappropriate upregulation of c-Myc as key leukemogenic events. Aptose scientists performed RT-qPCR expression
	analysis of KLF4 and CDX2 levels in normal PBMC and AML cell lines and confirmed the silencing of KLF4 expression and elevated
	expression of CDX2 in AML cells, and multiple publications have reported the elevation of c-Myc oncogene expression in AML cells.
	In addition to AML, similar roles for KLF4 silencing and c-Myc upregulation have been reported in subpopulations of adult T-cell
	leukemia, lymphoma, multiple myeloma and high-risk MDS. &nbsp;Induction of KLF4 expression and suppression of c-Myc by APTO-253
	may therefore be an effective therapeutic approach in these patient populations.&nbsp; Because of the robust scientific evidence
	linking KLF4 silencing and c-Myc upregulation to cellular transformation in hematologic malignancies, Aptose undertook an ongoing
	Phase 1b clinical study with escalating doses of APTO-253 followed by two planned disease-specific expansions in adults with hematologic
	malignancies. This Phase 1b trial is currently on clinical hold (see discussion below).
</P>
<P STYLE="COLOR: #943634; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="COLOR: #943634; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="COLOR: #943634; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Preclinical In Vitro Evaluation of APTO-253
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	APTO-253 demonstrated potent and selective
	in vitro antiproliferative activity against a variety of leukemia cell lines, including AML, ALL and chronic myeloid leukemia (CML),
	as well as non-Hodgkin&rsquo;s lymphoma (NHL) cell lines, with IC50 values ranging from ~0.007 &ndash; 0.3 &micro;M. These hematologic
	cell lines appeared to be far more sensitive to APTO-253 than the solid tumor cell lines, including colon cancer, non-small cell
	lung cancer (NSCLC), prostate cancer and melanoma, which exhibited IC50 values of ~0.04&ndash; 2.6 &micro;M, which had previously
	served to support the completed Phase 1 solid tumor study.&nbsp;&nbsp;However, new insights from academic publications into the
	significance of KLF4 suppression in patients with hematologic malignancies appear to be broadly corroborated by these data.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	APTO-253 Induces Expression of the KLF4 Gene
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Inappropriate expression of CDX2 in AML
	cells results in epigenetic silencing of the KLF4 gene and subsequent downstream silencing of the pro-apoptotic p21 gene. To characterize
	the effect of APTO-253 treatment of AML cells, the levels of CDX2, KLF4 and p21 gene expression were measured as a function of
	the concentration of APTO-253 and as a function treatment time. As shown in Figure 3, KLF4 and p21 gene expression increased in
	cells treated with APTO-253, while there was no change in the levels of CDX2 expression.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: RED; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/30/0001171843-16-008903_GRAPH.JPG">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: #943634">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: #943634">
	APTO-253 Induces Expression of
	KLF4 and p21
</FONT>
<FONT STYLE="COLOR: #C00000">
<B>
	.
</B>
<I>
</I>
</FONT>
<I>
	The MV4-11 AML cell line was treated with the indicated
	concentrations of APTO-253 or Vehicle for 24 hours (left panel) or with 500 nM APTO-253 or Vehicle for the indicated period of
	time (right panel) and the expression of KLF4, p21 and CDX2 mRNA levels were determined by qRT-PCR.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Because AML cells are known to exhibit
	extreme epigenetic plasticity and to have inappropriate expression of the c-Myc oncogene, we queried if APTO-253 might also inhibit
	the expression of c-Myc. Indeed, APTO-253 induced a dose-dependent inhibition of c-Myc mRNA expression in three different AML cell
	lines, and caused reductions in the c-Myc protein. In a time course assay, APTO-253 induces the simultaneous induction of the KLF4
	gene and the suppression of the c-Myc gene in AML cells. Moreover, in studies conducted to evaluate apoptotic events, AML cells
	treated with APTO-253 displayed changes in apoptotic markers, including high level induction of caspase-3 activity.&nbsp; APTO-253-treated
	AML cells demonstrated a high percentage of apoptotic (Annexin V-positive) cells that correlated with drug concentration. Together,
	these preclinical studies demonstrate that APTO-253 can affect critical oncogenic process (expression of KLF4, c-Myc and p21 genes)
	which should lead to programmed cell death in AML cells.
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	Phase
	Ib Trial
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	APTO-253 is being evaluated by Aptose in
	a Phase 1b relapsed / refractory hematologic malignancy study.&nbsp; For the study, a modified dose schedule was selected, such
	that APTO-253 is being administered on the first two days of each 7-day dosing period of a 28-day cycle (i.e., days 1, 2, 8, 9,
	15, 16, 22, 23).&nbsp; This results in lower per-administration dose levels to provide the same overall exposure per cycle achieved
	in the prior Phase 1 solid tumor study, and to more consistently achieve the minimum exposure levels at the end of each dosing
	period that may be important for efficacy.
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Approximately 15 patients will be enrolled
	in each of two arms of the dose escalation phase of the study: arm (A) will include patients with acute leukemias (including AML)
	and high-risk myelodysplastic syndromes, or MDS; arm (B) will include patients with lymphomas (Hodgkin&rsquo;s and non-Hodgkin&rsquo;s
	Lymphoma) and multiple myeloma, followed by enrollment of an additional 15 patients in each of two separate disease-specific expansion
	cohorts, for a total estimated enrollment of 60 patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For future development, upon selection
	of a lead hematologic indication from this Phase 1b study, combination of APTO-253 with a standard therapy will be considered.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: #943634">
<B>
<I>
	Indications for APTO-253
	Clinical Studies
</I>
</B>
</FONT>
<BR>
<FONT STYLE="COLOR: WINDOWTEXT">
	APTO-253 is being administered to patients who have any of the following hematologic malignancies
	that have failed standard therapies.
</FONT>
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<LI STYLE="MARGIN: 0PT 0; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Acute leukemias (including AML, but not including acute promyelocytic
	leukemia)
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	High-risk MDS
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Lymphoma (Hodgkin&rsquo;s and Non-Hodgkin&rsquo;s)
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Multiple myeloma
</LI>
</UL STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Upon completion of the dose-escalation
	stage of the study and determination of the recommended Phase 2 dose (RP2D), two hematologic cancer indications will be selected
	from those indications studied in the dose-escalation phase, for enrollment in two disease-specific single-agent expansion cohorts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Clinical Hold
	and Current Status
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	We announced in
	November 2015 that the&nbsp;Food and Drug Administration&nbsp;(FDA), following a voluntary suspension of dosing by us and discussions
	with us, placed our Phase Ib clinical trial of APTO-253 in patients with hematologic cancers on clinical hold. This hold was intended
	to ensure patient safety within the trial and to ensure manufacturing and dosing procedures are consistent with the appropriate
	documented quality standards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	The voluntary
	suspension of dosing by Aptose was initiated as a result of a preliminary review, which was accelerated to evaluate manufacturing
	processes and procedures upon the report of an operational difficulty with an IV infusion pump at a clinical site. The pump experienced
	back pressure during IV patient dosing at the point of the filter. Further review discovered preliminary concerns regarding the
	documentation records of the manufacturing procedures of the drug product associated with APTO-253. A complete safety review of
	all patient files had been completed prior to initial discovery of the manufacturing documentation irregularities, and there have
	been no drug-related serious adverse events (SAEs) reported. The observed pharmacokinetic levels in the patients treated were within
	the expected range. Thus, the clinical hold is based on a manufacturing issue and is not related to safety, efficacy or pharmacokinetics.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="COLOR: WINDOWTEXT">
	Currently,
	Aptose is guiding a qualified CMO to introduce new procedures to formulate APTO-253 into a drug product that is safe and
	stable, and which should not result in filter clogging events in the future.
</FONT>
	The CMO now has manufactured new GMP
	batches of the Active Pharmaceutical Ingredient (&ldquo;API&rdquo;) to provide material for formulation studies and to supply
	the clinical trials into the future. Aptose also qualified a separate CMO with expertise in liquid formulations to
	perform formulation development studies and to manufacture the final form of the drug product for return to the clinic. The
	CMO has performed numerous formulation studies using a variety of methodologies and is now evaluating their solubility and
	stability over time to select the best methodology to manufacture the new batch of drug product to take to the FDA.
<FONT STYLE="COLOR: WINDOWTEXT">
	In order to have the clinical hold lifted and to return APTO-253 to the clinical trial, Aptose must articulate the root
	cause of the filter clogging incident to the FDA and demonstrate to the FDA that a newly manufactured batch of GMP-grade
	APTO-253 drug substance has been formulated and is unlikely to cause such incidents in the future. The ultimate decisions
	regarding the lift of the clinical hold, the appropriateness of the new drug product, and the starting dose for the trial
	will reside with the FDA.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: #943634">
<B>
<I>
	Biomarker Strategy for APTO-253
	in a Clinical Setting
</I>
</B>
</FONT>
<BR>
<FONT STYLE="COLOR: WINDOWTEXT">
	Previous basic research studies have utilized RT-qPCR analyses of CDX2, KLF4 and p21 transcripts
	in AML cell lines and the primary blood cells of AML patients (Scholl et al., 2007; Faber et al., 2013).&nbsp; Aptose has now optimized
	the RT-qPCR reagents and procedures for measurement of the CDX2, KLF4 and p21 mRNA expression levels in human AML cells. Consequently,
	analytically validated RT-qPCR assays for the relative quantification of CDX2, KLF4 and p21 transcripts may be used to select patients
	expected to be most sensitive for response to APTO-253 therapy. &nbsp;In addition, these assays may be used to monitor on-treatment
	responses.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Biopsies are collected from lymphoma patients
	that are enrolled in the clinical trial.&nbsp; Blood and bone marrow are collected from AML patients and bone marrow aspirates
	are collected from MDS patients.&nbsp; FFPE core needle biopsy tissue and CD34+ cell pellets derived from blood and bone marrow
	will be used for gene expression profiling.&nbsp; A RT-qPCR method is being developed, optimized and validated for the analysis
	of CDX2, KLF4 and p21 target transcripts and appropriate reference gene transcripts in the samples collected from patients enrolled
	in the clinical trial.
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	BEAT
	AML Preclinical Studies of APTO-253 Against Patient Isolates
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On September 29, 2014, we announced, along
	with the Knight Cancer Institute at Oregon Health &amp; Science University (OHSU) and The Leukemia &amp; Lymphoma Society (LLS)
	that we entered into a formal collaboration with the Beat AML initiative. Beat AML is a groundbreaking research initiative that
	includes industry and academic collaborators led by top scientists within the Knight Cancer Institute in collaboration with The
	Leukemia &amp; Lymphoma Society. Its goal is to accelerate development of potential therapies for AML.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During the 2015 American Society of Hematology
	(ASH) Conference, Aptose&rsquo;s collaborators at OHSU&rsquo;s Knight Cancer Institute presented preclinical data on APTO-253
	that are derived from our participation in the Beat AML Initiative with Dr. Brian Druker
<B>
	.
</B>
	The poster presentation was
	entitled &ldquo;
<FONT STYLE="COLOR: #9B1931; BACKGROUND-COLOR: WHITE">
<I>
<U>
	Broad Activity of APTO-253 in AML and Other Hematologic
	Malignancies Correlates with KLF4 Expression Level
</U>
</I>
</FONT>
	&rdquo;. The Beat AML initiative, a groundbreaking initiative
	that was formed in collaboration with The Leukemia &amp; Lymphoma Society and the Knight Cancer Institute, has allowed Aptose
	to evaluate the effect of APTO-253, alone or in combination with other anti-cancer agents, in fresh bone marrow isolates from
	patients with AML, myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the 2015 OHSU ASH presentation, researchers
	used a range of doses, from low nanomolar to ten micromolar, and found that APTO-253 killed AML cells at an IC50 of less than 1uM
	in a significant number of AML patient samples, with a trend toward correlation with baseline KLF4 expression level. Moreover,
	APTO-253 demonstrated enhanced killing of AML patient samples when combined with two other therapeutic strategies, the BET bromodomain
	inhibitor JQ1 and the FLT3 inhibitor quizartinib. Such data support the development of APTO-253 for the treatment of AML, support
	the role of KLF4 in the mechanism of action of APTO-253, and support the ultimate use of APTO-253 in combination with other high
	profile drugs under development for the treatment of AML. OHSU continues to evaluate APTO-253 in additional samples across AML
	and other hematologic malignancies, along with other novel therapeutic combinations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	Multi-Targeting
	Bromodomain Program
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In November, 2015, Aptose entered into
	a definitive agreement with Moffitt Cancer Center for exclusive global rights to potent, multi-targeting, single-agent inhibitors
	for the treatment of hematologic and solid tumor cancers. These small molecule agents are highly differentiated inhibitors of the
	Bromodomain and Extra-Terminal motif (BET) protein family members, which simultaneously target specific kinase enzymes. The molecules
	developed by Moffitt exhibit single-digit nanomolar potency against the BET family members and specific oncogenic kinases which,
	when inhibited, are synergistic with BET inhibition. Under the agreement, Aptose will gain access to the drug candidates developed
	by Moffitt and the underlying intellectual property covering the chemical modifications enabling potent bromodomain (BRD) inhibition
	on the chemical backbone of a kinase inhibitor. Aptose expects lead clinical candidates to emerge from the collaboration by late
	2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In December, 2015, collaborators from
	Moffitt Cancer Center presented preclinical data for one of the candidates in the collaboration, MA2-014, at the 57th Annual American
	Society of Hematology (ASH) Meeting. The MA2-014 program was developed to inhibit both the bromodomain 4 (BRD4) protein and
	the Janus kinase 2 (JAK2) for the potential treatment of various hematologic and solid tumor cancers. Moffitt researchers presented
	data for MA2-014 that exhibited similar anti-JAK2 activity as a known JAK2 inhibitor, TG101209, with an approximate ten-fold improvement
	in anti-BRD activity. Moffitt researchers also demonstrated a ten-fold improvement in the ability of MA2-014 to inhibit JAK2-V617F
	signaling over TG101209, and comparable to ruxolitinib. Ruxolitinib is the only FDA approved JAK inhibitor for MPNs. However,
	MA2-014 retained its potency against ruxolitinib-resistant cells. Moffitt researchers also determined in long-term culture assays
	that JAK2-V617F driven MPN Uke1 cells do not experience resistance to MA2-014 as readily as they do to TG101209 or ruxolitinib.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	Multi-Targeting
	Epigenetic Program
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In November 2015, Aptose also announced
	an exclusive drug discovery partnership with Laxai Avanti Life Sciences (LALS) for their expertise in next generation epigenetic-based
	therapies. Under the agreement, LALS will be responsible for developing multiple clinical candidates, including optimizing candidates
	derived from Aptose's relationship with the Moffitt Cancer Center. Aptose will own global rights to all newly discovered candidates
	characterized and optimized under the collaboration, including all generated intellectual property.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	financing
	activities
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	equity
	financings
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	At-The-Market (&ldquo;ATM&rdquo;)
	Facility
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On April 2, 2015, we entered into an ATM
	equity facility with Cowen and Company, LLC, acting as sole agent. Under the terms of this facility, we may, from time to time,
	sell shares of our common stock having an aggregate offering value of up to US$20 million through Cowen and Company, LLC on the
	Nasdaq Capital Market. We determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.
	During the twelve months ended December 31, 2015 the Company issued 1,504 common shares under the ATM at a price of US$5.20 per
	share for gross proceeds of approximately Cdn $10 thousand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	April 2014
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In April 2014, we completed a public offering
	of common shares. Aptose issued 4,708,334 (56,500,000 pre-consolidation) common shares at a purchase price of $6.00 ($0.50 pre-consolidation)
	per common share, including 541,667 (6,500,000 pre-consolidation) common shares pursuant to the partial exercise of an over-allotment
	option, for aggregate gross proceeds of $28.3 million. The total costs associated with the transaction were approximately $2.7
	million which includes a cash commission of $2.0 million based on 7% of the gross proceeds received as part of the offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	December 2013
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In December 2013, Aptose completed a public
	offering of common shares. Aptose issued 1,060,833 (pre-consolidation 12,730,000) common shares at a price of $6.60 (pre-consolidation
	$0.55) per common share and an additional 159,125 (pre-consolidation 1,909,500) common shares upon the exercise of the overallotment
	option for aggregate gross proceeds of $8.1 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The total costs associated with the transaction
	were approximately $1.1 million which include a cash commission of $483 thousand based on 6% of the gross proceeds received as
	part of the offering, and the issuance of 73,198 (pre-consolidation 878,370) broker warrants with an estimated fair value of $350
	thousand. The fair value of these warrants was determined using the Black Scholes model with a 24 month time to maturity, an assumed
	volatility of 130% and a risk free interest rate of 1.5%. Each broker warrant was exercisable into one common share of the Company
	at a price of $6.60 (pre-consolidation $0.55) for a period of twenty four months following closing of the offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	warrant
	exercises
</B>
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_54"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Warrants exercised during the twelve months ended December 31, 2015:
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9PT; TEXT-INDENT: -9PT">
	Number
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Proceeds
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: 0IN">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	86
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	June 2013 private placement warrants (ii)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	141
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 2013 broker warrants (iii)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	121
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	81
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	348
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 71.8PT 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to the cash proceeds received,
	the original fair value related to these warrants of $155 thousand was transferred from warrants to share capital. This resulted
	in a total amount of $503 thousand credited to share capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_55"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Warrants exercised during the seven months ended December 31, 2014:
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Number
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Proceeds
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: 0IN">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	48
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	June 2012 private placement warrants (iv)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,223
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,231
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6,648
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to the cash proceeds received,
	as a result of the exercise of the warrants, the original fair value related to these warrants of $1.2 million was transferred
	from the warrants to the share capital of the Company. This resulted in a total amount of $7.8 million credited to share capital
	following the exercise of the warrants.
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Warrants exercised during the year ended May 31, 2014:
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
<A NAME="FIS_UNIDENTIFIED_TABLE_56"></A>
	(in thousands)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Number
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Proceeds
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: 0IN">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	327
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,764
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	June 2012 private placement warrants (iv)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	409
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,210
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	June 2012 finder warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	103
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	June 2013 private placement warrants (iii)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	88
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	868
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	4,458
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to the cash proceeds received,
	as a result of the exercise of the warrants, the original fair value related to these warrants of $964 thousand was transferred
	from the warrants to the share capital of the Company. This resulted in a total amount of $5.4 million credited to share capital
	following the exercise of the warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Summary of outstanding warrants:
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
<A NAME="FIS_UNIDENTIFIED_TABLE_57"></A>
	(in thousands)
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31, 2015
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31, 2014
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: 0IN">
	August 2011 warrants (i)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	73
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	89
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	June 2013 private placement warrants (ii)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 2013 broker warrants (iii)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	73
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of warrants outstanding, end of year
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	73
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	209
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40.3PT">
</TD>
<TD STYLE="WIDTH: 22.3PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(i)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 1IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	August 2011 warrants are exercisable into
	common shares of Aptose at a price per share of $5.40 and expire in August 2016.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40.3PT">
</TD>
<TD STYLE="WIDTH: 22.3PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(ii)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 1IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	June 2013 private placement warrants were
	exercisable into common shares of Aptose at a price per share of $3.00 and expired in June 2015.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40.3PT">
</TD>
<TD STYLE="WIDTH: 22.3PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(iii)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 1IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	December 2013 broker warrants were exercisable
	into common shares of Aptose at a price per share of $6.60 and expired in December 2015.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40.3PT">
</TD>
<TD STYLE="WIDTH: 22.3PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(iv)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 1IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	June 2012 private placement warrants were
	exercisable into common shares of Aptose at a price per share of $5.40 ($0.45 pre-consolidation) and expired on June 8, 2014
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	promissory
	notes and warrants
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In June 2013, we completed a private placement
	of units (&ldquo;Units&rdquo; in this section) at a price of $1 thousand per unit, for aggregate gross proceeds of $918 thousand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Each Unit consisted of (i)&nbsp;a $1 thousand
	principal amount of unsecured promissory note and (ii)&nbsp;83 (pre-consolidation 1,000) common share purchase warrants. The promissory
	notes bore interest at a rate of 10% per annum, payable monthly and were due June 19, 2014. Each warrant entitled the holder thereof
	to acquire one common share of Aptose a price per common share equal to $3.00 (pre-consolidation $0.25) at any time until June
	19, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Units contained a liability component
	and an equity component represented by the warrants to purchase common shares. The fair value of the liability component of $843
	thousand was estimated by discounting the future cash flows associated with the debt at a discounted rate of approximately 19%
	which represents the estimated borrowing cost to Aptose for similar promissory notes with no warrants. The residual value of $75
	thousand was allocated to the warrants. We incurred costs associated with the financing of $23 thousand. These costs were amortized
	using the effective interest rate method over the 12 month life of the notes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These notes and any interest accrued thereon
	were repaid in full in April 2014.
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Convertible
	promissory notes
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In September 2013, we completed a private
	placement of convertible promissory notes for aggregate gross proceeds of $600 thousand. Each convertible promissory note consisted
	of a $1 thousand principal amount of unsecured promissory note convertible into common shares of Aptose at a price per share of
	$3.60. The promissory notes bore interest at a rate of 10% per annum, payable quarterly and were due September 26, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The promissory notes were a compound financial
	instrument containing a liability component and an equity component represented by the conversion feature. The fair value of the
	liability component upon issuance was estimated by discounting the future cash flows associated with the debt at a discounted rate
	of approximately 19% which represented the estimated borrowing cost to us for similar promissory notes with no conversion feature.
	The residual value of $88 thousand was allocated to the conversion feature.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Subsequent to initial recognition, the
	promissory notes were accounted for at amortized cost using the effective interest rate method. We incurred costs associated with
	the financing of $17 thousand. These costs along with the adjustment for the conversion feature were being accreted using the effective
	interest rate method over the 24 month life of the notes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During the year ended December 31, 2015,
	all of the outstanding promissory notes were converted into common shares of Aptose.
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Loans
	payable
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In September 2013, we entered into loan
	agreements for proceeds of $150 thousand. The loans were unsecured, bore interest at a rate of 10% per annum payable quarterly
	and were due September 30, 2015. We repaid the loans and all accrued and unpaid interest thereon on April 25, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	LIQUIDITY
	AND CAPITAL RESOURCES
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Since its inception, Aptose has financed
	its operations and technology acquisitions primarily from equity and debt financing, proceeds from the exercise of warrants and
	stock options, and interest income on funds held for future investment. We plan to continue our development programs from internal
	resources as they are available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We currently do not earn any revenues from
	our drug candidates and are therefore considered to be in the development stage. The continuation of our research and development
	activities and the commercialization of the targeted therapeutic products are dependent upon our ability to successfully finance
	and complete our research and development programs through a combination of equity financing and payments from strategic partners.
	We have no current sources of significant payments from strategic partners.
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Cash
	Position
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: WINDOWTEXT">
	At December
	31, 2015, we had cash and cash equivalents and investments of $19.7 million compared to $30.5 million at December 31, 2014. We
	generally invest our cash in excess of current operations requirements in highly rated and liquid instruments. Investment decisions
	are made in accordance with an established investment policy administered by senior management and overseen by the Board. As at
	December 31, 2015, our cash was invested in
</FONT>
	cash of $761 thousand (December 31, 2014 - $293 thousand) and funds deposited
	into high interest savings accounts totaling $10.742 million (December 31, 2014 - $14.072 million).
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="COLOR: WINDOWTEXT">
	Working capital (representing primarily cash, cash equivalents and investments other current
	assets less current liabilities
</FONT>
	)
<FONT STYLE="COLOR: WINDOWTEXT">
	at December 31, 2015
</FONT>
<FONT STYLE="COLOR: WINDOWTEXT">
	was
	$18.5 million (December 31, 2014 - $29.1 million).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We do not expect to generate positive cash
	flow from operations for the foreseeable future due to additional research and development costs, including costs related to drug
	discovery, preclinical testing, clinical trials, manufacturing costs and operating expenses associated with supporting these activities.
	It is expected that negative cash flow from operations will continue until such time, if ever, that we receive regulatory approval
	to commercialize any of our products under development and/or royalty or milestone revenue from any such products exceeds expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	RESULTS
	OF OPERATIONS
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our net loss and comprehensive loss for
	the year ended December 31, 2015 was $14.6 million ($1.23 per share) compared with a loss of $7.8 million ($0.67 per share) in
	the seven months ended December 31, 2014 and with a loss of $10.6 million ($2.02 per share post-consolidation) in the year ended
	May 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The increase in net loss and comprehensive
	loss in the year ended December 31, 2015 compared with the seven months ended December 31, 2014 is due to a twelve month period
	compared with a seven month period as well as increased research and development costs associated with the APTO-253 Phase Ib clinical
	trial described above for which the first patient was enrolled in January 2015. The increased research and development costs were
	offset by a higher finance income related to foreign currency gains on our USD cash and cash equivalents balances due to the devaluation
	of the Canadian dollar.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The increase in annualized net loss and
	comprehensive loss in the seven months ended December 31, 2014 compared with the twelve months ended May 31, 2014 is due to increased
	research and development costs associated with the initiation of the APTO-253 Phase Ib clinical trial described above as well as
	increased general and administrative costs associated with corporate activities during the seven month period including our name
	change and rebranding initiates, the NASDAQ listing and associated costs as well as increased patent costs and anticipated relocation
	costs associated with our former facilities in Toronto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We utilized cash of $12.7 million in our
	operating activities in the year ended December 31, 2015 compared with $6.7 million in the seven months ended December 31, 2014
	and $8.5 million in the year ended May 31, 2014. The increase in cash utilized in the current year is due to increased research
	and development activities offset by an increased in finance income.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2015, we had cash and cash
	equivalents and investments of $19.7 million compared to $30.5 million at December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	SELECTED
	ANNUAL FINANCIAL DATA
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following selected consolidated financial
	data have been derived from, and should be read in conjunction with, the accompanying audited consolidated financial statements
	for the year ended December 31, 2015 (the&nbsp;&ldquo;Financial Statements&rdquo;) which are prepared in accordance with International
	Financial Reporting Standards (&ldquo;IFRS&rdquo;) as issued by the International Accounting Standards Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_58"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="COLOR: #943634; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<P STYLE="COLOR: #943634; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Consolidated
	Statements of Loss and Comprehensive Loss
</I>
</B>
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Year ended
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	December 31,
</B>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	7 months ended
<BR>
	December 31,
</B>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Year ended
<BR>
	May 31,
</B>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(amounts in Canadian thousands except for per common share data)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	REVENUE
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	EXPENSES
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,254
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,404
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,015
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	General and administrative
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,845
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,542
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,317
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Operating expenses
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	16,099
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,946
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,332
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Finance expense
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	43
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	104
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	297
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Finance income
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,516
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(279
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Net finance expense (income)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,473
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(175
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	221
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Net loss and total comprehensive loss for the period
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	14,626
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	7,771
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	10,553
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Basic and diluted loss per common share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1.23
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	0.67
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	2.02
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Weighted average number of common shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;outstanding used in the calculation of:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted loss per share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	11,906
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,605
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,216
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total Assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,249
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	31,600
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	30,899
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Total Long-term liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	528
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_59"></A>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Research and Development
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Research and development expenses totaled
	$6.3 million in the year ended December 31, 2015 compared with $2.4 million in the seven months ended December 31, 2014 and $3.0
	million in the twelve months ended May 31, 2014. Research and development expenses consist of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	Year ended
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<B>
</B>
	7 months ended
</P>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Research and development costs
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,015
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,371
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,287
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Severance cost for former officer
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	326
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Deferred share unit (&ldquo;DSU&rdquo;) costs
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Stock-based compensation
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	210
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	296
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Depreciation of equipment
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	29
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	6,254
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2,404
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	3,015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Expenditures for the year ended December
	31, 2015 increased significantly over the seven months ended December 31, 2014 (on an annualized basis) due to the following:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Costs associated with the Phase 1b clinical
	trial of APTO-253
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	in patients with relapsed or refractory hematologic malignancies
</FONT>
	including clinical site costs, patient costs, contract research organization and consulting charges. The first patient in the trial
	was enrolled in January 2015;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Development costs related to the Moffit/LALS
	programs which were initiated in the fourth quarter of 2015;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Formulation, manufacturing and compliance
	costs related to the development of APTO-253 including costs related to the clinical hold described above;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additional payroll related costs in the
	clinical department due to restructuring to support ongoing activities; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The increased cost of US dollar denominated
	expenditures due to the devaluation of the CDN dollar in 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Expenditures for the seven month period
	ended December 31, 2014 increased on an annualized basis in comparison to the twelve months ended May 31, 2014. The increase in
	expenditures in the seven months ended December 31, 2014 related primarily to our
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Phase Ib
	clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies, which was initiated in late 2014,
	whereas no clinical development activity was ongoing in the twelve months ended May 31, 2014. In addition to the clinical costs
	associated with APTO-253, activity related to supporting the advancement of APTO-253 as a drug candidate through research and development
	activities increased significantly in the seven months ended December 31, 2014 compared with the prior year. These costs include
	research collaborations, animal studies and drug formulation work.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the twelve months ended May 31, 2014
	we incurred one time severance costs associated with a former officer of the Company which were paid in full in April 2014. The
	total severance amount of $1.1 million was allocated between general and administrative ($762 thousand) and research and development
	($326 thousand). There are no ongoing obligations related to the severance payment. The allocation was based upon the time spent
	by the former officer on research and development versus general and administrative activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There were no DSUs outstanding in the year
	ended December 31, 2015 or the seven months ended December 31, 2014. In the twelve months ended May 31, 2014 DSU costs increased
	due to an increase in the share price of Aptose and the associated fair value of the units. In April 2014, 65,000 (780,000 pre-consolidation)
	common shares of Aptose were issued in payment of the outstanding DSU liability with a fair value of $444 thousand. There were
	no outstanding DSUs as of May 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Stock-based compensation expense increased
	in the year ended December 31, 2015 compared with the seven months ended December 31, 2014 primarily due to option grants to new
	employees and advisors during the year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Stock-based compensation expense was lower
	in the seven months ended December 31, 2014 compared with the twelve months ended May 31, 2014 due primarily to the timing of option
	grants as well as options granted in the twelve months ended May 31, 2014 which vested immediately resulting in increased expenses
	for that year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_60"></A>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	General and Administrative
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	General and administrative expenses totaled
	$9.8 million for the year ended December 31, 2015 compared with $5.5 million in the seven months ended December 31, 2014 and $7.3
	million in the twelve months ended May 31, 2014. General and administrative expenses consisted of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27.35PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27.35PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	(in thousands)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	12 months ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	7 months ended
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
	12 months ended
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May, 31
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	General and administrative excluding salaries
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,327
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,421
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,620
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	Salaries
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,849
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,505
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,217
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Severance cost of former officer
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	762
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	DSU costs
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	183
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Stock-based compensation
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,602
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,598
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,530
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Depreciation and amortisation
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	67
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	9,845
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	7,317
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On an annualized basis, general and administrative
	costs excluding salaries have increased slightly in the year ended December 31, 2015 compared with the seven months ended December
	31, 2014. The increase is attributable to increased costs associated with our NASDAQ listing (initiated late 2014) including listing
	fees and insurance charges, internal control documentation work completed during the year as well as the devaluation of the Canadian
	dollar which has increased the cost of our US dollar denominated expenditures including, board fees, legal and other corporate
	costs. These increases have been offset by the charges related to the termination of the Toronto lease in December 2014 as well
	as costs incurred in 2014 related to our rebranding for which no comparable costs were incurred in the current year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Salary costs on an annualized basis have
	increased slightly in the year ended December 31, 2015 compared with the seven months ended December 31, 2014. While the majority
	of our salary costs are incurred in US dollars and therefore have increased during the year, this increase has been offset by a
	reduction in bonus payments made to executives in the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Stock-based compensation on an annualized
	basis in the year ended December 31, 2015 is consistent compared with the seven months ended December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	General and administrative expenses excluding
	salaries increased on an annualized basis in the seven months ended December 31, 2014 compared with the twelve months ended May
	31, 2014. The increased costs were the result of the following corporate activities:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20.5PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our name change (described above) and
	related rebranding initiatives;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20.5PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our listing on NASDAQ and the subsequent
	increase in Directors and Officers insurance costs;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20.5PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The change in year end from May 31, to
	December 31;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20.5PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Increased patent filing and maintenance
	costs;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20.5PT">
</TD>
<TD STYLE="WIDTH: 15.5PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Costs associated with additional corporate
	offices and the estimated increased cost of restoring the current Toronto office location; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20.5PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Increased travel costs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Salary costs increased on an annualized
	basis in the seven months ended December 31, 2014 compared with the twelve months ended May 31, 2014 as the new executives hired
	in October and November 2013 were employed for the entire operating period in the seven month period rather than a partial year
	in the prior period. These increased costs were offset by the termination of a former officer of the Company in the twelve months
	ended May 31, 2014 and therefore no further costs in the current seven month period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Stock-based compensation expense on an
	annualized basis was significantly higher in the seven months ended December 31, 2014 compared with the year ended May 31, 2014
	due to option grants in June and July 2014 which vested 50% in the first year with no comparative grants in the year ended May
	31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The severance costs related to the former
	officer of the Company were paid in full in April 2014 and the details are described under &lsquo;Research and Development&rsquo;
	above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	DSU costs are described under &ldquo;Research
	and Development&rdquo; above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_61"></A>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Finance Expense
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Finance expense totaled $43 thousand for
	the year ended December 31, 2015 compared with $104 thousand in the seven months ended December 31, 2014 and $297 thousand in the
	year ended May 31, 2014. The components of finance expense are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 62.65PT 0PT 27.35PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 62.65PT 0PT 27.35PT; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	7 months ended
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Interest expense
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	129
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Accretion expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	130
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Foreign exchange loss on cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	46
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 1PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	43
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	104
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	297
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Interest and accretion expense incurred
	in the year ended December 31, 2015 and the seven months ended December 31, 2014 relates to the 10% convertible promissory notes
	described above. Interest and accretion expense incurred in the year ended May 31, 2014 relates to the 10% promissory notes issued
	in June 2013 and repaid in April 2014 as well as the 10% convertible promissory notes and non-convertible promissory notes issued
	in September 2013 described above. There were no interest-bearing liabilities outstanding at December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_62"></A>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Finance Income
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Finance income totaled $1.5 million in
	the year ended December 31, 2015 compared with $279 thousand in the seven months ended December 31, 2014 and $76 thousand in the
	year ended May 31, 2014. The components of finance income are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 58.3PT 0PT 27.35PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 58.3PT 0PT 27.35PT; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9PT; TEXT-INDENT: -9PT">
	Year ended
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	7 months ended
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Year ended
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	December 31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Interest income
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	286
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	279
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	76
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Foreign exchange gain on cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,230
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,516
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	279
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	76
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Interest income represents interest earned
	on our cash and cash equivalent and investment balances. The increase in interest income during the seven months ended December
	31, 2014 compared with the prior year is the result of a higher average cash and cash equivalents balance throughout the period
	following the April 2014 public offering described above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The foreign exchange gain realized in the
	year ended December 31, 2015 is due to the depreciation of the Canadian dollar and the subsequent increase in value of our US dollar
	currency balances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Net loss and total comprehensive
	loss for the year
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our net loss and total comprehensive loss
	for the year ended December 31, 2015 was $14.6 million ($1.23 per share) compared with $7.8 million ($0.67 per share) in the seven
	months ended December 31, 2014 and with $10.6 million ($2.02 per share) in year ended May 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The increase in net loss and comprehensive
	loss in the year ended December 31, 2015 compared with the seven months ended December 31, 2014 is due to a twelve month period
	compared with a seven month period as well as increased research and development costs associated with the APTO-253 Phase Ib clinical
	trial described above for which the first patient was enrolled in January 2015. The increased research and development costs were
	offset by a higher finance income related to foreign currency gains on our USD cash and cash equivalents balances due to the devaluation
	of the Canadian dollar.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The increase in annualized net loss and
	comprehensive loss in the seven months ended December 31, 2014 compared with the twelve months ended May 31, 2014 is due to increased
	research and development costs associated with the initiation of the APTO-253 Phase Ib clinical trial described above as well as
	increased general and administrative costs associated with corporate activities during the seven month period including our name
	change and rebranding initiates, the NASDAQ listing and associated costs as well as increased patent costs and anticipated relocation
	costs associated with our former facilities in Toronto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_63"></A>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	QUARTERLY
	FINANCIAL INFORMATION (UNAUDITED)
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The selected financial information provided
	below is derived from the Company&rsquo;s unaudited quarterly financial statements for each of the last eight quarters prepared
	in accordance with IFRS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Q4
</B>
</P>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Q3
</B>
</P>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Q2
</B>
</P>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Q1
</B>
</P>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Four
<BR>
	months
<BR>
	ended
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Q4
</B>
</P>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Q3
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(Amounts in 000&rsquo;s except for per
<BR>
	common share data)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Dec 31,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	2015
</B>
</P>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Sept 30,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	2015
</B>
</P>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	June 30,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	2015
</B>
</P>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Mar 31,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	2015
</B>
</P>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Dec 31,
<BR>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Sept 30,
<BR>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	May 31,
<BR>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Feb 28,
<BR>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#8213;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#8213;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#8213;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#8213;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#8213;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#8213;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#8213;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&#8213;
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 28%; TEXT-ALIGN: LEFT">
	Research and development expense
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	2,340
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	1,722
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	1,308
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	884
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	1,093
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	1,311
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	1,012
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	597
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	General and administrative expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,364
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,248
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,504
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,729
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,554
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,988
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,192
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,751
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,431
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,261
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,365
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,584
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,187
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,221
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,433
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	Basic and diluted&nbsp;&nbsp;net loss per share
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.49
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cash (used in) operating activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,619
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,567
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,296
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,182
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,745
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,926
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,926
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,171
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Research and development expenditures were
	lower in the quarter ended February 28, 2014 as the Company focused its efforts on a strategic review and securing adequate financing
	for future development. In the quarter ended May 31, 2014, expenditures increased due to the allocation of severance costs related
	to a former Officer of the Company to research and development of $326 thousand. In the four months ended September 30, 2014 and
	in following quarters, research and development activities have increased as we prepared and subsequently launched the APTO-253
	Phase Ib clinical trial. In the third and fourth quarters of 2015 research and development expenditures increased further due to
	costs associated with the clinical trial as well as the quality, manufacturing and formulation work including the Clinical Hold
	described above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The increase in general and administrative
	expense in the three months ended May 31, 2014 is due to severance costs associated with a former officer of the Company of $762
	thousand, bonus costs, and increased Board, consulting and legal fees associated with activities during the quarter. In the four
	months ended September 30, 2014, the general and administrative expense is higher due to a four-month versus three-month period
	in relation to the change in the financial year of the Company discussed above as well as option grants during the quarter which
	increased option-related expenses. During the three months ended December 31, 2014, we incurred additional expenses related to
	our listing on NASDAQ and recognized an increase in expected costs to terminate our current Toronto lease which led to higher general
	and administrative expenses in the quarter. General and administrative costs in the three months ended March 31, 2015 again were
	higher due to the relocation of the Toronto office and related clean-up costs as well as costs related to our NASDAQ listing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Cash used in operating activities fluctuates
	significantly due primarily to timing of payments and increases and decreases in the accounts payables and accrued liabilities
	balances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Three
	months ended december 31, 2015 and 2014 (unaudited)
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_64"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	(Amounts in 000&rsquo;s except for per common share data)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Dec 31,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	2015
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Dec 31,
<BR>
	2014
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Research and development expense
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,340
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,093
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	General and administrative expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,364
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,554
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Operating expenses
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,704
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,647
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Finance expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	55
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Finance income
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(273
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(118
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Net financing income
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(273
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(63
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Net loss
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,431
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(3,584
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Basic and diluted&nbsp;&nbsp;net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.38
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.31
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our net loss and comprehensive loss for
	the three months ended December 31, 2015 increased to $4.4 million compared with $3.6 million in the three months ended December
	31, 2014. The increase in net loss is primarily the result of increased research and development activities of $1.2 million offset
	by reduced general and administrative costs of $190 thousand in the three months ended December 31, 2015 compared with the three
	months ended December 31, 2014 as well as an increase in net financing income of $210 thousand in the three months ended December
	31, 2015 which reduced the net loss in comparison to the prior year period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The increased research and development
	expense in the three months ended December 31, 2015 compared with the three months ended December 31, 2014 results from the APTO-253
	Phase Ib clinical trial for which the first patient was enrolled in January 2015 and related personnel and consulting costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	General and administrative expenses decreased
	to $2.4 million in the three months ended December 31, 2015 compared with $2.6 million in the three months ended December 31, 2014.
	The decrease despite the increased cost of our US dollar expenditures due to the devaluation of the Canadian dollar is related
	to a reduction in bonus expense for Executives as well as costs related to the termination of our Toronto lease recognized in the
	final quarter of 2014, for which no comparable costs exist in the current year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	use
	of proceeds
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table provides an update
	on the anticipated use of proceeds raised in the December 2013 and April 2014 equity offerings along with amounts actually expended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015 the following expenditures
	have been incurred:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_65"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Previously
</B>
</FONT>
<B>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	disclosed
</FONT>
</B>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Additional
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Costs
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Spent to
<BR>
	Date
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Remaining
	to
</B>
</FONT>
<B>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	be spent
</FONT>
</B>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: JUSTIFY">
	Phase Ib clinical trial
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<B>
	3,350
</B>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	**
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	2,052
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<B>
	**
</B>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Depending on the Phase Ib clinical trial of APTO-253 results, fund single agent expansion and drug combination focused Phase 2 Trials in both AML and MDS patients
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<B>
	7,800
</B>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: -0.1IN">
	nil
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<B>
	7,800
</B>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	APTO-253 manufacturing program
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<B>
	2,250
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	**
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,608
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	**
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Research and development programs
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<B>
	2,000
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<B>
	-
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	General and corporate purposes
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<B>
	15,869
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	14,593
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<B>
	1,276
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<B>
	31,269
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	**
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	20,253
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	**
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
<SUP>
	&nbsp;
</SUP>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	We have utilized all of the funds allocated from the December 2013 and April 2014 equity offerings
	to Research and Development programs and continue to fund expenses through proceeds related to warrant and stock option exercises
	for which no allocations were stipulated.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	**
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In November 2015, the ongoing Phase 1b clinical trial was placed on clinical
	hold (as described above). We are diligently working on reinitiating the clinical trial, however the
	ultimate decisions, and the related costs, regarding the lift of the clinical hold, the appropriateness of the new drug product,
	and the starting dose for the trial will depend on the outcome of our discussions with the FDA and may vary significantly. As such,
	we are not currently in a position to reasonably estimate the total costs to be incurred to complete the Phase 1b clinical trial
	and associated manufacturing program and do not anticipate to be in such a position until we receive additional feedback from the
	FDA.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage127"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We do not anticipate initiating the Phase
	2 trials until the results of the Phase Ib are available and only then if the results warrant further clinical investigation. It
	is currently anticipated that the remaining balance of the general and corporate costs will be allocated in accordance with the
	previously disclosed use of proceeds and additional costs will be funded through proceeds related to warrant and stock option exercises.
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	CRITICAL
	ACCOUNTING POLICIES
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="COLOR: #943634; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -1.3IN">
	Critical
	Accounting Policies and Estimates
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We periodically review our financial reporting
	and disclosure practices and accounting policies to ensure that they provide accurate and transparent information relative to the
	current economic and business environment. As part of this process, Aptose has reviewed its selection, application and communication
	of critical accounting policies and financial disclosures. Management has discussed the development and selection of the critical
	accounting policies with the Audit Committee of the Board of Directors and the Audit Committee has reviewed the disclosure relating
	to critical accounting policies in this MD&amp;A. Other important accounting policies are described in note 3 of the audited financial
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	(a) Valuation of stock-based compensation
	and share purchase warrants:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Management measures the costs for stock-based
	payments and share purchase warrants using market-based option valuation techniques. Assumptions are made and judgment is used
	in applying valuation techniques. These assumptions and judgments include estimating the future volatility of the share price,
	expected dividend yield, future employee turnover rates and future share option and share purchase warrant behaviors and corporate
	performance. Such judgments and assumptions are inherently uncertain. The increase or decrease of one of these assumptions could
	materially increase or decrease the fair value of share-based compensation and share purchase warrants issued and the associated
	expense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	(b) Valuation of tax accounts:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Uncertainties exist with respect to the
	interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we have deductible temporary
	differences which would create a deferred tax asset. Deferred tax assets are recognized for all deductible temporary differences
	to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences
	can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon
	the likely timing and the level of future taxable profits together with future tax planning strategies. To date, we have determined
	that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses
	from prior years and prior year research and development expenses. These tax pools relate to entities that have a history of losses,
	have varying expiry dates, and may not be used to offset taxable income. As well, there are no taxable temporary differences or
	any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets. The
	generation of future taxable income could result in the recognition of some portion or all of the remaining benefits, which could
	result in an improvement in our results of operations through the recovery of future income taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	(c) Valuation of contingent liabilities:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We utilize considerable judgment in the
	measurement and recognition of provisions and Aptose&rsquo;s exposure to contingent liabilities. Judgment is required to assess
	and determine the likelihood that any potential or pending litigation or any and all potential claims against us may be successful.
	We must estimate if an obligation is probable as well as quantify the possible economic cost of any claim or contingent liability.
	Such judgments and assumptions are inherently uncertain. The increase or decrease of one of these assumptions could materially
	increase or decrease the fair value of the liability and the associated expense.
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage128"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Accounting
	pronouncements adopted during the year
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There were no new accounting policies adopted
	during the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Recent
	Accounting pronouncements not yet adopted
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	IFRS 9, Financial Instruments (&quot;IFRS
	9&quot;):
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IFRS 9 (2014) introduces new requirements
	for the classification and measurement of financial assets. Under IFRS 9 (2014), financial assets are classified and measured based
	on the business model in which they are held and the characteristics of their contractual cash flows. The standard introduces additional
	changes relating to financial liabilities and also amends the impairment model by introducing a new &lsquo;expected credit loss&rsquo;
	model for calculating impairment. IFRS&nbsp;9 (2014) also includes a new general hedge accounting standard which aligns hedge accounting
	more closely with risk management. The Company intends to adopt IFRS 9 (2014) in its consolidated financial statements for the
	annual period beginning on January 1, 2018. The extent of the impact of adoption of the standard has not yet been determined.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Amendments to IAS 1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On December 18, 2014, the
<B>
</B>
	IASB issued
	amendments to IAS 1 Presentation of Financial Statements as part of its major initiative to improve presentation and disclosure
	in financial reports. The amendments are effective for annual periods beginning on or after 1 January 2016. Early adoption is permitted.
	The Company intends to adopt these amendments in its consolidated Financial Statements for the annual period beginning on January
	1, 2016. The impact of adoption of the amendments is not expected to have a material impact on the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	IFRS 16, Leases (&ldquo;IFRS 16&rdquo;)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On January 13, 2016, the IASB issued IFRS
	16 Leases. The new standard is effective for annual periods beginning on or after January 1, 2019. Earlier application is permitted
	for entities that apply IFRS 15 Revenue from Contracts with Customers at or before the date of initial adoption of IFRS 16. IFRS
	16 will replace IAS 17 Leases. This standard introduces a single lessee accounting model and requires a lessee to recognize assets
	and liabilities for all leases with a term of more than 12 months, unless the underlying asset is of low value. The extent of the
	impact of adoption of the standard has not yet been determined.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Related
	Party Transactions
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2015, the Company entered into
	an agreement with the Moores Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services
	to the Company. Dr. Stephen Howell is the Acting Chief Medical Officer of Aptose and is also a Professor of Medicine at UCSD and
	will be overseeing the laboratory work. The research services will be provided from April 1, 2015 to March 31, 2016 for an annual
	fee of US$154,456 to be paid to UCSD in monthly installments. This research services agreement was approved by the Aptose Board
	of Directors on February 23, 2016 for an additional 12 month period beginning April 1, 2016 and for an annual fee of up to US$200,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	This transaction is in the normal course
	of business and will be measured at the amount of consideration established and agreed to by the related parties.
</P>
<P STYLE="COLOR: #3366FF; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	See note 14 to the audited financial statements
	for disclosures of key management personnel compensation and directors&rsquo; compensation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Contractual
	Obligations and Off-Balance Sheet Financing
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: WINDOWTEXT">
	At
</FONT>
	December 31, 2015
<FONT STYLE="COLOR: WINDOWTEXT">
	,
	we had contractual obligations requiring annual payments as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID">
	Less than 1 year
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID">
	1 - 3 years
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID">
	3 - 5 years
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 1.5PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Operating leases
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	587
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	907
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	319
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,813
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company has entered into various contracts
	with service providers with respect to the clinical development of APTO-253. These contracts will result in future payment commitments
	of up to approximately $4 million over the related service period. Of this amount, $544 thousand has been paid and $574 thousand
	has been accrued at December 31, 2015. The payments are based on services performed and amounts may be higher or lower based on
	actual services performed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage129"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company enters into research, development
	and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary
	technologies. Milestone and royalty payments that may become due under various agreements are dependent on, among other factors,
	clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which
	is uncertain. Under the license agreement with the Moffitt Cancer Centre, the Company has future contingent milestones payable
	totalling US$9 million relating to the first patient dosed in a phase I, II and III clinical trial and regulatory and commercial
	milestones totalling US$16 million. The Company does not anticipate making any payments under this license agreement in 2016. Under
	the Laxai-Avanti Life Science agreement the Company has total future contingent milestones payable of US$5.3 million related to
	certain research achievements as well as upon the first patient dosed in a phase I, II and III clinical trial and regulatory milestones
	totalling US$5 million. The Company expects to make payments totalling US$300 thousand under this agreement in 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As at December 31, 2015, we have not entered
	into any off-balance sheet arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Financial
	instruments
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
	(a) Financial instruments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have classified our financial instruments
	as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As at December 31,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_66"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Financial assets:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	Cash and cash equivalents, consisting
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;&nbsp;of high interest savings accounts,
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;&nbsp;measured at amortized cost
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	11,503
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	14,365
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	Investments, consisting of
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;&nbsp;guaranteed investment certificates,
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;&nbsp;measured at amortized cost.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,245
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Financial liabilities:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	Accounts payable, measured at amortized cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	522
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	256
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	Accrued liabilities, measured at amortized cost
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,834
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,662
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT">
	Convertible promissory notes,
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-LEFT: 10PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;&nbsp;&nbsp;measured at amortized cost
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	410
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2015, there are no significant
	differences between the carrying values of these amounts and their estimated market values due to their short-term nature.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
	(b) Financial risk management
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	We have exposure to credit risk,
	liquidity risk and market risk. Our Board of Directors has the overall responsibility for the oversight of these risks and reviews
	our policies on an ongoing basis to ensure that these risks are appropriately managed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	(i)
	Credit risk
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Credit risk is the risk of financial
	loss to us if a customer, partner or counterparty to a financial instrument fails to meet its contractual obligations, and arises
	principally from our cash and cash equivalents. The carrying amount of the financial assets represents the maximum credit exposure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage130"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	We manage credit risk for our
	cash and cash equivalents by maintaining minimum standards of R1-low or A-low investments and we invest only in highly rated Canadian
	corporations with debt securities that are traded on active markets and are capable of prompt liquidation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	(ii)
	Liquidity risk
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Liquidity risk is the risk that
	we will not be able to meet our financial obligations as they come due. To the extent that we do not believe we have sufficient
	liquidity to meet our current obligations, the Board considers securing additional funds through equity, debt or partnering transactions.
	We manage our liquidity risk by continuously monitoring forecasts and actual cash flows. All of our financial liabilities are due
	within the current operating period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	(iii)
	Market risk
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Market risk is the risk that
	changes in market prices, such as interest rates, foreign exchange rates and equity prices will affect our income or the value
	of our financial instruments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	We are subject to interest rate
	risk on our cash and cash equivalents and investment balances. We do not believe that the results of operations or cash flows would
	be affected to any significant degree by a sudden change in market interest rates relative to interest rates on the investments,
	owing to the relative short-term nature of the investments. We do not have any interest bearing liabilities subject to interest
	rate fluctuations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Currency risk is the risk that
	future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. We are exposed to currency
	risk from employee costs as well as the purchase of goods and services primarily in the United States and on cash balances held
	in foreign currencies. Fluctuations in the US dollar exchange rate could have a significant impact on our results. Assuming all
	other variables remain constant, a 10% depreciation or appreciation of the Canadian dollar against the US dollar would result in
	an increase or decrease in loss for the year and comprehensive loss of $576 thousand (December 31, 2014- $50 thousand, May 31,
	2014 - $18 thousand). Balances in foreign currencies are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_67"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	US$ Balances
</B>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	December 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	May 31,
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	5,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	66
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	594
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accounts payable and accrued liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(838
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(565
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(769
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Balance, end of period
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	4,162
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(175
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	We do not have any forward exchange
	contracts to hedge this risk.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	We do not invest in equity instruments
	of other corporations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.7PT">
<B>
	(c)
	Capital management
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.7PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our primary objective when managing
	capital is to ensure that we have sufficient cash resources to fund our development and commercialization activities and to maintain
	our ongoing operations. To secure the additional capital necessary to pursue these plans, we may attempt to raise additional funds
	through the issuance of equity or by securing strategic partners.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	We include cash and cash equivalents
	and short-term deposits in the definition of capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	We are not subject to externally
	imposed capital requirements and there has been no change with respect to the overall capital management strategy during the year
	ended December 31, 2015.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	Outlook
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Until
	one of our drug candidates receives regulatory approval and is successfully commercialized, Aptose will continue to incur operating
	losses. The magnitude of these operating losses will be largely affected by the timing and scope of future research and development,
	clinical trials and the Company&rsquo;s ability to raise additional and ongoing working capital and/or establish effective partnerships
	to share the costs of development and clinical trials.
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage131"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	RISK
	FACTORS
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Investing in our securities involves a
	high degree of risk. Before making an investment decision with respect to our common shares, you should carefully consider the
	following risk factors, in addition to the other information included or incorporated by reference into the most recently filed
	annual information form, as well as our historical consolidated financial statements and related notes. Management has reviewed
	the operations of the Company in conjunction with the Board of Directors and identified the following risk factors which are monitored
	on a bi-annual basis and reviewed with the Board of Directors. The risks set out below are not the only risks we face. If any of
	the following risks occur, our business, financial condition, prospects or results of operations and cash flows would likely suffer.
	In that case, the trading price of our common shares could decline and you may lose all or part of the money you paid to buy our
	common shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We are an early stage development
	company.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are at an early
	stage of development. In the past five years, none of our potential products has obtained regulatory approval for commercial use
	and sale in any country and as such, no significant revenues have resulted from product sales. Significant additional investment
	will be necessary to complete the development of any of our product candidates. Preclinical and clinical trial work must be completed
	before our potential products could be ready for use within the markets that we have identified. We may fail to develop any products,
	obtain regulatory approvals, enter clinical trials or commercialize any products. We do not know whether any of our potential product
	development efforts will prove to be effective, meet applicable regulatory standards, obtain the requisite regulatory approvals,
	be capable of being manufactured at a reasonable cost or be accepted in the marketplace. We also do not know whether sales, license
	fees or related royalties will allow us to recoup any investment we make in the commercialization of our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The product candidates
	we are currently developing are not expected to be commercially viable for at least the next several years and we may encounter
	unforeseen difficulties or delays in commercializing our product candidates. In addition, our potential products may not be effective
	or may cause undesirable side effects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our product candidates
	require significant funding to reach regulatory approval assuming positive clinical results. For example, our lead product candidate
	APTO-253 began enrolment in a Phase I clinical trial in patients with relapsed or refractory hematologic malignancies and was placed
	on clinical hold by the United States Food and Drug Administration (&ldquo;
<B>
	FDA
</B>
	&rdquo;) following a voluntary suspension
	of dosing by us. We are currently working with the FDA to have such hold lifted but significant additional funding or a partnership
	will be necessary to complete, if required, Phase II or Phase III clinical trials. Such funding may be very difficult, or impossible
	to raise in the public or private markets or through partnerships. If funding or partnerships are not attainable, the development
	of these product candidates may be significantly delayed or stopped altogether. The announcement of a delay or discontinuation
	of development would likely have a negative impact on our share price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We need to raise additional capital.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have an ongoing
	need to raise additional capital. To obtain the necessary capital, we must rely on some or all of the following: additional share
	issues, debt issuances (including promissory notes), collaboration agreements or corporate partnerships and grants and tax credits
	to provide full or partial funding for our activities. Additional funding may not be available on terms that are acceptable to
	us or in amounts that will enable us to carry out our business plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our need for capital
	may require us to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	engage in equity financings that could
	result in significant dilution to existing investors;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delay or reduce the scope of or eliminate
	one or more of our development programs;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtain funds through arrangements with
	collaborators or others that may require us to relinquish rights to technologies, product candidates or products that we would
	otherwise seek to develop or commercialize ourselves; or
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	license rights to technologies, product
	candidates or products on terms that are less favourable to us than might otherwise be available;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	considerably reduce operations; or
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	cease our operations.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage132"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We have a history of operating losses.
	We expect to incur net losses and we may never achieve or maintain profitability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have not been profitable
	since our inception in 1986. We reported net losses of $14.6 million in the fiscal year ended December 31, 2015, $7.8 million in
	the 7 months ended December 31, 2014 and $10.6 million in the fiscal years ended May 31, 2014, and as of December 31, 2015, we
	had an accumulated deficit of $232.9 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have not generated
	any significant revenue to date and it is possible that we will never have sufficient product sales revenue (if any) to achieve
	profitability. We expect to continue to incur losses for at least the next several years as we or our collaborators and licensees
	pursue clinical trials and research and development efforts. To become profitable, we, either alone or with our collaborators and
	licensees, must successfully develop, manufacture and market our current product candidate APTO-253 as well as continue to identify,
	develop, manufacture and market new product candidates. It is possible that we will never have significant product sales revenue
	or receive royalties on our licensed product candidates. If funding is insufficient at any time in the future, we may not be able
	to develop or commercialize our products, take advantage of business opportunities or respond to competitive pressures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Clinical trials are long, expensive
	and uncertain processes and the United States FDA or Health Canada may ultimately not approve any of our product candidates. We
	may never develop any commercial drugs or other products that generate revenues.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In the past five years,
	none of our product candidates has received regulatory approval for commercial use and sale in North America. We cannot market
	a pharmaceutical product in any jurisdiction until it has completed thorough preclinical testing and clinical trials in addition
	to that jurisdiction&rsquo;s extensive regulatory approval process. Approval in one country does not assure approval in another
	country. In general, significant research and development and clinical studies are required to demonstrate the safety and effectiveness
	of our product candidates before we can submit any regulatory applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Clinical trials are
	long, expensive and uncertain processes. Clinical trials may not be commenced or completed on schedule and the FDA or Health Canada
	or any other regulatory body may not ultimately approve our product candidates for commercial sale. The clinical trials of any
	of our drug candidates could be unsuccessful, which would prevent us from advancing, commercializing or partnering the drug.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Even if the results
	of our preclinical studies or clinical trials are initially positive, it is possible that we will obtain different results in the
	later stages of drug development or that results seen in clinical trials will not continue with longer term treatment. Positive
	results in Phase I clinical trials may not be repeated in larger Phase II or Phase III clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our preclinical studies
	and clinical trials may not generate positive results that will allow us to move towards the commercial use and sale of our product
	candidates. Furthermore, negative preclinical or clinical trial results may cause our business, financial condition, or results
	of operations to be materially adversely affected. For example, our lead product candidate APTO-253 has entered a Phase Ib testing
	in patients with relapsed or refractory hematologic malignancies for which there is a long development path ahead that will take
	many years to complete and is prone to the risks of failure or delays inherent in drug development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Preparing, submitting
	and advancing applications for regulatory approval is complex, expensive and time intensive and entails significant uncertainty.
	A commitment of substantial resources to conduct time-consuming research, preclinical studies and clinical trials is required if
	we are to complete development of our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Clinical trials of
	our products require that we identify and enroll a large number of patients with the illness under investigation. We may not be
	able to enroll a sufficient number of appropriate patients to complete our clinical trials in a timely manner, particularly in
	smaller indications and indications where there is significant competition for patients. If we experience difficulty in enrolling
	a sufficient number of patients to conduct our clinical trials, we may need to delay or terminate ongoing clinical trials and will
	not accomplish objectives material to our success. Delays in planned patient enrolment or lower than anticipated event rates in
	our current clinical trials or future clinical trials also may result in increased costs, program delays, or both.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage133"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition, unacceptable
	toxicities or adverse side effects may occur at any time in the course of preclinical studies or human clinical trials or, if any
	product candidates are successfully developed and approved for marketing, during commercial use of any approved products. The appearance
	of any unacceptable toxicities or adverse side effects could interrupt, limit, delay or abort the development of any of our product
	candidates or, if previously approved, necessitate their withdrawal from the market. Furthermore, disease resistance or other unforeseen
	factors may limit the effectiveness of our potential products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our failure to develop
	safe, commercially viable drugs would substantially impair our ability to generate revenues and sustain our operations and would
	materially harm our business and adversely affect our share price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	We may not achieve our projected development goals in
	the time frames we announce and expect.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We set goals for, and
	make public statements regarding, the expected timing of the accomplishment of objectives material to our success, such as the
	commencement and completion of clinical trials and our ability to secure the financing necessary to continue the development of
	our product candidates. The actual timing of these events can vary dramatically due to factors within and beyond our control, such
	as delays or failures in our clinical trials, issues related to the manufacturing of drug supply, uncertainties inherent in the
	regulatory approval process, market conditions and interest by partners in our product candidates among other things. Our clinical
	trials may not be completed; we may not make regulatory submissions or receive regulatory approvals as planned; or we may not secure
	partnerships for any of our product candidates. Any failure to achieve one or more of these milestones as planned would have a
	material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Delays in clinical testing could
	result in delays in commercializing our product candidates, and our business may be substantially harmed.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	cannot predict whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule,
	or at all. Our product development costs will increase if we experience delays in clinical testing. Significant clinical trial
	delays could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow
	our competitors to bring products to market before us, which would impair our ability to successfully commercialize our product
	candidates and may harm our financial condition, results of operations and prospects. The commencement and completion of clinical
	trials for our products, including the APTO-253 phase I clinical trial, may be delayed for a number of reasons, including delays
	related, but not limited, to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	failure by regulatory authorities to grant permission to proceed or placing the clinical trial on hold;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	patients failing to enroll or remain in our trials at the rate we expect;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	suspension or termination of clinical trials by regulators for many reasons, including concerns about patient safety or failure of our contract manufacturers to comply with cGMP requirements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	any changes to our manufacturing process that may be necessary or desired;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays or failure to obtain clinical supply from contract manufacturers of our products necessary to conduct clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	product candidates demonstrating a lack of safety or efficacy during clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	patients choosing an alternative treatment for the indications for which we are developing any of our product candidates or participating in competing clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	patients failing to complete clinical trials due to dissatisfaction with the treatment, side effects or other reasons;
</FONT>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	reports of clinical testing on similar technologies and products raising safety and/or efficacy concerns;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	competing clinical trials and scheduling conflicts with participating clinicians;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	clinical investigators not performing our clinical trials on their anticipated schedule, dropping out of a trial, or employing methods not consistent with the clinical trial protocol, regulatory requirements or other third parties not performing data collection and analysis in a timely or accurate manner;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	failure of our contract research organizations, or CROs, to satisfy their contractual duties or meet expected deadlines;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	inspections of clinical trial sites by regulatory authorities or Institutional Review Boards, or IRBs, or ethics committees finding regulatory violations that require us to undertake corrective action, resulting in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	one or more IRBs or ethics committees rejecting, suspending or terminating the study at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage134"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	failure to reach agreement on acceptable terms with prospective clinical trial sites.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Our product development
	costs will increase if we experience delays in testing or approval or if we need to perform more or larger clinical trials than
	planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend study protocols to reflect
	these changes. Amendments may require us to resubmit our study protocols to regulatory authorities or IRBs or ethics committees
	for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development
	costs may have a material adverse effect on our business, financial condition and prospects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We rely on contract manufacturers
	over whom we have limited control. If we are subject to quality, cost or delivery issues with the preclinical and clinical grade
	materials supplied by contract manufacturers, our business operations could suffer significant harm.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	rely on contract manufacturing organizations, or CMOs, to manufacture our product candidates for some preclinical studies and clinical
	trials. We rely on CMOs for manufacturing, filling, packaging, storing and shipping of drug product in compliance with cGMP regulations
	applicable to our products. The FDA ensures the quality of drug products by carefully monitoring drug manufacturers&rsquo; compliance
	with cGMP regulations. The cGMP regulations for drugs contain minimum requirements for the methods, facilities and controls used
	in manufacturing, processing and packing of a drug product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	have contracted with multiple CMOs for the manufacture of APTO-253 to supply both the API
	as well as to perform formulation and optimization studies with the intent of supplying drug product acceptable to the FDA for
	our phase I clinical trial. The formulation and manufacture of APTO-253 is a complex process with many variables involved. We
	believe these pre-qualified CMOs have the capacity, the systems and the experience to supply APTO-253 for our phase I clinical
	trial and future clinical trials. We have qualified the manufacturing facilities and the FDA has also performed site audits for
	our selected CMOs. Any manufacturing failures, delays or compliance issues could cause further delays in the re-initiation of
	the phase I clinical trial. If we are able to re-initiate the phase I clinical trial any manufacturing failures, delays or compliance
	issues could impact our ability to complete the phase I clinical trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	There
	can be no assurances that CMOs will be able to meet our timetable and requirements. We have not contracted with alternate suppliers
	in the event our current CMOs are unable to scale up production, or if our current CMOs otherwise experience any other significant
	problems. If we are unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms or in
	a timely manner, we may be further delayed in the development of our product candidates. Further, contract manufacturers must operate
	in compliance with cGMP and failure to do so could result in, among other things, the disruption of product supplies. Our dependence
	upon third parties for the manufacture of our products may adversely affect our profit margins and our ability to develop and deliver
	products on a timely and competitive basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	If we have difficulty enrolling
	patients in clinical trials, the completion of the trials may be delayed or cancelled.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	As
	our product candidates advance from preclinical testing to clinical testing, and then through progressively larger and more complex
	clinical trials, we will need to enroll an increasing number of patients that meet our eligibility criteria. There is significant
	competition for recruiting cancer patients in clinical trials, and we may be unable to enroll the patients we need to complete
	clinical trials on a timely basis or at all. Certain factors that affect enrollment of patients onto our clinical trials are impacted
	by external forces that may be beyond our control. Such factors include, but are not limited to, the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	size and nature of the patient population;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	eligibility and exclusion criteria for the trial;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	design of the study protocol;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	competition with other companies for clinical sites or patients;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the perceived risks and benefits of the product candidate under study;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the patient referral practices of physicians; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the number, availability, location and accessibility of clinical trial sites.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage135"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	If we are
	unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience significant delays in
	doing so, we may not achieve marketing approval or realize the full commercial potential of our therapeutic product candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	plan to develop companion diagnostics for our therapeutic product candidates. We expect that, at least in some cases, regulatory
	authorities may require the development and regulatory approval of a companion diagnostic as a condition to approving our therapeutic
	product candidates. We have limited experience and capabilities in developing or commercializing diagnostics and plan to rely in
	large part on third parties to perform these functions. We do not currently have any agreement in place with any third party to
	develop or commercialize companion diagnostics for any of our therapeutic product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Companion
	diagnostics are subject to regulation by the FDA, Health Canada and comparable foreign regulatory authorities as medical devices
	and may require separate regulatory approval or clearance prior to commercialization. If we,&nbsp;or any third parties that we
	engage to assist us, are unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience
	delays in doing so, our business may be substantially harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We rely
	and will continue to rely on third parties to conduct and monitor many of our preclinical studies and our clinical trials, and
	their failure to perform as required could cause substantial harm to our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	rely and will continue to rely on third parties to conduct a significant portion of our preclinical and clinical development activities.
	Preclinical activities include in vivo studies providing access to specific disease models, pharmacology and toxicology studies,
	and assay development. Clinical development activities include trial design, regulatory submissions, clinical patient recruitment,
	clinical trial monitoring, clinical data management and analysis, safety monitoring and project management, contract manufacturing
	and quality assurance. If there is any dispute or disruption in our relationship with third parties, or if they are unable to provide
	quality services in a timely manner and at a feasible cost, our active development programs will face delays. Further, if any of
	these third parties fails to perform as we expect or if their work fails to meet regulatory requirements, our testing could be
	delayed, cancelled or rendered ineffective.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We heavily
	rely on the capabilities and experience of our key executives and scientists and the loss of any of them could affect our ability
	to develop our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	The
	loss of Dr.&nbsp;William G. Rice, our Chairman, President and Chief Executive Officer, or other key members of our staff, including
	Gregory Chow, our Senior Vice President and Chief Financial Officer, or Avanish Vellanki, our Senior Vice President and Chief Business
	Officer, could harm us. We have employment agreements with Dr. Rice and Mr. Chow and Mr. Vellanki, although such employment agreements
	do not guarantee their retention. We also depend on our scientific and clinical collaborators and advisors, all of whom have outside
	commitments that may limit their availability to us. In addition, we believe that our future success will depend in large part
	upon our ability to attract and retain highly skilled scientific, managerial, medical, clinical and regulatory personnel, particularly
	as we expand our activities and seek regulatory approvals for clinical trials. We routinely enter into consulting agreements with
	our scientific and clinical collaborators and advisors, key opinion leaders and academic partners in the ordinary course of our
	business. We also enter into contractual agreements with physicians and institutions who will recruit patients into our clinical
	trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition
	for these types of personnel from other companies, research and academic institutions, government entities and other organizations.
	We cannot predict our success in hiring or retaining the personnel we require for continued growth. The loss of the services of
	any of our executive officers or other key personnel could potentially harm our business, operating results or financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Our employees may engage in misconduct
	or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse
	effect on our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with FDA
	regulations, provide accurate information to the FDA, comply with manufacturing standards we have established, comply with federal
	and state health-care fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized
	activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive
	laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations
	may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs
	and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course
	of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. If any such actions are instituted
	against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a substantial impact
	on our business and results of operations, including the imposition of substantial fines or other sanctions.
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage136"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We may expand our business through
	the acquisition of companies or businesses or by entering into collaborations or by in-licensing product candidates, each of which
	could disrupt our business and harm our financial condition.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We may in the future
	seek to expand our pipeline and capabilities by acquiring one or more companies or businesses, entering into collaborations or
	in-licensing one or more product candidates. For example in November 2015 we licensed intellectual property from the Moffitt Cancer
	Center&nbsp;for exclusive global rights to potent, multi-targeting, single-agent inhibitors for the treatment of hematologic and
	solid tumor cancers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Acquisitions, collaborations
	and in-licenses involve numerous risks, including, but not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	substantial cash expenditures;
</FONT>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	technology development risks;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	potentially dilutive issuances of equity securities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	difficulties in assimilating the operations of the acquired companies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	potential disputes regarding contingent consideration;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	diverting our management&rsquo;s attention away from other business concerns;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	entering markets in which we have limited or no direct experience;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&bull;
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	potential loss of our key employees
	or key employees of the acquired companies or businesses; and failure of the in-licenses agents or technologies to deliver
	the desired activities or functions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	have experience in entering collaborations and in-licensing product candidates, however, we cannot provide assurance that any acquisition,
	collaboration or in-license will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth
	of an acquired company or business or in-licensed product candidate. In addition, our future success would depend in part on our
	ability to manage the rapid growth associated with some of these acquisitions, collaborations and in-licenses. We cannot assure
	you that we would be able to successfully combine our business with that of acquired businesses, manage a collaboration or integrate
	in-licensed product candidates. Furthermore, the development or expansion of our business may require a substantial capital investment
	by us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Negative results from clinical
	trials or studies of others and adverse safety events involving the targets of our products may have an adverse impact on our future
	commercialization efforts
</I>
</B>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	From
	time to time, studies or clinical trials on various aspects of biopharmaceutical products are conducted by academic researchers,
	competitors or others. The results of these studies or trials, when published, may have a significant effect on the market for
	the biopharmaceutical product that is the subject of the study. The publication of negative results of studies or clinical trials
	or adverse safety events related to our product candidates, or the therapeutic areas in which our product candidates compete, could
	adversely affect our share price and our ability to finance future development of our product candidates, and our business and
	financial results could be materially and adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	As a result of intense competition
	and technological change in the biotechnical and pharmaceutical industries, the marketplace may not accept our products or product
	candidates, and we may not be able to compete successfully against other companies in our industry and achieve profitability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Many of our competitors have:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	drug products that have already been approved
	or are in development, and operate large, well-funded research and development programs in the biotechnical and pharmaceutical
	fields;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	substantially greater financial, technical
	and management resources, stronger intellectual property positions and greater manufacturing, marketing and sales capabilities,
	areas in which we have limited or no experience; and
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage137"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	significantly greater experience than
	we do in undertaking preclinical testing and clinical trials of new or improved pharmaceutical products and obtaining required
	regulatory approvals.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Consequently, our competitors
	may obtain FDA, Health Canada and other regulatory approvals for product candidates sooner and may be more successful in manufacturing
	and marketing their products than we or our collaborators are.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our competitor&rsquo;s
	existing and future products, therapies and technological approaches will compete directly with the products we seek to develop.
	Current and prospective competing products may be more effective than our existing and future products insofar as they may provide
	greater therapeutic benefits for a specific problem or may offer easier delivery or comparable performance at a lower cost.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Any product candidate
	that we develop and that obtains regulatory approval must then compete for market acceptance and market share. Our products may
	not gain market acceptance among physicians, patients, healthcare payers, insurers, the medical community and other stakeholders.
	Further, any products we develop may become obsolete before we recover any expenses we incurred in connection with the development
	of these products. As a result, we may never achieve profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may be unable to obtain patents
	to protect our technologies from other companies with competitive products, and patents of other companies could prevent us from
	manufacturing, developing or marketing our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Patent protection
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The patent positions
	of pharmaceutical and biotechnology companies are uncertain and involve complex legal and factual questions. The United States
	Patent and Trademark Office and many other patent offices in the world have not established a consistent policy regarding the breadth
	of claims that they will allow in biotechnology patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our pending patent
	applications may not result in issued patents and our issued patents may not be held valid and enforceable if challenged. Competitors
	may be able to circumvent any such issued patents by adoption of a competitive, though non-infringing product or process. Interpretation
	and evaluation of pharmaceutical or biotechnology patent claims present complex and often novel legal and factual questions. Our
	business could be adversely affected by increased competition in the event that any patent granted to it is held to be invalid
	or unenforceable or is inadequate in scope to protect our operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Allowable patentable
	subject matter and the scope of patent protection obtainable may differ between jurisdictions. If a patent office allows broad
	claims, the number and cost of patent interference proceedings in the United States, or analogous proceedings in other jurisdictions
	and the risk of infringement litigation may increase. If it allows narrow claims, the risk of infringement may decrease, but the
	value of our rights under our patents, licenses and patent applications may also decrease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The scope of the claims
	in a patent application can be significantly modified during prosecution before the patent is issued. Consequently, we cannot know
	whether our pending applications will result in the issuance of patents or, if any patents are issued, whether they will provide
	us with significant proprietary protection or will be circumvented, invalidated or found to be unenforceable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Publication of discoveries
	in scientific or patent literature often lags behind actual discoveries. Patent applications filed in the United States generally
	will be published 18 months after the filing date unless the applicant certifies that the invention will not be the subject of
	a foreign patent application. In many other jurisdictions, such as Canada, patent applications are published 18 months from the
	priority date. We may not be aware of such literature. Accordingly, we cannot be certain that the named inventors of our products
	and processes were the first to invent that product or process or that we were the first to pursue patent coverage for our inventions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition, U.S. patent
	laws may change which could prevent or limit us from filing patent applications or patent claims in the United States to protect
	our products and technologies or limit the exclusivity periods that are available to patent holders for U.S. patents. For example,
	the Leahy-Smith America Invents Act, (the &ldquo;
<B>
	Leahy-Smith Act
</B>
	&rdquo;) was signed into law in 2011 and includes a number
	of significant changes to U.S. patent law. These include changes to transition from a &ldquo;first-to-invent&rdquo; system to a
	&ldquo;first-to-file&rdquo; system and to the way issued patents are challenged. These changes may favour larger and more established
	companies that have more resources to devote to patent application filing and prosecution. It is not clear what, if any, impact
	the Leahy-Smith Act will ultimately have on the cost of prosecuting our patent applications in the United States, our ability to
	obtain patents in the United States based on our discoveries and our ability to enforce or defend our U.S. issued patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage138"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Until such time, if
	ever, that further patents are issued to us, we will rely upon the law of trade secrets to the extent possible given the publication
	requirements under international patent treaty laws and/or requirements under foreign patent laws to protect our technology and
	our products incorporating the technology. In this regard, we have adopted certain confidentiality procedures. These include: limiting
	access to confidential information to certain key personnel; requiring all directors, officers, employees and consultants and others
	who may have access to our intellectual property to enter into confidentiality agreements which prohibit the use of or disclosure
	of confidential information to third parties; and implementing physical security measures designed to restrict access to such confidential
	information and products. Our ability to maintain the confidentiality of our technology is crucial to our ultimate possible commercial
	success. The procedures adopted by us to protect the confidentiality of our technology may not be effective, third parties may
	gain access to our trade secrets or disclose our confidential technology. Further, by seeking patent protection in various countries,
	it is inevitable that a substantial portion of our technology will become available to our competitors, through publication of
	such patent applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Enforcement of intellectual property
	rights
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Protection of the rights
	revealed in published patent applications can be complex, costly and uncertain. Our commercial success depends in part on our ability
	to maintain and enforce our proprietary rights. If third parties engage in activities that infringe our proprietary rights, our
	management&rsquo;s focus will be diverted and we may incur significant costs in asserting our rights. We may not be successful
	in asserting our proprietary rights, which could result in our patents being held invalid or a court holding that the third party
	is not infringing, either of which would harm our competitive position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Others may design around
	our patented technology. We may have to participate in interference proceedings declared by the United States Patent and Trademark
	Office, European opposition proceedings, or other analogous proceedings in other parts of the world to determine priority of invention
	and the validity of patent rights granted or applied for, which could result in substantial cost and delay, even if the eventual
	outcome is favourable to us. Our pending patent applications, even if issued, may not be held valid or enforceable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Trade secrets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We also rely on trade
	secrets, know-how and confidentiality provisions in our agreements with our collaborators, employees and consultants to protect
	our intellectual property. However, these and other parties may not comply with the terms of their agreements with us, and we might
	be unable to adequately enforce our rights or obtain adequate compensation for the damages caused by unauthorized disclosure or
	use of our trade secrets or know how. Our trade secrets or those of our collaborators also may be independently discovered by others.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our products and product candidates
	may infringe the intellectual property rights of others, or others may infringe on our intellectual property rights which could
	increase our costs.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our success also depends
	on avoiding infringement of the proprietary technologies of others. In particular, there may be certain issued patents and patent
	applications claiming subject matter which we or our collaborators may be required to license in order to research, develop or
	commercialize APTO-253, our lead product candidate. In addition, third parties may assert infringement or other intellectual property
	claims against us. An adverse outcome in these proceedings could subject us to significant liabilities to third-parties, require
	disputed rights to be licensed from third-parties or require us to cease or modify our use of the technology. If we are required
	to license third-party technology, a license under such patents and patent applications may not be available on acceptable terms
	or at all. Further, we may incur substantial costs defending ourselves in lawsuits against charges of patent infringement or other
	unlawful use of another&rsquo;s proprietary technology. We may also need to bring claims against others who we believe are infringing
	our rights in order to become or remain competitive and successful. Any such claims can be time consuming and expensive to pursue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage139"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may incur substantial cost in
	defending our intellectual property.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	While we believe that
	our products and technology do not infringe proprietary rights of others, third parties may assert infringement claims in the future
	and such claims could be successful. Even if challenges are unsuccessful, we could incur substantial costs in defending ourselves
	against patent infringement claims brought by others or in prosecuting suits against others. In addition, others may obtain patents
	that we would need to license, which may not be available to us on reasonable terms. Whether we are able to obtain a necessary
	license would depend on the terms offered, the degree of risk of infringement and the need for the patent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	If product liability, clinical trial
	liability or environmental liability claims are brought against us or we are unable to obtain or maintain product liability, clinical
	trial or environmental liability insurance, we may incur substantial liabilities that could reduce our financial resources.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The clinical testing
	and commercial use of pharmaceutical products involves significant exposure to product liability, clinical trial liability, environmental
	liability and other risks that are inherent in the testing, manufacturing and marketing of our products. These liabilities, if
	realized, could have a material adverse effect on the Company&rsquo;s business, results of operations and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have obtained limited
	product liability insurance coverage for our clinical trials on humans; however, our insurance coverage may be insufficient to
	protect us against all product liability damages. Regardless of merit or eventual outcome, liability claims may result in decreased
	demand for a future product, injury to reputation, withdrawal of clinical trial volunteers, loss of revenue, costs of litigation,
	distraction of management and substantial monetary awards to plaintiffs. Additionally, if we are required to pay a product liability
	claim, we may not have sufficient financial resources to complete development or commercialization of any of our product candidates
	and our business and results of operations will be adversely affected. In general, insurance will not protect us against some of
	our own actions, such as negligence.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As the Company&rsquo;s
	development activities progress towards the commercialization of product candidates, our liability coverage may not be adequate,
	and the Company may not be able to obtain adequate product liability insurance coverage at a reasonable cost, if at all. Even if
	the Company obtains product liability insurance, its financial position may be materially adversely affected by a product liability
	claim. A product liability claim could also significantly harm the Company&rsquo;s reputation and delay market acceptance of its
	product candidates. Additionally, product recalls may be issued at the direction of the FDA, other government agencies or other
	companies having regulatory control for pharmaceutical sales. If a product recall occurs in the future, such a recall could adversely
	affect our business, financial condition or reputation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may be unable to obtain partnerships
	for our product candidates, which could curtail future development and negatively affect our share price. In addition, our partners
	might not satisfy their contractual responsibilities or devote sufficient resources to our partnership.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our strategy for the
	research, development and commercialization of our products requires entering into various arrangements with corporate collaborators,
	licensors, licensees and others, and our commercial success is dependent upon these outside parties performing their respective
	contractual responsibilities. The amount and timing of resources that such third parties will devote to these activities may not
	be within our control. These third parties may not perform their obligations as expected and our collaborators may not devote adequate
	resources to our programs. In addition, we could become involved in disputes with our collaborators, which could result in a delay
	or termination of the related development programs or result in litigation. We intend to seek additional collaborative arrangements
	to develop and commercialize some of our products. We may not be able to negotiate collaborative arrangements on favourable terms,
	or at all, in the future, and our current or future collaborative arrangements may not be successful.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If we cannot negotiate
	collaboration, license or partnering agreements, we may never achieve profitability and we may not be able to continue to develop
	our product candidates. Phase II and Phase III clinical trials for APTO-253 would require significant amounts of funding and such
	funding may not be available to us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage140"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Exchange rate risk
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are exposed to fluctuations
	of the Canadian dollar against certain other currencies because we publish our financial statements and hold most of our investments
	in Canadian dollars, while we incur many of our expenses in foreign currencies, primarily the United States dollar. Fluctuations
	in the value of currencies such as the recent depreciation of the Canadian dollar against the United States dollar could cause
	us to incur currency exchange losses. We do not currently employ a hedging strategy against exchange rate risk. We cannot assert
	with any assurance that we will not suffer losses as a result of unfavorable fluctuations in the exchange rates between the Canadian
	dollar, the United States dollar and other currencies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Extensive Government Regulation
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Government regulation
	is a significant factor in the development, production and marketing of the Company&rsquo;s products. Research and development,
	testing, manufacture, marketing and sales of pharmaceutical products or related products are subject to extensive regulatory oversight,
	often in multiple jurisdictions, which may cause significant additional costs and/or delays in bringing products to market, and
	in turn, may cause significant losses to investors. The regulations applicable to the Company's product candidates may change.
	Even if granted, regulatory approvals may include significant limitations on the uses for which products can be marketed or may
	be conditioned on the conduct of post-marketing surveillance studies. Failure to comply with applicable regulatory requirements
	can, among other things, result in warning letters, the imposition of civil penalties or other monetary payments, delay in approving
	or refusal to approve a product candidate, suspension or withdrawal of regulatory approval, product recall or seizure, operating
	restrictions, interruptions of clinical trials or manufacturing, injunctions or criminal prosecution. In addition, regulatory agencies
	many not approve the labeling claims that are necessary or desirable for the successful commercialization of the Company&rsquo;s
	product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Requirements for regulatory
	approval vary widely from country to country. Whether or not approved in Canada or the United States, regulatory authorities in
	other countries must approve a product prior to the commencement of marketing the product in those countries. The time required
	to obtain any such approval may be longer or shorter than in Canada or the United States. Approved drugs, as well as their manufacturers,
	are subject to continuing and ongoing review, and discovery of problems with these products or the failure to adhere to manufacturing
	or quality control requirements may result in regulatory restrictions being imposed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Our Common Shares
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Our share price
	has been and is likely to continue to be volatile and an investment in our Common Shares could suffer a decline in value.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	You should consider
	an investment in our Common Shares as risky and invest only if you can withstand a significant loss and wide fluctuations in the
	market value of your investment. The market price of our Common Shares has been highly volatile and is likely to continue to be
	volatile.
<B>
</B>
	This leads to a heightened risk of securities litigation pertaining to such volatility.
<B>
</B>
	Factors affecting
	our Common Share price include but are not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our ability to raise
	additional capital;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the progress of our clinical trials:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	our ability to obtain partners and collaborators to assist with the future development of our products;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	general market conditions;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	announcements of technological innovations or new product candidates by us, our collaborators or our competitors;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	published reports by securities analysts;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	developments in patent or other intellectual property rights;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the cash and investments held by us and our ability to secure future financing;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	public concern as to the safety and efficacy of drugs that we and our competitors develop;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	shareholder interest in our Common Shares; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	low liquidity in the daily trading volume of our Common Shares.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage141"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Future sales
	of our Common Shares by us or by our existing shareholders could cause our share price to fall.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The issuance of Common
	Shares by us could result in significant dilution in the equity interest of existing shareholders and adversely affect the market
	price of our Common Shares. Sales by existing shareholders of a large number of our Common Shares in the public market and the
	issuance of shares issued in connection with strategic alliances, or the perception that such additional sales could occur, could
	cause the market price of our Common Shares to decline and have an undesirable impact on our ability to raise capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We are susceptible
	to stress in the global economy and therefore, our business may be affected by the current and future global financial condition.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If the increased level
	of volatility and market turmoil that have marked recent years continue, our operations, business, financial condition and the
	trading price of our Common Shares could be materially adversely affected. Furthermore, general economic conditions may have a
	great impact on us, including our ability to raise capital, our commercialization opportunities and our ability to establish and
	maintain arrangements with others for research, manufacturing, product development and sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	An active trading
	market in our Common Shares may not be sustained.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our Common Shares are
	listed for trading on the NASDAQ Capital Market (&ldquo;
<B>
	NASDAQ
</B>
	&rdquo;) and the Toronto Stock Exchange (&ldquo;
<B>
	TSX
</B>
	&rdquo;).
	However, an active trading market in our Common Shares on the stock exchanges may not be sustained and we may not be able to maintain
	our listings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	It may be difficult
	for non-Canadian investors to obtain and enforce judgments against us because of our Canadian incorporation and presence.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are a corporation
	existing under the laws of Canada. Some of our directors and officers, and many of the experts named in this Annual Report and
	the documents incorporated by reference into this Annual Report, are residents of Canada, and all or a substantial portion of their
	assets, and a substantial portion of our assets, are located outside the United States. Consequently, although we have appointed
	an agent for service of process in the United States, it may be difficult for holders of our shares who reside in the United States
	to effect service within the United States upon our directors and officers and experts who are not residents of the United States.
	It may also be difficult for holders of our shares who reside in the United States to realize in the United States upon judgments
	of courts of the United States predicated upon our civil liability and the civil liability of our directors, officers and experts
	under the United States federal securities laws. Investors should not assume that Canadian courts (i) would enforce judgments of
	United States courts obtained in actions against us or our directors, officers or experts predicated upon the civil liability provisions
	of the United States federal securities laws or the securities or &ldquo;blue sky&rdquo; laws of any state within the United States
	or (ii) would enforce, in original actions, liabilities against us or our directors, officers or experts predicated upon the United
	States federal securities laws or any such state securities or &ldquo;blue sky&rdquo; laws. In addition, we have been advised by
	our Canadian counsel that in normal circumstances, only civil judgments and not other rights arising from United States securities
	legislation are enforceable in Canada and that the protections afforded by Canadian securities laws may not be available to investors
	in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We are likely
	a &ldquo;passive foreign investment company&rdquo; which may have adverse U.S. federal income tax consequences for U.S. shareholders.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	U.S.
	investors in our Common Shares should be aware that the Company believes it was classified as a passive foreign investment company
	(&ldquo;PFIC&rdquo;) during the tax year ended December 31, 2015, and based on the nature of our business, the projected composition
	of our gross income and the projected composition and estimated fair market value of our assets, the Company expects to be a PFIC
	for the current tax year ending December 31, 2016 and may be a PFIC in subsequent tax years. If the Company is a PFIC for any
	year during a U.S. shareholder&rsquo;s holding period, then such U.S. shareholder generally will be required to treat any gain
	realized upon a disposition of Common Shares, or any so-called &ldquo;excess distribution&rdquo; received on its Common Shares,
	as ordinary income, and to pay an interest charge on a portion of such gain or distributions, unless the shareholder makes a timely
	and effective &ldquo;qualified electing fund&rdquo; election (&ldquo;QEF election&rdquo;) or a &ldquo;mark-to-market&rdquo; election
	with respect to the Common Shares. A U.S. shareholder who makes a QEF election generally must report on a current basis its share
	of the Company&rsquo;s net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the
	Company distributes any amounts to its shareholders. However, U.S. shareholders should be aware that we do not intend to satisfy
	record keeping requirements that apply to a qualified electing fund, and we do not intend to supply U.S. shareholders with information
	that such U.S. shareholders require to report under the QEF election rules, in the event that we are a PFIC and a U.S. shareholder
	wishes to make a QEF election. Thus, U.S. shareholders should assume that they will not be able to make a QEF election with respect
	to their Common Shares. A U.S. shareholder who makes the mark-to-market election generally must include as ordinary income each
	year the excess of the fair market value of the Common Shares over the taxpayer&rsquo;s basis therein. This paragraph is qualified
	in its entirety by the discussion below under the heading &ldquo;Certain United States Federal Income Tax Considerations.&rdquo;
	Each U.S. shareholder should consult its own tax advisor regarding the U.S. federal, U.S. local, and foreign tax consequences
	of the PFIC rules and the acquisition, ownership, and disposition of our Common Shares.
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage142"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<B>
<I>
	We are an
	&ldquo;emerging growth company,&rdquo; and we cannot be certain if the reduced reporting requirements applicable to emerging growth
	companies will make our common shares less attractive to investors.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	are an &ldquo;emerging growth company,&rdquo; as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act.
	For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements
	that are applicable to other public companies that are not emerging growth companies, including not being required to comply with
	the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
	compensation in our periodic reports and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation
	and shareholder approval of any golden parachute payments not previously approved.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	will cease to be an emerging growth company upon the earliest of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<LI STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the last day
	of the fiscal year during which we have total annual gross revenues of $1,000,000,000 (as such amount is indexed for inflation
	every five years by the SEC or more;
</LI>
<LI STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the last day
	of our fiscal year following the fifth anniversary of the completion of our first sale of common equity securities pursuant to
	an effective registration statement under the Securities Act;
</LI>
<LI STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the date on
	which we have, during the previous three-year period, issued more than $1,000,000,000 in non- convertible debt; or
</LI>
<LI STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the date on
	which we are deemed to be a &ldquo;large accelerated filer&rdquo;, as defined in Rule 12b&ndash;2 of the Exchange Act, which would
	occur if the market value of our ordinary shares and ADSs that are held by non-affiliates exceeds $700,000,000 as of the last day
	of our most recently-completed second fiscal quarter.
</LI>
</UL STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	We
	cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors
	find our Common Shares less attractive as a result, there may be a less active trading market for our Common Shares and our share
	price may be more volatile.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Any failure
	to maintain an effective system of internal controls may result in material misstatements of our consolidated financial statements
	or cause us to fail to meet our reporting obligations or fail to prevent fraud; and in that case, our shareholders could lose confidence
	in our financial reporting, which would harm our business and could negatively impact the price of our common shares.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Section
	404(a) of the Sarbanes-Oxley Act of 2002, as amended, or SOX, requires that our management assess and report annually on the effectiveness
	of our internal controls over financial reporting and identify any material weaknesses in our internal controls over financial
	reporting. Although Section 404(b) of the SOX requires our independent registered public accounting firm to issue an annual report
	that addresses the effectiveness of our internal controls over financial reporting, we have opted to rely on the exemptions provided
	to us by virtue of being a foreign private issuer and an emerging growth company, and consequently will not be required to comply
	with SEC rules that implement Section 404(b) of SOX until we lose our emerging growth company status.
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage143"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Effective
	internal controls are necessary for us to provide reliable financial reports and prevent fraud. If we fail to maintain an effective
	system of internal controls, we might not be able to report our financial results accurately or prevent fraud; and in that case,
	our shareholders could lose confidence in our financial reporting, which would harm our business and could negatively impact the
	price of our common shares. While we believe that we have sufficient personnel and review procedures to allow us to maintain an
	effective system of internal controls, we cannot assure you that we will not experience potential material weaknesses in our internal
	control. Even if we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability
	of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with IFRS,
	as issued by the International Accounting Standards Board, because of its inherent limitations, internal control over financial
	reporting may not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties
	encountered in their implementation, could harm our results of operations or cause us to fail to meet our future reporting obligations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	If
	we fail to timely achieve and maintain the adequacy of our internal control over financial reporting, we may not be able to produce
	reliable financial reports or help prevent fraud. Our failure to achieve and maintain effective internal control over financial
	reporting could prevent us from complying with our reporting obligations on a timely basis, which could result in the loss of investor
	confidence in the reliability of our consolidated financial statements, harm our business and negatively impact the trading price
	of our common shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<B>
<I>
	As a foreign
	private issuer, we are not subject to certain United States securities law disclosure requirements that apply to a domestic United
	States issuer, which may limit the information which would be publicly available to our shareholders.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	As
	a foreign private issuer, we are exempt from certain rules under the Exchange Act that impose disclosure requirements as well as
	procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and
	principal shareholders are exempt from the reporting and &ldquo;short-swing&rdquo; profit recovery provisions of Section 16 of
	the Exchange Act. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or
	as promptly as a company that files as a domestic issuer whose securities are registered under the Exchange Act, nor are we generally
	required to comply with the SEC&rsquo;s Regulation FD, which restricts the selective disclosure of material non-public information.
	For as long as we are a &ldquo;foreign private issuer&rdquo; we intend to file our annual financial statements on Form 20-F and
	furnish our quarterly updates on Form 6-K to the SEC for so long as we are subject to the reporting requirements of Section 13(g)
	or 15(d) of the Exchange Act. However, the information we file or furnish is not the same as the information that is required in
	annual and quarterly reports on Form 10-K or Form 10-Q for U.S. domestic issuers. Accordingly, there may be less information publicly
	available concerning us than there is for a company that files as a domestic issuer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #943634">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	DISCLOSURE
	CONTROLS AND INTERNAL CONTROL OVER FINANCIAL REPORTING
</B>
</FONT>
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company has implemented
	a system of internal controls that it believes adequately protects the assets of the Company and is appropriate for the nature
	of its business and the size of its operations. Our internal control system was designed to provide reasonable assurance that all
	transactions are accurately recorded, that transactions are recorded as necessary to permit preparation of financial statements
	in accordance with IFRS, and that our assets are safeguarded. These internal controls include disclosure controls and procedures
	designed to ensure that information required to be disclosed by the Company is accumulated and communicated as appropriate to allow
	timely decisions regarding required disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Internal
	control over financial reporting means a process designed by or under the supervision of the Chief Executive Officer and the Chief
	Financial Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
	statements for external purposes in accordance with IFRS as issued by the IASB. The internal controls are not expected to prevent
	and detect all misstatements due to error or fraud.
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There were no changes in our internal control
	over financial reporting that occurred during the year ended December 31, 2015 that have materially affected, or are reasonably
	likely to materially affect, our internal control over financial reporting
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015, the Company&rsquo;s
	management has assessed the effectiveness of our internal control over financial reporting and disclosure controls and procedures
	using the Committee of Sponsoring Organizations of the Treadway Commission&rsquo;s 2013 framework. Based on their evaluation, the
	Chief Executive Officer and the Chief Financial Officer have concluded that these controls and procedures are effective.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT; TEXT-ALIGN: RIGHT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage144"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	UPDATED
	SHARE INFORMATION
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of March 29, 2016, the Company had 12,047,455
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #333333; BACKGROUND-COLOR: WHITE">
</FONT>
	common shares issued and outstanding. In addition, as of February 23, 2016 there were 1,681,296 common shares issuable upon
	the exercise of outstanding stock options and 72,605 common shares issuable upon the exercise of common share purchase warrants
	priced at $5.40 and expiring in August 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	ADDITIONAL
	INFORMATION
</FONT>
</P>
<P STYLE="COLOR: #943634; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.3IN; TEXT-INDENT: -1.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: WINDOWTEXT">
	Additional
	information relating to Aptose, including Aptose' December 31, 2015 annual report on form 20-F and other disclosure documents,
	are available on SEDAR at
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	www.sedar.com
</FONT>
<FONT STYLE="COLOR: WINDOWTEXT">
	and on EDGAR at
</FONT>
	www.sec.gov/edgar.shtml.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	33
</P>
<P STYLE="MARGIN: 0">
</P>
<HR NOSHADE SIZE="4" STYLE="COLOR: BLACK; WIDTH: 100%; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_15>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
